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Abstract 
 
 
Invariant  natural  kiler  T (iNKT) cels are a subpopulation  of lymphocytes that 
express both a CD1d-restricted αβ T cel receptor (TCR) and NK cel markers.  iNKT 
cel perturbations are implicated in a wide variety of autoimmune diseases including 
Multiple  Sclerosis (MS).  Our results confirmed a significant reduction in the 
percentage of iNKT cels in MS patients with respect to healthy donors. In order to 
understand the immunological significance of iNKT cel reduction in MS, we aimed 
to  define iNKT subsets in a cohort  of  MS  patients of  diferent  disease types, 
Clinicaly Isolated  Syndrome  patients (CIS) and  patients  on  diferent treatments  by 
means of multiparameter flow cytometry and TCR analysis. 
 
TCR analysis showed that Vα24 CDR3 region is highly conserved between healthy 
controls and  MS  patients,  while TCR  Vβ11  CDR3 region in iNKT cels  of  MS 
patients appeared constrained relative to the pool of cels in healthy controls. 
 
As activation, diferentiation and maturation processes can be involved in the reduced 
frequency  of iNKT cels,  we investigated the role  of  CD25,  CD62L,  CD69,  CD161 
and CD195. Initial observation suggested that co-expression of CD25 and CD161 on 
iNKT cels is significantly higher in MS patients compared to healthy controls, while 
CD161 alone is  decreased, suggesting that a subpopulation  of iNKT cels  might  be 
acting as “regulatory subsets” in MS. 
 
Because  many  genetic studies  have shown that specific kiler cel immunoglobulin-
like receptor (KIR) family have a strong association  with  MS,  we evaluated the 
expression of KIR2DL1/S1, KIR2DL2/L3 and KIR3DL1 on iNKT cels. Our results 
showed that expression  of  KIR2DL1/S1 and  KIR3DL1 is lower in progressive  MS 
patients compared to  healthy controls.  RRMS  untreated  patients  have lower 
expression  of  both  KIR2DL2/L3 and  KIR3DL1 than  patient treated  with 
Natalizumab, while the contrary is true when looking at expression of KIR2DL1/S1. 
 
Al together  our  data showed that  perturbation  of iNKT cels is associated  with 
expression  of specific surface receptors, thus  defining subsets  of iNKT cels that 
might be related to progression of disease or used as disease markers.  
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1. Introduction 
 
1.1 Multiple Sclerosis 
	  
1.1.1 Epidemiology and clinical features 
	  
Multiple sclerosis (MS) is a chronic, autoimmune  disorder  of the central  nervous 
system (CNS), characterised  by  demyelination, axonal injury and  multifocal  white 
mater inflammatory  plaque formation,  mainly in the spinal cord,  brain stem,  optic 
nerve and  white  mater tract  of the  periventricular regions (De Jager and  Hafler, 
2007). 
 
MS  prevalence  varies according to  geographic location and diferent racial/ethnic 
groups, with an approximate  100-140  per  100,000  prevalence rate in  England and 
Wales, around  170 in  Northern Ireland and reaching  190 in  Scotland (Rosati,  2001; 
Alonso et al.,  2007), making MS the  most common cause  of  disabling  neurological 
disorder in young adults. A new prevalence study in Northern Scotland recorded the 
MS  prevalence rates  per  100,000 as  402 in  Orkney,  295 in  Shetland and  229 in 
Aberdeen (Visser et al.,  2012).  Females are  more frequently afected than  males, 
particularly among white populations of Northern European ancestry, with a peak of 
incidence being around age of thirty (Confavreux et al., 1980; Hauser and Oksenberg, 
2006).  
 
Around  80%  of  patients  present  with an initial clinical episode  of  demyelination 
involving one or several sites of the CNS, described as Clinicaly Isolated Syndrome 
(CIS) (Richards et al.,  2002;  Fisniku et al.,  2008). Not al  CIS  patients  develop  MS 
and of those who are eventualy diagnosed with MS, disability is extremely variable 
(Fisniku et al., 2008). Predictors of conversion from CIS to MS include the presence 
of magnetic resonance imaging (MRI) abnormalities at presentation (Morissey et al., 
1993; Jacobs et al., 1997;  O’Riordan et al.,  1998;  Beck et al.,  2003;  Miler et al., 
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2005) and the presence of oligoclonal bands (Paty et al., 1988; Lee et al., 1991).	  It has 
been reported that two or more infratentorial lesions (Minneboo et al., 2004) and T2 
lesion accumulation in the first five years (Rudick et al., 2006a; Fisniku et al., 2008) 
corelate with long-term disability	  and clinical disease severity.	   
 
Approximately  85-90%  of  MS  patients  present  with a relapsing remiting  disease 
(RRMS), which is characterised by an initial atack (CIS) with symptoms developing 
gradualy folowed  by complete  or  partial recovery (Hafler,  2004;  De Jager and 
Hafler,  2007).  Relapses are  unpredictable and associated  with inflammatory cels 
infiltration leading to demyelination and axonal damage. Relapse rates were time and 
age  dependent,  decreasing slowly as the  disease  progresses,  with the  decline  being 
greater for patients who were older at the onset of the disease (Tremlet et al., 2008). 
 
Around  60%  of  RRMS  patients  develop secondary  progressive  MS (SPMS), 
characterised  by absence  of relapses,  progressive ilness and chronic 
neurodegeneration (De Jager and Hafler, 2007). Around 10-20% of patients wil from 
the onset of disease show a primary progressive MS (PPMS) course, characterised by 
gradual  neurological  deterioration and the absence  of acute relapses from the  onset 
(Thompson et al.,  1997; Cotrel et al.,  1999;  Hafler,  2004;  De Jager and  Hafler, 
2007). 
 
Patients with MS have a wide range of signs and symptoms depending on which part 
of the  CNS is afected. In  most cases, the cerebrum,  visual  pathway,  brainstem, 
cerebelum and spinal cord are involved, thus leading to  motor,  visual, sensory and 
autonomic  dysfunction.  Symptoms include  double  vision,  partial  or complete  visual 
loss,  weakness in  one  or  more limbs,  gait instability, fatigue, ataxia,  numbness, 
sensory  disturbance and  bladder symptoms (Hauser and  Oksenberg,  2006). The 
degree of neurologic impairment of disability in MS is evaluated and monitored using 
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the Expanded Disability Status Scale (EDSS). The scale ranges from 0 (asymptomatic 
with normal neurological examination) to 10 (death due to MS) (Kurtzke, 1983). It is 
an accepted notion that inflammation is responsible for clinical relapses in RRMS and 
is associated with enhanced permeability of the blood brain barier (BBB) with acute 
peripheral immune cels migration into the CNS (Reynolds et al., 2011), while axonal 
injury and loss refers to accumulation of neurological deficit and clinical progression 
(Reynolds et al., 2011). 
 
 
1.1.2 Environmental risk factors 
 
The causes of MS remain unknown, but epidemiological studies have long indicated a 
combination  of environmental factors,  genetic susceptibility and infectious agents 
(Kurtzke,  1975;  Ebers et al.,  1996). The environmental component  of  MS is 
emphasized by diferences in incidence with latitude and by migration studies (Elian 
et al., 1990; Dean and Elian, 1997). A skewed geographic distribution of MS has been 
observed.  The  geographical  distribution  of  MS shows that the risk increases  with 
distance from equator, and there is a  higher incidence  of  MS in the  Northern 
hemisphere than the  Southern  hemisphere (Kurtzke,  1975;  Kurtzke,  1977;  Rosati, 
2001).  Migration studies  have  demonstrated that susceptibility to  MS is acquired 
before adolescence and  migration from  high-risk to low-risk areas  has  been 
demonstrated to  protect individuals from  developing  MS (Kurtzke,  1993; Dean and 
Elian, 1997).  
 
Studies  have shown that circulating  vitamin  D levels and  bone  mineral  density are 
reduced in MS patients,  which  were atributed to ambulatory status and functional 
capacity (Nieves et al.,  1994;  Cosman et al.,  1998;  Soilu-Hanninen et al.,  2005; 
Ozgocmen et al.,  2005;  Van  der  Mei et al.,  2007).  Also, it  was found that levels  of 
vitamin  D  were lower  during  MS relapses than in remission (Soilu-Hanninen et al., 
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2005) and higher serum vitamin D levels in MS patients are associated with reduction 
in risk  of relapse (Soilu-Hanninen et al.,  2005;  Simpson et al.,  2010;  Mowry et al., 
2010; Mowry et al., 2012; Runia et al., 2012).  High vitamin D intake and circulating 
levels of vitamin D have been demonstrated to reduce the risk of MS (Munger et al., 
2004; Munger et al.,  2006;  Kampman and  Stefensen,  2010). Interestingly, it  was 
demonstrated that expression of the major locus determining genetic susceptibility in 
MS, the  HLA-DRB1*1501 alele  of the  human leukocyte antigen-DR  (HLA-DR) 
gene, is regulated  by  vitamin  D  via a  highly conserved  vitamin  D response element 
(VDRE) (Ramagopalan et al., 2009). 
 
Moreover hormonal influences may play a major role in the disease since MS afects 
females  more than  males, and relapses  decrease  during  pregnancy  but increase in 
puerperioum (Vukusic et al.,  2004; Helwig et al.,  2008). Studies  have shown that 
oestrogen ameliorates  disease  development in experimental autoimmune 
encephalomyelitis (EAE) (Jansson et al.,  1994;  Bebo et al.,  2001; Ito et al.,  2001; 
Polanczyk et al., 2003; Liu et al., 2003; Garidou et al., 2004; Wang et al., 2009). Also, 
treatment  of RRMS  patients  with  oestrogens significantly reduced the  number and 
volume of gadolinium enhancing lesion on MRI images (Sicote et al., 2002; Soldan 
et al., 2003). 
 
A version of the “hygiene hypothesis” has been suggested to explain the relationship 
between MS and underlying infectious agents. This hypothesis suggested that MS is 
corelated  with childhood environment and sanitation level, such that lack  of 
childhood exposure to infectious agents  may  predispose  vulnerable individuals to 
autoimmune  diseases later in life (Fleming and  Fabry,  2007).  Several studies  have 
demonstrated temporal corelations  between  viral  or  bacterial infections and the 
triggering  of  MS relapses (Sibley et al.,  1985;  Rapp et al.,  1995; Tremlet et al., 
2008). 
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There are a large  number of studies  on a  possible association  between  Epstein-Bar 
virus (EBV) and MS aetiology. EBV seropositivity has been shown to contribute to 
MS risk. The risk is particularly associated with late infection with EBV, past history 
of infectious mononucleosis (IM) and elevated levels of anti-EBV antibodies (Haahr 
et al.,  1995;  Haahr et al., 2004; Levin et al.,  2005; Lucas et al.,  2011). An updated 
meta-analysis found that a  history  of IM  was associated  with a  higher risk  of  MS 
(Handel et al., 2010). Similarly, another meta-analysis reported a decreased MS risk 
in association  with  EBV seronegativity; and  EBV antibodies existed in al  MS 
patients (Ascherio and Munch, 2000; Pakpoor et al., 2012). The incidence of MS is 
higher among individuals  who  developed  EBV-induced infectious  mononucleosis 
during adolescence (Goldacre et al., 2004; Thacker et al., 2006). Interestingly, it has 
been  demonstrated that elevations  of  EBV-specific antibody titers  occured several 
years  before the  onset  of  MS and  persisted thereafter (Ascherio et al.,  2001; 
Sundstrom et al., 2004; DeLorenze et al., 2006). The co-occurence of elevated EBV 
antibody titers and HLA-DRB1*15 aleles resulted in a marked synergistic increase in 
MS risk compared to  not  having  both (Ascherio et al.,  2001;  De Jager et al.,  2008; 
Sundqvist et al., 2012). Angelini and coleagues demonstrated expansion of CD8+ T 
cel responses to EBV lytic antigens in untreated RRMS patients with active disease 
compared to  RRMS  patients treated  with  Natalizumab and relapse free  untreated 
RRMS patients (Angelini et al., 2013). Although EBV is not solely responsible to be 
the cause of MS, it has been proposed as a co-factor in disease pathogenesis. 
 
Lastly, cigarete smoking is a further environmental risk factor that has been linked to 
increased MS susceptibility and more rapid disease progression (Handel et al., 2011; 
Wingerchuk,  2012).  Studies  have shown that smoking is associated  with increased 
risk of disease progression and the early progression from CIS to MS (Hernan et al., 
2005; Di  Pauli et al.,  2008; Sundstrom et al.,  2008;  Healy et al.,  2009; Pitas et al., 
	   22	  
2009; D'Hooghe et al., 2012). Smoking is also associated with greater EDSS scores, 
lesion volumes, and more atrophy in MS patients (Healy et al., 2009; Zivadinov et al., 
2009). 
 
1.1.3 Genetic risk factors 
	  
MS is not a classic hereditary disease but a large number of genes are implicated in 
the risk of developing MS. This is emphasized by the studies of the concordance in 
monozygotic twins,  which is  ~30% (Cendrowski,  1968; Ebers,  1986;  Ebers et al., 
1996) and the incidence of MS is higher within first-degree relatives compared to the 
general population (Sadovnick et al., 2000). Candidate gene studies and more recent 
data from genome-wide association studies (GWAS) studies have implicated multiple 
genes and  markers  with susceptibility to  MS.  Studies  dating  back to the  mid-1970s 
established the association of MS with the major histocompatibility complex (MHC) 
(or human leucocyte antigen (HLA) (Jersild et al., 1972), the relatively strong genetic 
association within the HLA complex on chromosome 6p21.3 being then confirmed by 
GWAS (Sawcer et al., 2011). The haplotype carying DRB1*1501, and DQB2*0602 
is linked to a raised risk  of  MS in North  European  Caucasians, (Olerup and  Hilert, 
1991; Haegert and Francis, 1993; Schmidt et al., 2007; Compston and Coles, 2008), 
while HLA-C*05 and HLA-DRB1*11 show a protective efect (Ramagopalan et al., 
2007; Yeo et al., 2007).  
 
A series  of GWAS and  meta-analyses  were caried  out to identify other  MS 
susceptibility loci outside the MHC (Wang et al., 2011). Hafler and coleagues used 
DNA  microaray technology in family trios (involving an afected child and  both 
parents), and identified two single-nucleotide  polymorphisms (SNPs)  within the 
interleukin-2 receptor alpha  gene (IL2RA,  CD25) and  nonsynonymous  SNP in the 
interleukin-7 receptor alpha gene (IL7RA, CD127) that were strongly associated with 
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MS (Hafler et al.,  2007).  Other candidate  gene studies confirmed the association  of 
IL2RA and IL7RA aleles with MS, which support a role for altered T cel function in 
MS pathogenesis (Matesanz et al., 2007; Gregory et al., 2007; Lundmark et al., 2007; 
Akkad et al., 2009; Perera et al., 2009). 
 
GWAS also found a  positive corelation  within the  CLEC16A  gene (Hafler et al., 
2007).  SNPs  within the  CLEC16A  gene  were also found to  be associated  with  MS 
susceptibility in Sardinian samples (Zoledziewska et al., 2009) and African American 
population (Johnson et al., 2010). 
 
Sawcer and coleagues confirmed that among al classical and  SNP aleles 
DRB1*15:01 is the strongest and most replicated associated gene with MS (Sawcer et 
al., 2011). This most recent larger scale GWAS study confirmed a multitude of genes 
of immunological relevance associated with MS including genes involved in cytokine 
pathway (CXCR5, IL2RA, IL7R, IL7, IL12RB1, IL22RA2, IL12A, IL12B, IRF8, 
TNFRSF1A,  TNFRSF14,  TNFSF14), co-stimulatory (CD37,  CD40,  CD58,  CD80, 
CD86,  CLECL1) and signal transduction (CBLB,  GPR65,  MALT1,  RGS1,  STAT3, 
TAGAP,  TYK2) (Sawcer et al.,  2011).  Moreover, they have identified a range  of 
genetic  variants associated  with  Vitamin  D  metabolism (CYP27B1,  CYP24A1) and 
MS therapies such as  Natalizumab (VCAM1) and  Daclizumab (IL2RA) (Sawcer et 
al.,  2011).  Deluca and coleagues investigated the influence  of  HLA-DRB1*15  on 
pathological  outcome in  post-mortem cohort  of  MS cases and found that  HLA-
DRB1*15 significantly increased the extent  of  demyelination and inflammation in 
MS spinal cord revealing the association  between  genes and clinical  phenotypes  of 
neurological disorders (Deluca et al., 2013).  
 
GWAS analysis  has  now identified  multiple regions that impact  on a  very large 
number  of  pathways, a large  number  of them  within immune  mechanisms.  The 
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substantial chalenge now wil be to cary these findings into the post-GWAS phase, 
establishing the nature of some of these functional pathways and identifying potential 
therapeutic targets. 
 
1.1.4 Diagnosis 
	  
Diagnosis  of  MS is  based  on  medical  history and  neurological examination that is 
confirmed using a range of tests. MRI has proven to be the best tool in establishing 
the diagnosis for MS and has some use in monitoring disease progression. 
 
MS lesions are refered to as hyper intense T2-weighted MRI,  which are  often 
periventricular and calosal (Fazekas et al.,  1988; Paty et al.,  1988; Gean-Marton et 
al., 1991; Barkhof et al., 1997). Gadolinium enhancing lesions on T1-weighted MRI 
imaging indicate active inflammation  (Grossman et al.,  1986),  while  brain atrophy 
corelates  with  disability  progression (Lossef et al.,  1996).  There is evidence 
demonstrating the involvement of normal-appearing white mater (NAWM) and grey 
mater (GM) occuring at the earliest clinical phase of the disease (Rocca et al., 2008) 
and they can be one of the key determinants of long-term outcome of disability in MS 
(Agosta et al., 2006). The presences of NAWN and GM changes have some use in the 
prediction of long-term disability in MS patients (Agosta et al., 2006). The presence 
of progressive  GM pathology in patients at their early  presentation  with CIS 
corelates with clinical disability and suggestive of MS (Dalton et al., 2004; Calabrese 
et al., 2007; Henry et al., 2008). In CIS patients, the number of white mater (WM) 
lesions detected on MRI is the best indicator to diagnose MS at that point or its future 
development (Morissey et al.,  1993;  O’Riordan et al.,  1998;  Beck et al.,  2003; 
Minneboo et al.,  2004;  Fisniku et al.,  2008). Advanced  MRI techniques such as 
magnetic resonance spectroscopy (MRS) and magnetization transfer imaging (MTI) 
have a superior sensitivity to  describe and  measure changes in lesions  over time 
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compared to conventional  MRI  but their  use clinicaly is stil  under  development 
(Filippi and  Rovaris,  2000; Inglese et al.,  2001; Tedeschi et al.,  2002). MRS 
techniques provide  physiological and chemical information  on metabolic  markers 
such as N-acetylaspartate (NAA),  which is  decreased in  neuronal/axonal loss 
(Narayana,  2005). MTI identifies quantitative changes in macromolecules  density 
found within tissue structures such as myelin, and therefore visualize tissue damage in 
respect to  demyelination and remyelination (Horsfield,  2005); their  use as routine 
clinical tools is stil under development. 
 
The McDonald criteria are the guidelines used for identifying and distinguishing MS 
symptoms from  other  neurological  diseases (Table  1.1) (Polman et al.,  2011). 
Examination  of cerebrospinal fluid (CSF)  by lumbar  puncture is  used to identify 
oligoclonal IgG bands that are positive in over 90% of MS patients (Andersson et al., 
1994;  Compston and  Coles,  2008).  Visual evoked  potentials (VEPs) can show 
prolonged latency, indicating the efect  of  demyelination  on  nerve conduction 
(Haliday et al., 1972; Compston and Coles, 2008). 
Clinical Presentation Additional Data Needed 
Two or more relapses 
Two or more objective clinical lesions None; clinical evidence wil suffice 
Two or more relapses 
One objective clinical lesion 
One or more T2 MRI lesions in at least 2 MS typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, or spinal 
cord), or further relapses involving different CNS site 
One Relapse 
Two or more objective clinical lesions 
Presence of asymptomatic gadolinium enhancing and 
nonenhancing lesions; Or 
New T2 and/or gadolinium-enhancing lesions; 
Or second clinical atack 
One Relapse 
One Objective clinical lesion 
For dissemination in space (DIS): one or more T2 lesions in at 
least 2 MS characteristic regions; or second clinical atack 
involving different CNS site 
For dissemination in time (DIT): Presence of asymptomatic 
gadolinium enhancing and nonenhancing lesions; or 
gadolinium-enhancing lesions; Or second clinical atack 
Insidious neurological progression 
suggestive of MS 
One year of disease progression and two of the folowing a. 
Positive brain MRI (one or more T2 lesions in MS characteristic 
regions) b. Positive spinal cord MRI (two or more focal T2 
lesions) c. Positive CSF 
Table 1.1: The McDonald criteria for diagnosis of multiple sclerosis.  
Extracted from Polman et al., 2011. 
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1.1.5 Treatment 
	  
There is  no  known cure for  MS,  however, there are  various available treatments, 
which reduce relapses, relieve symptoms and  which  may slow  disease  progression 
and further disability. Interferon beta-1b  (IFNβ-1b) was the first disease modifying 
therapy approved  by the  FDA for  MS.  Since then there  has  been an increase in the 
number of drugs licensed for MS with IFNβ and glatiramer acetate (GA) considered 
as first line therapy (Revel et al., 1995; Johnson et al., 1998). A range of licensed and 
more efective  options, including  oral  products and  monoclonal antibodies, are  now 
available and  under investigation for the future treatment  of  MS with a  more 
convenient mode of administration. 
 
1.1.5.1 Interferon beta (IFNβ)	  
	  
The immune-modulatory drug IFNβ is used as first-line therapy for RRMS, relapsing 
SPMS and  CIS  patients  with  MRI features consistent  with  MS (Jacobs et al.,  2000; 
Kappos et al.,  2006). Diferent formulations are curently available for  MS: 
intramuscular IFNβ-1a administered once per week (Avonex), subcutaneous IFNβ-1a 
administered three times per week (Rebif) and subcutaneous IFNβ-1b injected every 
other day (Betaferon/Extavia). 
 
The exact  mechanism  of action  of IFNβ is  unclear.  However, a large  number  of 
potential  mechanisms have  been  proposed, including its inhibitory efects  on 
leukocyte activation and immune cel proliferation by down-regulating the expression 
of HLA class I, so restricting autoantigen presentation required for T cel activation 
and  proliferation (Jiang et al.,  1995).  Moreover, IFNβ reduces the activation  of 
myelin-reactive T cels by preventing the interaction of CD80 and CD40/CD40L co-
stimulatory  molecules (Genc et al.,  1997;  Teleshova et al.,  2000). IFNβ  has  been 
proposed also to up-regulate the expression  of  Fas surface  molecules and the 
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intracelular co-stimulatory molecule CTLA4 on CD4 T lymphocytes that contributes 
to apoptosis of autoreactive T-cels (Halal-Laongo et al., 2007). IFNβ administration 
also leads to elevation of vascular cel adhesion molecule-1 (VCAM-1) levels which 
bind with the very late antigen-4 (VLA-4) receptor to form the VCAM/VLA-4 ligand 
and  block leukocyte adhesion to the  vascular endothelial  basement  membrane and 
migration into the CNS (Graber et al., 2005; Dhib-Jalbut and Marks, 2010). 
 
Introduction of IFNβ has proven efective by reducing the rate of relapses by ~30% 
(PRISMS,  1998). Recent randomized cohort trial  with 21  years folow  up after the 
start  of the IFNβ-1b showed that early treatment  with IFNβ-1b reduced the  hazard 
rate  of  death  by  47% compared  with  placebo  groups (Goodin et al.,  2012). MS 
patients with one or more relapses during the first two years of treatment with IFNβ 
developed early disability progression (Bosca et al., 2008). Some MS patients treated 
with IFNβ continue to  progress and  have relapses and  MRI activity.  This  group  of 
patients are refered to as non-responders and early identification of these patients is 
essential so as  ofer alternative therapy and  decrease the risk  of increased  disability 
(Rio et al., 2006). 
 
Studies revealed that IFNβ  preparations are frequently  wel tolerated  with no 
increased malignancy risk (Bloomgren et al., 2012), although some side efects have 
been  observed including injection site reactions, flu-like symptoms and abnormal 
hepatic enzyme activity (Murdoch and Lyseng-Wiliamson, 2005) 
 
1.1.5.2 Glatiramer acetate (GA)	  
	  
Glatiramer acetate (Copaxone®) is a four-amino acid synthetic co-polymer that is 
immunologicaly cross-reactive  with  myelin  basic  protein, one  of the  main  myelin 
autoantigens involved in  MS and EAE (Bornstein et al.,  1987; Ziemssen and 
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Schrempf,  2007). GA is administered subcutaneously  once  daily to RRMS  patients 
and to CIS patients who have features consistent with MS on MRI. GA was found to 
reduce relapse rate, improve  disability and reduce the cumulative number  of 
enhancing lesions and new T2 lesions in RRMS patients (Johnson et al., 1995; Comi 
et al., 2001). GA is usualy wel tolerated with no serious side efercts with injection 
site reactions  being the  most common (Johnson et al.,  1998). The  postulated 
mechanism  of action  of  GA involves a  unique regulatory  property  on  Th17 
diferentiation (Chen et al.,  2009), induction  of  CD8+ and  CD4+CD25+Foxp3+ 
regulatory  T cels (Jee et al.,  2007) and type-I  monocytes (Weber et al.,  2007), 
inhibits autoreactive T cels and activation of Th2 T cels in the periphery which then 
are  believed to cross the  BBB and  have an important impact  on the induction and 
maintenance  of regulatory/suppressive immune cels (Neuhaus et al.,  2001;  Dhib-
Jalbut, 2003; Kala et al., 2011). 
 
1.1.5.3 Mitoxantrone 
	  
Mitoxantrone is a cytotoxic drug of the anthracenedione family, which is approved to 
reduce, relapse rates and slow disease progression in patients with SPMS, progressive 
relapsing and worsening relapsing-remiting MS (Edan e al., 1997; Milefiorini et al., 
1997;  Hartung et al.,  2002).  Mitoxantrone is a type I topoisomerase inhibitor; it 
inhibits DNA synthesis and DNA repair (Martineli et al.,  2009). Mitoxantrone is 
given as an intravenous infusion  once every three  months for  24  months. Although 
mitoxantrone enhances  T-cel suppressor function, inhibits  B-cel function and 
antibody production, and reduces the production of pro-inflammatory cytokines in the 
periphery (Volmer et al., 2010), it can cross the disrupted BBB and exerts cytotoxic 
and immunomodulatory efects  by inducing  microglial cel  death (Li et al.,  2012). 
Mitoxantrone has a wide range of actions but has serious risks such as cardiotoxicity 
and leukemia that limit its use (Cohen and Mikol, 2004). 
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1.1.5.4 Natalizumab 
	  
Natalizumab (Tysabri) was first explored in trials as a treatment for MS in 2004, but 
was  withdrawn after a smal  number  of  patients  developed  progressive  multifocal 
leucoencephalopathy (PML), resulting from reactivation  of JC  virus in the  CNS 
(Kleinschmidt-DeMasters and  Tyler,  2005;  Rudick et al.,  2006b).  Natalizumab  was 
re-approved in  2006 for  use in  more active cases  of  RRMS  patients  who  did  not 
respond to IFNβ and GA and is infused intravenously over one hour every four weeks 
(Yousry et al., 2006; Brown, 2009). Natalizumab is humanized monoclonal antibody 
raised against the adhesion molecule α4 subunit of α4β1 integrin (VLA-4) (Tubridy 
et al.,  1999;  Stuve et al.,  2008). It is  presumed to act  by  preventing leukocyte 
migration across the  BBB through  blocking the interactions  between  VCAM-1 and 
VLA-4 (Brown,  2009).  Studies  demonstrated that  Natalizumab reduces the relapse 
rate in  MS individuals  by around  62% and reduce  disability  progression  by  42% 
(Miler et al.,  2003;  Polman et al.,  2006;  Miler et al.,  207). In the large scale 
randomized  AFFIRM trials, the  percentage  of  patients  on  Natalizumab therapy for 
over  24  month  period and free  of  new active  MRI lesions  was  57.7% compared to 
14.2% for placebo. Moreover, the percentage of patients who had no new active MRI 
lesions and free  of clinical relapses  was  39.7% compared to  7.2% for  placebo 
(Havrdova et al., 2008). 
 
1.1.5.5 Fingolimod 
	  
In  September  2010,  Fingolimod (Gilenya;  FTY720) was approved  by the  FDA as a 
daily  oral treatment for  RRMS (Castro-Borero et al.,  2012).  It is a synthetic 
compound derived from the fungal (Isaria sinclairi) secondary metabolite myriocin 
(ISP-I) (Aktas et al.,  2010). Fingolimod is  phosphorylated in vivo  by sphingosine 
kinase  2 to form fingolimod-phosphate, which  binds to sphingosine-1-phosphate 
receptor on lymphocytes, results in its internalisation, preventing their migration from 
	   30	  
lymphoid organs to the CNS (Foster et al. 2007; Coelho et al. 2007; Miron et al. 2008; 
Chun and Hartung,  2010).  Fingolimod  was shown to reduce the risk  of  disability 
progression and the rate of relapses (Kappos et al., 2010; Cohen et al., 2010; Radue et 
al.,  2012).  However,  Fingolimod therapy  has  been associated  with some serious 
adverse efects including  bradycardia, atrioventricular conduction  block,  herpes 
infection, skin cancers, hepatotoxicity and  macular  oedema (Kappos et al.,  2006; 
Aktas et al., 2010; Cohen et al., 2010; Kappos et al., 2010; Khatri et al., 2011) 
 
1.1.5.6 Alemtuzumab 
	  
Alemtuzumab (Campath1H) was originaly used to treat lymphoid malignancies, bone 
marow transplantation, kidney transplantation and islet cel transplantation 
(Riechmann et al.,  1988). Alemtuzumab is a humanized  monoclonal antibody given 
annualy by intravenous infusion that targets the CD52 antigen, which is expressed on 
the surface of T and B cels, NK cels, macrophages and dendritic cels (Riechmann et 
al., 1988; Moreau et al., 1996; Coles et al., 2004; Rommer et al., 2008). 
 
The  main  mechanism  of alemtuzumab-mediated  depletion  of immune cels is 
complement-dependent cytotoxicity (CDC) (Zent et al.,  2008; Rowan et al.,  1995), 
since it  depletes  CD52-bearing cels,  which  mediate antibody-dependent celular 
cytotoxicity (ADCC) (Stauch et al., 2009; Hu t al., 2009). Immune cel repopulation 
was shown to take  place involving early  B cels repopulation,  which is folowed  by 
augmentation of CD25high T cels during later T cel re-population (Cox et al., 2005; 
Muraro and Bielekova, 2007; Thompson et al., 2010; Hil-Cawthorne et al., 2012) 
 
Early studies demonstrated that alemtuzumab had a significant efect on the reduction 
of  new contrast-enhancing lesions (CEL)  on  MRI and clinical relapses  but  did  not 
afect the progression of disability in SPMS patients (Coles et al., 1999a; Paolilo et 
al., 1999; Coles et al., 2006). However, alemtuzumab stabilized disease progression in 
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clinicaly active MS patients with litle accumulated disability (Coles et al., 2006). A 
large, 36 month single blinded, phase I trial compared subcutaneous IFNβ-1a to two 
IV  doses  of alemtuzumab (12mg/d  or  24  mg/d in annual cycles) in  patients  with 
RRMS (Coles et al.,  2008).  Alemtuzumab significantly reduced the rate  of relapse, 
risk  of sustained  disability and MRI  data (contrast enhancing lesion and  T2 lesion 
load) compared to IFNβ-1a (Coles et al., 2008; Hirst et al., 2008; Coles et al., 2011; 
Coles et al.,  2012;  Fox et al.,  2012). Two large  phase II trials  were  performed, 
(CARE-MS I) in treatment-naïve  MS  patients and (CARE-MS I) in  patients with 
poor response to immune-modulatory therapies. The CARE-MS I results  provided 
more promising data regarding the efectiveness of alemtuzumab via reduction in the 
risk  of sustained accumulation  of  disability and reduction in the  number  of  patients 
with new T2 lesions. 
 
Documented adverse reactions include an infusion reaction,  which is  mediated  by 
cytokine release syndrome (Coles et al., 2008). Other reported side efects, which are 
related to the  development  of antibody-mediated autoimmunity including 
autoimmune thyroid  disorders (Coles et al.,  1999b;  Cree,  2006;  Coles et al.,  2008), 
idiopathic thrombocytopenic  purpura (ITP) (Coles et al.,  2008), and  Goodpasture’s 
syndrome (Clatworthy et al.,  2008;  Coles et al.,  2012). Autoimmune complications 
have  been linked to elevated levels  of IL-21 (Jones et al.,  2009). Also,  patients  on 
alemtuzumab were more prone to infections than IFNβ-1a treated patients including 
upper respiratory tract infections and oral herpes (Coles et al., 2008). Development of 
melanoma was reported after alemtuzumab therapy (Pace and Zajicek, 2009) and also 
Burkit’s lymphoma,  breast cancer and cervical cancer-in-situ (Pace and  Zajicek, 
2009). 
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1.1.5.7 Rituximab 
	  
Rituximab is a monoclonal antibody given by intravenous infusion every two weeks 
that targets the CD20 antigen, which is expressed only on mature B cels (Bar-Or et 
al., 2008). Rituximab has been licensed by the FDA to treat rheumatoid arthritis and 
non-Hodgkin’s lymphoma. 
 
In a 72-week,  open labeled,  phase  1 trial  of  patients  with  RRMS,  Rituximab was 
shown to reduce the  number  of relapses,  new  T2 lesions and  CELs (Bar-Or et al., 
2008).  Similar results were reported in a 48 week, double-blinded, phase I trial of 
patients with RRMS (Hauser et al., 2008). In a 52 week phase I trial, Rituximab was 
investigated as add-on therapy in  patients  with relapses  despite the  use  of  disease-
modifying therapy and  was found to reduce the  number  of  CELs (Naismith et al., 
2010). 
 
The  main mechanism  of action  of rituximab is  B cel  depletion (Voso et al.,  2002). 
The depletion of B cels is rapid occurs within two weeks through ADCC (Cartron et 
al., 2002) and to a lesser extent CDC (Golay et al., 2000; Voso et al., 2002; Hauser et 
al., 2008; Gurcan et al., 2009). Antibody synthesis is afected by Rituximab, but only 
those  produced  by  memory  B cels rather than  plasma cels.  According to the 
“immune complex decoy hypothesis,” the formation of Rituximab-bound B cels may 
deplete the functional activity  of  macrophages and  FcγR expressing efector cels 
redirecting them from sites of immune complex formation and chronic inflammation 
(Taylor and  Lindorfer,  2007).  Rituximab therapy  has also  been associated  with 
reductions in T and NK cels since CD20 was found to be expressed on them but in 
very smal  quantities (Kessel et al.,  2008).  Cases  of  PML  have  been reported in 
patients treated with Rituximab (Carson et al., 2009). 
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1.1.5.8 Daclizumab 
	  
Daclizumab  was  originaly  developed to  prevent alograft rejection after tissue 
transplantation and is a promising new therapy for MS. It is a humanized monoclonal 
antibody against IL-2RA given by intravenous infusion, which blocks CD25 antigen, 
found at  high levels  on activated  T cels  but at low levels  on resting  human  T cels 
(Bielekova et al., 2006; Vlad et al., 2007; Muraro et al., 2007). However, Daclizumab 
does not afect CD25+FOXP3+ T regulatory populations and they are fuly functional 
(Vlad et al., 2007). 
 
Daclizumab therapy in MS leads to expansion of CD56bright NK cels, which mediate 
lysis  of activated  T cels (Bielekova et al.,  2006;  Bielekova et al.,  2009). Bielekova 
and coleagues reported a strong corelation between inhibition of inflammation and 
stabilization  of  disease  progression and expansion  of  CD56bright  NK cels to 
Daclizumab therapy (Bielekova et al., 2009; Wynn et al., 2010). Other mechanisms of 
action include  mild inhibition  of  T cel activation and  proliferation (Wuest et al., 
2011), inhibition of survival of CD4+CD25high Treg cels (Binder et al., 2007; Wang et 
al., 2008) and direct inhibition of CD40L expression (Snyder et al., 2007). 
 
The first phase I open label trial of Daclizumab therapy reported a 78% reduction in 
new CELs  with significant improvement in  disability scores in  MS  patients failing 
IFNβ therapy (Bielekova et al., 2004). Other open label phase I studies supported the 
use  of  Daclizumab as  monotherapy in  MS  being efective in inhibition  of 
inflammation and stabilization of disease progression (Rose et al., 2004; Bielekova et 
al., 2009). A phase I, randomised, double-blind, placebo-controled (CHOICE study) 
reported that add-on Daclizumab treatment decreased disease activity and the number 
of  new  or enlarged  gadolinium  CELs to a  greater extent than IFNβ alone in active 
relapsing  MS  patients (Wynn et al.,  2010). The second randomised,  double-blind, 
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placebo-controled (SELECT study) evaluated two  doses (150 and  300mg)  of 
Daclizumab  monotherapy and  placebo in 600 RRMS  patients.  Daclizumab 
monotherapy demonstrated a significant efect on MS activity including reduction in 
the annual relapse rate,  number  of  new  or enlarging  CELs and/or  T2 lesion and 
sustained  disability  progression.  The  most common adverse efects are skin rashes, 
lymphadenopathy, transient elevations of liver enzymes (Rose et al., 2004; Oh et al., 
2009). 
 
1.1.5.9 Ocrelizumab 
	  
 
Ocrelizumab is a humanised version of rituximab against CD20 antigen, which leads 
to B cel depletion (Genovese et al., 2008; Morschhauser et al., 2010). Ocrelizumab 
has a similar  mechanism  of action to  Rituximab  but increased  CDC,  ADCC and  Fc 
binding afinity (Genovese et al., 2008; Kausa et al., 2009). 
 
In a  phase  2, multicentre, randomised,  paralel,  double-blind,  placebo-controled,  24 
week study, the total number of CEL was 89% lower in the 600 mg group and 96% 
lower in the  2000  mg  group compared to the  placebo  group and the annual relapse 
rate  was  80% lower in the low  dose  group and  73% lower in the  high  dose  group 
compared to people on IFNβ and placebo group (Kappos et al., 2011). 
 
1.1.6 Socio-economic aspects of MS 
 
Being a chronic neurological disease characterised by progressive degeneration, MS 
has  personal, social, health and  work related  negative impacts for  patients and their 
families. Patients with MS had drasticaly higher healthcare, medication and indirect 
ilness costs as  wel as  high  unemployment rates causing significant socioeconomic 
burden (Morales-Gonzales et al.,  2004;  Kobelt et al.,  2006a;  Kobelt et al.,  2006b). 
This  has  major social and economic consequences for the  person  with  MS and for 
society (Jennum et al., 2012). The hospitalization costs for MS were examined from 
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1993 to  2006 in the  USA,  based  on the  Nationwide Inpatient  Sample of the 
Healthcare Cost and Utilization Project of an average of 20,000 admissions annualy 
(Lad et al.,  2010).  According to this study,  on average  between 1993 and  2006 the 
annual cost for each  MS  patient increased significantly from  USD  8,000 to  20,00 
(Kesselring, 2010). 
 
1.1.7 MS Animal models 
 
1.1.7.1 Experimental Autoimmune Encephalomyelitis  
	  
Much of the recent understanding of immune mechanisms involved in MS arises from 
the  use  of  EAE animal  models.  The relevance  of  EAE to  human  demyelinating 
disease was noted in 1947 when acute disseminated encephalomyelitis was produced 
in rhesus  monkey and its  pathology  was similar to  human  demyelinating  disease 
(Wolf et al., 1947). EAE is induced by administration of autoantigens combined with 
strong immune adjuvants resulting in  T cel  mediated immune  damage to the  CNS 
and associated cascades  of innate immune responses,  which reproduce some 
histopathological and  neurobiological features  of  MS. The  most commonly  used 
antigens for immunization are spinal cord  homogenate  or myelin  proteins including 
Myelin  Basic  Protein (MBP), Myelin-associated  Oligodendrocyte  Basic  Protein 
(MOBP)  or Proteolipid  Protein (PLP) emulsified in complete  Freund’s adjuvant 
(Freund, 1956; Zamvil et al., 1986; Tuohy et al., 1986; Greer et al., 1992; Kaye et al., 
2000). EAE  has  been a  useful tool for studying autoimmunity associated  with  CNS 
inflammation and injury.   Limitations of the EAE model have to some extent been 
addressed by the creation of transgenic and knockout mouse models, ofering beter 
convergence with the human immunogenetics and manipulation of immune pathways 
(Goverman et al., 1993; Lafaile et al., 1994; Brabb et al., 1997; Madsen et al., 1999; 
Waldner et al., 2000; Betelli et al., 2003; Polinger et al., 2009). 
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1.1.7.2 Line 7 mouse model 
	  
Line  7  mice  were  generated in  Professor  Danny  Altmann’s  Lab  by  Drs  Stephan 
Elmerich and Katalin Takacs. Line 7 is a transgenic animal model (Elmerich et al., 
2004), which express an MS  derived  TCR  with  HLA-DR15.   Mice  develop 
spontaneous paralysis, demyelination and axonal degeneration, which corelate with T 
cel responses to  HLA-DR15 restricted epitopes against some  myelin components 
including MBP, myelin  oligodendrocyte  glycoprotein (MOG), and αB-crystalin 
(Elmerich et al.,  2005).  This  model  ofers  promise for  modeling the 
immunopathogenesis  of  MS since the  disease  occurs in the absence  of adjuvants 
otherwise required to activate autoreactive CD4 T cels. The Line 7 model may thus 
help us gain a beter understanding of the molecular aspects and celular interactions 
implicated in disease progression. 
 
1.1.8 Immunological mechanisms in MS 
 
1.1.8.1 T cels 
	  
The epidemiological  data support the  notion  of an as  yet  uncharacterised initiating 
event, acting in individuals  with appropriate  polygenic susceptibility.  At some later 
stage,  T cels,  possibly  both  CD4+  T and  CD8+  T cels, cross the  BBB  where they 
recognize antigens  of the  myelin sheath including,  but  not limited to,  MBP,  MOG, 
PLP and MOBP (Hafler 2004; Steinman, 2007). 
 
For several years, data both from MS patients and from the EAE murine model was 
considered to argue for a predominant role of Th1 cels in pathogenesis (Baron et al., 
1993). The overwhelming atention towards IFN-γ producing T cels in MS patients 
evolved from the observation that myelin-specific CD4+ Th1 cels were suficient to 
induce  EAE (Ben-Nun and  Cohen,  1982;  Ando et al.,  1989;  Yura et al.,  2001). T 
lymphocytes  producing IFN-γ in response to autoantigens  were  higher in  peripheral 
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blood and CSF of MS patients (Olsson et al., 1990; Link et al., 1992; Soderstrom et 
al.,  1993). In active  MS lesions IFN-γ co-localized  with infiltrating cels  mostly  on 
astrocytes (Traugot and  Lebon,  1988). Treatment  of  RRMS  patients  with IFN-γ 
resulted in activation of the immune system and exacerbated the disease (Panitch et 
al.,  1987).  However,  other studies  demonstrated that IFN-γ  knockout  mice  were 
susceptible to EAE folowing immunization with MBP and the disease seemed to be 
very severe since  histologic analysis revealed  vast lymphocytes,  macrophages, and 
granulocytes infiltration to the  CNS (Wilenborg et al.,  1996;  Ferber et al.,  1996). 
Together, these data suggested that myelin autoreactive CD4+ T cels were suficient 
to induce  EAE  but the  presence  of IFN-γ  was  not  necessary, causing researchers to 
investigate other cytokines that may influence pathogenic capacity of T cels. 
 
Cua and coleagues then showed that IL-23 knockout mice were protected from EAE 
(Cua et al., 2003), while IL-12 knockouts were not, leading to an explosion of studies 
in  mice and  humans showing a role  of  Th17 cels (Kebir et al.,  2009; Jager et al., 
2009). Kroenke et al (2008) reported that transfer of IL-12p70 or IL-23 polarized T 
cels into recipient  mice initiated ascending  paralysis. EAE  was significantly 
suppressed in IL-17 knockout mice since these mice presented with delayed disease 
onset and  decreased severity scores (Komiyama et al.,  2006).  However, it  has  been 
shown that the deletion of IL-17A and IL-17F slightly afected the severity of EAE 
since treatment with IL-17A monoclonal antibody had only marginal beneficial efect 
on disease development (Haak et al. 2009). It is known that IL-17-producing helper T 
cels are protective but cels producing both IL-17+ and IFN-γ+ are pathogenic and IL-
23 enhances the  development  of IL-17+/IFN-γ+  population  of  T cels (Ahern et al. 
2010;  Hirota et al.  2011). Recent reports  have reconsidered the relative role  of  Th1 
and  Th17  CD4+ cels in  EAE and  MS  pathogenesis (El-Behi et al.,  2010),  with the 
possibility that  both cel types are involved at  diferent stages  of  CNS ingress 
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(O’Connor et al., 2008). 
 
Activated  T cels express α4β1 integrins  which  promotes their  binding to  VCAM-1 
by  which they  pass through the extracelular  matrix  before crossing the  BBB 
(Laschinger and Engelhardt,  2000). In the  EAE  model, it  has  been shown that 
antibodies against α4-integrins  prevent relapse in the  disease (Stuve et al.,  2008; 
Bauer et al., 2009). 
 
EAE and TCR transgenic studies showed that myelin-specific CD8+ T cels can cause 
CNS autoimmune disease in mice, suggesting that CD8+ cels could similarly have a 
role in  MS  pathogenesis (Huseby et al.,  2001). A raised frequency  of autoreactive 
myelin specific CD8+ T cels has been found in the peripheral blood of MS patients 
by flow cytometry (Crawford et al.,  2004). However,  other studies found that the 
frequency of myelin-reactive CD8 T cels is not increased in MS patients compared to 
healthy controls (Berthelot et al.,  2008). A significant increase in  CD8+ T cels 
secreting lymphotoxin was demonstrated in patients with SPMS (Buckle et al., 2003). 
Human post-mortem studies demonstrated a significant number of CD8+ cels in MS 
lesions, indicating that the T cel infiltration in MS has a relative overepresentation 
of CD8+ cels (Hauser et al., 1986; Babbe et al., 2000; Friese and Fugger, 2005). This 
has led to the case being proposed for a possible role for CD8+ cels in MS (Huseby et 
al., 2001; Friese et al., 2008). 
 
 
1.1.8.2 B cels 
	  
There is a lack of consensus as to celular efector mechanisms in MS pathogenesis. 
Although it is often considered a T cel mediated autoimmune disease against myelin 
sheath components, evidence suggests a role in disease progression also for B cels. 
Studies identified autoantibodies in the CSF against the myelin antigen MOG, MBP 
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and PLP that are related to myelin damage in MS (Genain et al., 1999). It has been 
shown that CSF B cels account for the oligoclonal Ig bands, which are a diagnostic 
halmark of MS (Walsh et al., 1985; Obermeier et al., 2008). Additional evidence has 
suggested a possible role for B cels in the pathogenesis of MS, which may underpin 
the efectiveness  of anti-CD20  monoclonal antibodies that targets  B lymphocytes 
(Genain et al., 1999; Monson et al., 2005; Hauser et al., 2008; Kappos et al., 2011). 
Rituximab, a monoclonal antibody against CD20, led to T and B cels depletion in the 
CSF of RRMS not responded to immunomodulatory therapies (Cross et al., 2006). As 
discussed above, clinical trials show that Rituximab can  decrease  brain lesions and 
relapses (Hauser et al.,  2008). The contribution  of  B cels to  EAE  was  highlighted 
when  depletion  of  B cels influenced  disease initiation and  progression,  while 
administration  of  Rituximab  before immunization reduced  demyelination and 
leukocyte infiltration (Matsushita et al.,  2008). A reduction in  B cel  numbers in 
cerebral  perivascular spaces was  observed from autopsy  material  of a  patient  with 
gastrointestinal mantle-cel lymphoma treated with rituximab therapy (Martin Mdel et 
al., 2009). 
 
In MS, B cels displayed abnormal proinflammatory cytokine responses to activated 
stimuli including increased IL-10 ratios and  TNF-α secretion (Bar-Or et al.,  2010). 
On  histological examination, lymphoid folicles  with  germinal centres containing  B 
cels were detected in the cerebral meninges of SPMS patients (Serafini et al., 2004). 
The  presence  of  B cel folicles in the cerebral  meninges  of SPMS patients is 
corelated with severe cortical pathology (Magliozzi et al., 2007).  
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1.1.8.3 Mast cels  
	  
Mast cels are  best  known for their  vital role in  mediating alergic responses. It  has 
been shown that a dense population of mast cels resided in the meninges enabling T 
cels entry to the CNS (Sayed et al., 2010). The role of mast cels in MS has not been 
extensively investigated.  Mast cels  were identified in  MS  brain lesions,  mainly in 
demyelinated areas (Kruger et al.,  1990;  Toms et al.,  1990;  Kruger,  2001).  A 
significant decrease in mast cel frequency has been demonstrated in EAE rat brains 
and a  higher  proportion appeared  degranulated (Brenner et al.,  1994).  It  has  been 
reported that  mast cel  deficient  mice  presented  with  delayed  disease  onset and 
reduced clinical scores,  while reconstitution  of  mast cels restored susceptibility to 
EAE induction and severe  disease (Secor et al.,  2000). Microaray analysis  of 
meningeal tissues revealed  marked changes in the expression  of several immune 
response related  genes including  genes associated  with  mast cel and  neutrophil 
function (Christy et al.,  2012).  Moreover, they showed that  meningeal  mast cels 
activation  occured  within  24  hours  post-EAE induction,  which led to  meningeal 
inflammation via neutrophil recruitment (Christy et al., 2012).  
 
1.1.8.4 Dendritic cels  
	  
Dendritic cels (DCs) and macrophages are located in the CNS even in the absence of 
inflammation (Greter et al., 2005; Kivisakk et al., 2009). DCs were found in the CSF 
of  MS  patients suggesting  possible involvement in the  pathogenesis  of the  disease 
(Pashenkov et al., 2001). Another study demonstrated accumulation of DCs in white 
mater lesions  of  MS  brains (Lande et al.,  2008).  Moreover, impairment in  DC 
phenotype, maturation and regulatory functions has been reported in MS patients and 
treatment  with GA restores its functional  properties (Stasiolek et al.,  2006). In  MS 
patients leptomeninges and  perivascular spaces, extensive extracelular  myelin 
antigens  was  observed co-localized  with  DCs and  macrophages compared to non-
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neurological controls and  other  neurological  disease (Kooi et al.,  2009).  These 
findings suggest  possible functional abnormalities  of  DCs in  MS, though the exact 
mechanism in autoimmunity is not clear. 
 
1.1.8.5 Regulatory T cels 
	  
Another  major  T cel subset to consider  during autoimmunity is the regulatory  T 
(Tregs) cel  population.  Initial studies  demonstrated  poor function  of regulatory  T 
cels in  MS  patients peripheral  blood compared to  healthy controls  while they 
presented with the same frequency (Viglieta et al., 2004). Subsequently, some studies 
have  demonstrated a  decreased  number  of circulating  Tregs in  MS  patients,  mostly 
due to alteration in thymic release  of  T cels into the  periphery (Haas et al.,  2007), 
whereas  other  groups  demonstrated  no  diferences in Tregs frequencies in the 
periphery of MS patients and healthy controls (Haas et al., 2005; Feger et al., 2007). 
Elevated levels of Tregs were observed in the CSF of MS patients in comparison to 
peripheral  blood (Feger et al.,  2007).  Another study reported that  RRMS  patients 
show a significant reduction in  FoxP3  mRNA,  while  SPMS  patients  have  normal 
levels of FoxP3 expression (Venken et al., 2008). Interestingly, IFNβ treatment was 
reported to restore Treg function in MS by generating new, naive Tregs (de Andres et 
al.,  2007;  Korporal et al.,  2008;  Namdar et al.,  2010). Tregs  were  hardly  present in 
active brain lesions compared to CSF (Tzartos et al., 2008; Fritzsching et al., 2011). 
 
1.1.8.6 Natural Kiler cels 
	  
The  possible role  of  Natural  Kiler (NK) cels in either  MS  or  EAE  has  been an 
ongoing source of investigation in several labs, without reaching a clear consensus on 
whether their contribution is  pathogenic,  protective  or  both (Zhang et al.,  1997; 
Takahashi et al.,  2001;  Xu et al.,  2005; Winkler-Picket et al.,  2008).  NK cels 
represent 5-15% of circulating lymphocytes. NK cel activation, either for cytolysis or 
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cytokine production, depends on integration of a complex aray in inhibitory, ITIM-
linked receptors and activating, ITAM-linked receptors (Lanier,  2005). A smal 
longitudinal study concluded that a reduction in  NK cel function, in vitro 
immunoglobulin G secretion and concanavalin A-induced suppression corelate with 
disease activity as recognized  by large lesions  on  MRI (Oger et al.  1988).  Most 
studies reported that NK cytolytic activity was significantly reduced in the peripheral 
blood of MS patients compared to controls and patients are at higher risk for relapses 
during valeys in  NK cel  kiling activity (Kastrukof et al.,  1998;  Kastrukof et al., 
2003).  They reported a  positive corelation  between  valeys in  NK cel functional 
activity and development of active lesions on MRI (Kastrukof et al., 1998). 
 
The reduction of relapses during pregnancy was linked to a potential role of CD56bright 
regulatory NK cels in MS (Airas et al., 2008). Several studies have demonstrated an 
expansion of CD56bright NK cels with a reduction of cytotoxic CD56dim NK cels in 
the  peripheral  blood  of  MS  patients folowing IFNβ therapy (Saraste et al.,  2007; 
Vandenbark et al., 2009; Martinez- Rodriguez et al., 2010). This signifies a beneficial 
role  of the  CD56bright  NK cel subset in  MS.  Also,  Daclizumab led to a  marked 
expansion of CD56bright NK cels in the peripheral blood and CSF of RRMS patients 
(Bielekova et al., 2006; Bielekova et al., 2011). Another study demonstrated that NK 
cels from MS in remission state expressed higher levels of CD95 and produced larger 
amounts  of IL-5 than controls, suggesting that  NK cels  play an important role in 
maintaining the remission in MS (Takahashi et al., 2004).  
 
However, the role  of  NK cels in  MS as  deduced  using  EAE animal  models is 
controversial.  Some  groups  demonstrated that in vivo	  NK cel  depletion led to 
relapses and severe EAE (Zhang et al., 1997; Matsumoto et al., 1998). 
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Furthermore, Xu and coleagues showed that NK cel depletion exacerbated EAE and 
NK cels exerted a cytotoxic efect on PLP-specific, encephalitogenic T cels in PLP 
induced  EAE (Xu et al.,  2005).  Moreover,  NK cels expansion atenuated CNS 
inflammation and neurological deficits in EAE (Hao et al., 2011). In contrast,	  others 
have shown that  MOG  peptide failed to induce  EAE in IL-18  deficient  mice and 
administration of IL-18 restored features of EAE via induction of IFN-γ by NK cels 
(Shi et al.,  2000). Another study showed that  depletion  of  NK cels  diminished 
clinical disease activity in EAE (Winkler-Picket et al., 2008). 
 
1.1.8.7 Invariant NKT cels 
	  
Another subset implicated in several autoimmune  diseases, is the invariant  natural 
kiler  T (iNKT) cels subset.  Decreased levels  of iNKT cels  have  been shown in 
several autoimmune diseases including systemic lupus erythematosus (SLE) (Yang et 
al., 2003; Kojo et al., 2001; Van der Vilet et al., 2001), type 1 diabetes (Wilson et al., 
1998; Hong et al., 2001), MS (Ilés et al., 2000; Araki et al., 2003; Van der Vilet et 
al., 2001) and EAE (Singh et al., 2001) suggesting a protective efect of iNKT cels. 
	  
The contribution of iNKT cels has been investigated in mouse strains susceptible to 
EAE. Several studies have examined the role of giving the iNKT cel agonist ligand, 
α-galactosylceramide (αGalCer) injections in vivo, thus activating iNKT cels. It was 
found that in vivo stimulation  of iNKT cels  with αGalCer in the  presence  of anti-
CD86 antibody suppressed the onset of EAE (Pal et al., 2001). Additionaly, the EAE 
disease  process can  be controled  by administration  of a αGalCer analogue (OCH) 
that stimulates IL-4  production  by  NKT cels (Miyamoto et al.,  2001).  Moreover, 
studies  have shown that stimulation  of iNKT cels  with the αGalCer  protects  mice 
against EAE (Singh et al., 2001; Mars et al., 2002; Furlan et al., 2003). Interestingly, 
activation  of  NKT cels  via αGalCer administration can either exacerbate or inhibit 
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EAE  depending on  NKT cel responses (Jahng et al.,  2001). Protection  of  EAE is 
dependent  upon the secretion  of IL-4,  while exacerbation is  mediated  by IFN-γ 
secretion (Jahng et al., 2001). 
 
The protective efect of iNKT cels has been atributed to their ability to secrete IL-4 
and/or IL-10 (Godfrey et al.,  2000;  Miyamoto et al.,  2001). Singh and coleagues 
showed that cytokines (IL-4 and IL-10) secretion  by iNKT cels  upon αGalCer 
stimulation are critical for the protective efects against EAE leading to suppression 
of  pathogenic  T cel responses (Singh et al.,  2001). It  has  been reported that 
transgenic expression  of the invariant  TCR  of iNKT cels  protects  NOD  mice from 
EAE due to significant inhibition  of IFN-γ  production (Mars et al.,  2002). Other 
studies supported a critical role  of IFN-γ protection against  EAE in response to 
αGalCer stimulation (Furlan et al., 2003). These findings led the researchers to focus 
on  myeloid-derived suppressor cels (MDSCs) as celular targets for the cytokines 
released by iNKT cels. Parekh and coleagues demonstrated that αGalCer activated 
iNKT cels facilitated  protection against  EAE through the immunosuppressive 
activities  of  MDSCs (Parekh et al.,  2013).  The  protective efect  of αGalCer against 
EAE was abolished by selective depletion MDSCs, while adoptive transfer of MDSCs 
from αGalCer -treated mice led to protection against EAE (Parekh et al., 2013). This 
protective efect was due to cytokine secretion (GM-CSF, IL-4, and IFN-γ) by iNKT 
cels and (inducible  NO synthase, arginase-1, and IL-10)  by  MDSCs (Parekh et al., 
2013). 
 
Alterations in iNKT cels number and function have been implicated in a broad aray 
of autoimmune disease conditions including MS and EAE (Ilés et al., 2000; Van der 
Vliet et al., 2001; Araki et al., 2003). Using single strand conformation polymorphism 
(SSCP) to examine TCR repertoire, Ilés et al (2000) showed that MS patients have 
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decreased levels  of  Vα24  mRNA in the  blood compared to  healthy controls. 
Furthermore they showed an absence  of iNKT cel infiltrate in  MS lesions. 
Subsequent  work  has shown a  marked reduction  of iNKT cels frequency in the 
peripheral blood of MS patients by flow cytometry (Van der Vilet et al., 2001; Araki 
et al., 2003). This reduction was restricted to CD4-/CD8- and CD8+ iNKT cels during 
remission in MS patients (Araki et al., 2003). Furthermore, this study showed that the 
CD4+ iNKT cels from MS patients were biased to a Th2 profile in the remission state 
as they  produced  more IL-4,  which  may  be  protective  during the remission state 
(Araki et al., 2003). 
 
Curent MS treatments may afect iNKT cels frequency and function. O’Keefe and 
coleagues reported that iNKT cels from  MS  patients failed to expand and  produce 
IFN-γ upon αGalCer stimulation, suggesting a possible defect in the efector functions 
of this subset  during  disease (O’Keefe et al,  2008).  Gigli and coleagues 
demonstrated that IFNβ therapy significantly increased the percentage of circulating 
iNKT cels of  MS  patients and improved cytokine (IL-4, IL-5 and IFN-γ) secretion 
upon αGalCer stimulation via the  modulation  of  myeloid  DCs (Gigli et al,  2007). 
Therefore, I  would like to further investigate the involvement  of iNKT cels in  MS 
pathology. 
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1.2 Natural Kiler T cels 
 
Natural  Kiler  T (NKT) cels are a smal subset  of T lymphocytes that  have a 
fundamental role in initiation and modulation of immune responses. The terminology 
NKT cel  was  originated in  murine studies  on the characterization of  T cels co-
expressing the (NK 1.1) NK cel marker (Makino et al., 1995). The term NKT cel has 
been complicated  by the  description  of  other  T cel  population as  NKT cels as a 
result of the surface expression of CD56 and CD57 antigens on such cels. It has been 
proposed that NKT cels can be classified into three diferent categories (Godfrey et 
al., 2004). These subsets are type I classical NKT cels (invariant NKT cels), type I 
non-classical  NKT cels and  NKT-like cels.  As such, the  description encompasses, 
but is  not the same as, the iNKT cels  described above. In the course  of the 
experiments in this thesis I wil be describing characterisation of both iNKT and NKT 
cel populations. The classification is described in Table 1.2. 
 
 Type I NKT cels Type II NKT cels NKT-like cels 
Other names 
Classical NKT cels 
invariant NKT (iNKT) 
Vα14i NKT (mouse) 
Vα24i NKT (human) 
Non-classical NKT cels 
CD1d-independent 
NK1.1+ T cels 
CD3+ CD56+ T cels 
Restriction CD1d CD1d Other 
αGalCer 
reactivity + - - 
T cel receptor 
expression 
Vα14-Jα18/ 
Vβ2, 7, 8.1, 8.2, 
8.3(mouse) 
Vα24-Jα18/ 
Vβ11 (human) 
Diverse Diverse 
CD161 expression Yes (mature/resting) No (immature) Yes/no Yes 
Subsets CD4+, DN and CD8+ CD4+, DN CD4+, DN and CD8+ 
Major Cytokine 
produced IL-4, IFN-γ IL-4, IFN-γ IFN-γ 
Table 1. 2: NKT cel subset classification.  
Extracted from Godfrey et al., 2004. 
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1.3 The CD1 antigen presenting molecule  
	  
The  CD1  glycoprotein family are a  group  of  non-classical  MHC class I antigen-
presenting molecules that present self and microbial lipid antigens to T cels (Porceli 
and Modlin, 1995;  Bendelac et al.,  1997).  Two  groups  of  CD1  proteins  have  been 
described in humans based on sequence analysis, functional properties and paterns of 
expression (Calabi and Bradbury,  1991;  Porceli,  1995; Sugita and  Brenner,  2000). 
Group  1 consists  of  CD1a,  CD1b,  CD1c and  CD1e and  group  2 includes  CD1d 
(Martin et al., 1986; Balk et al., 1989; Porceli, 1995; Sugita and Brenner, 2000). 
 
Humans express al  CD1 isoforms (CD1a,  CD1b,  CD1c,  CD1e and  CD1d),  while 
mice express only CD1d (Porceli, 1995; Brigl and Brenner, 2004). The CD1 family 
has  been found in cow (MacHugh et al., 1988), rabbit (Calabi et al., 1989), rat 
(Ichimiya et al., 1994), sheep (Ferguson et al., 1996), cat (Woo and Moore, 1997) and 
guinea pig (Dascher et al., 1999). 
 
1.3.1 Structure of CD1 
 
CD1  molecules are similar to  MHC class I  proteins  with respect to the  overal 
structure  which consist  of α1, α2, and α3 extracelular  domains and non-covalent 
association with β2-microglobulin (β2m). The α1 and α2 domains of the extracelular 
region form the antigen  binding  groove  of the  CD1  molecule,  while the α3  domain 
ataches to a transmembrane region (Calabi and Bradbury, 1991; Zeng et al., 1997). 
 
In contrast to MHC class I, the CD1 family binding groove is deeper and larger, with 
a large hydrophobic pocket, adapted to bind to lipid antigens (Zeng et al., 1997; Grant 
et al., 1999; Burdin et al., 2000; Gadola et al., 2002; Zajonc and Wilson, 2007). The 
diference between CD1 isoforms is mainly related to the size and structural design of 
the antigen-binding groove. CD1b has the biggest groove size, while CD1a and CD1d 
contain only two pockets (Gadola et al., 2002; Zajonc and Wilson, 2007). 
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Unlike classical MHC class I, the CD1 glycoproteins are relatively non-polymorphic. 
A large cohort  of  donors from  diferent ethnic  backgrounds  were sequenced and 
analysed  using SSCP, showing that  CD1a,  CD1b,  CD1c,  CD1d and  CD1e are 
polymorphic in exon  2 (α1  domain), where CD1c and  CD1b contained silent 
mutations across al  donors (Oteo et al.,  1999;  Han et al.,  1999).  Another study  has 
reported that polymorphisms in exon  2  of  CD1a and  CD1e  genes are  very limited 
(Aureli et al., 2007). 
 
1.3.2 Traficking of CD1 molecules 
	  
The CD1 protein is assembled in the endoplasmic reticulum (ER), where it interacts 
with the chaperones calnexin and calreticulin and associates with β2m (Sugita et al., 
1997; Park et al.,  1998;  Morice and  Powis,  1998; Hutinger et al.,  1999; 
Jayawardena-Wolf et al., 2001; De Silva et al., 2002; Kang and Cresswel, 2002). The 
CD1 molecule then binds to the lipid antigen through the secretory pathways, either at 
the cel surface or after internalization by the interaction of the cytoplasmic tails with 
the adaptor complex  AP-2 (Park et al.,  2000; Briken et al.,  2002).  Recently,  more 
lipid exchange  proteins  have  been identified such as the  microsomal triglyceride 
transfer  protein (MTP) and  deletion  of  MTP resulted in  down-regulation  of  CD1d 
(Salio et al., 2010). Exogenous lipids enter cels with the carier proteins when bound 
to lipoproteins (Bendelac et al., 2007). 
 
Intracelular traficking of distinct CD1 molecules difers considerably. Human CD1a 
and CD1c can be found predominantly in early endosomes, while CD1b, CD1d and 
mouse  CD1d can  be  detected in late endosomes and lysosomes (Park et al.,  1998; 
Briken et al.,  2000; Sugita et al.,  2002; Moody and Porceli,  2003; Cernadas et al., 
2003; Elewaut et al., 2003). 
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The assembly and traficking of the CD1 molecule through the endocytic pathway is 
regulated by targeting motif in the cytoplasmic tail of CD1 (Porceli, 1995; Jackman 
et al.,  1998;  Cernadas et al.,  2003). Cytoplasmic tail  mutant  CD1  molecules fail to 
redistribute in the cel and acquire defects in antigen  presentation (Jackman et al., 
1998; Briken et al., 2000; Chiu et al., 2002; Sugita et al., 2002; Cernadas et al., 2003; 
Elewaut et al., 2003). The traficking capacity depends on the physical properties, size 
and polarity of the lipids (De Libero et al., 2009). 
 
1.3.3 Group 1 CD1 
	  
Group  1  CD1  molecules are expressed  on  professional antigen  presenting cels 
including DCs, macrophages and B cels (Canchis et al., 1993; Porceli, 1995; Amano 
et al., 1998; Sonoda and Stein-Streilein, 2002). 
 
It  has  been  demonstrated that in  DC  populations, reduction in  CD1a resulted in  up-
regulation of IL-10 production and down-regulation of IL-12 production (Cernadas et 
al.,  2009;  Cernadas et al.,  2010).  Other studies  have also shown that there is  no 
expression  of  CD1a,  CD1b  or  CD1c in  plasmacytoid  DC,  unlike  monocyte  derived 
DC (Liu, 2005). CD1c has also been found on normal and neoplastic B cels (Smith et 
al., 1988). 
 
The  CD1  molecules  bind to lipid and  glycolipid antigens for recognition  by  T cels 
(Briken et al., 2000; Gumperz et al., 2000). CD1b is the first member of group Ι CD1 
molecules that  has  been shown to recognize myolic acid lipid antigen from 
Mycobacterium tuberculosis (Beckman et al.,  1994). The  major  group  of antigens 
identified  by  group  1  CD1  molecules consists  of  mycobactin, acylated 
sulfoglycolipids and mycolic acids (Beckman et al., 1994; Cohen et al., 2009). 
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Mycobactin and lipoarabinomannan are lipids  presented  by  CD1a  molecule,  which 
plays a role in microbial pathogenesis leading to cytotoxic responses (Stenger et al., 
1997; Rosat et al., 1999). 
 
1.3.4 Group 2 CD1 family 
	  
CD1d  molecule is the  only  member  of  group  2  CD1 family and is the  only  CD1 
molecule that is  preserved in  mice (Porceli, 1995; Brigl and  Brenner,  2004). The 
expression of CD1d is extensively broader than group Ι CD1 molecules. It is highly 
expressed in the thymus. Extrathymicaly, it is  highly expressed  on  professional 
antigen  presenting cels including  B cels,  granulocytes,  macrophages and  DCs 
(Brossay et al., 1997; Roark et al., 1998). Additionaly, CD1d appears to be expressed 
on smooth muscle cels in the liver and gut and is also present on epithelial cels and 
parenchymal cels (Blumberg et al., 1991; Canchis et al., 1993). In mouse, CD1d can 
be found in lymph  nodes, thymus, spleen, liver,  kidney and lung (Bradbury et al., 
1990; Brossay et al., 1997). 
 
Based on the crystal structure of CD1d, unlike interactions with classical MHC Class 
I  molecules, the TCR adopts a  unique, paralel docking  mode to  CD1d-glycolipid 
complex orientation, while the  TCR is  positioned in a  diagonal  orientation to  MHC 
Class I molecules (Figure 1.1) (Koch et al., 2005; Borg et al., 2007). 
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The  marine sponge  derivative αGalCer is the  model  CD1d ligand for iNKT cel 
activation. It was first identified during an anti-tumour reagent screening in  mouse 
liver and this revealed the potential of CD1d in anti-tumour responses (Morita et al., 
1995; Kobayashi et al., 1995). A range of glycosylated ceramides, such as αGalCer 
and glycosylphosphatidylinositol have been found to stimulate NKT cels (Kawano et 
al., 1997; Joyce et al., 1998; Burdin et al., 1998). 
 
The ligand αGalCer  has  been a  useful  marker for the analysis  of  CD1d-restricted  T 
cels via activating mouse and human iNKT cels (Morita et al., 1995; Kawano et al., 
1997; Brossay et al., 1998a; Spada et al., 1998; Matsuda et al., 2000). 
 
The glycolipid αGalCer contains an α-anomeric sugar with an 18C sphingosine chain 
and  26C long acyl chain.  The two chains are linked to the  galactose  head  via α 
linkage (Figure 1.2) (Morita et al., 1995; Kawano et al., 1997; Brossay et al., 1998a; 
Figure  1.1: Comparison  of the crystal structures  of TCR recognition  of CD1d 
and MHC class I molecules. 
(a)  NKT  TCR  docking  of  human  CD1d αGalCer complex (b)  TCR  MHC class I 
complex (c)  Paralel  docking  mode  of  NKT  TCR  CDR loops into  human  CD1d-
αGalCer (d) Diagonal docking mode of TCR interaction with MHC class I. Extracted 
from Borg et al. 2007. 
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Spada et al., 1998; Matsuda et al., 2000). CD1d-αGalCer loaded tetramers have been 
created as a more sensitive tool than antibody to identify  both  mouse and  human 
iNKT cels using flow cytometry (Figure 1.2) (Matsuda et al., 2000; Benlagha et al., 
2000). The first synthetic analogue of αGalCer is known as KRN7000, which is used 
to identify and activate  mouse and  human iNKT cel  populations (Kawano et al., 
1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other than αGalCer, α-glycuronosylceramides including α-galacturonosyl 
and α-glucuronosylceramide, a  bacterial  glycosphingolipids expressed  by 
Sphingomonas species, can also  be  presented  by  CD1d and stimulate  NKT cels 
(Kinjo et al.,  2005; Matner et al.,  2005; Sriram et al.,  2005). Another recent study 
found that phosphatidylcholine and sphingomyelin are also commonly recognized by 
the group 2 CD1 family, being the main CD1d associated celular ligands (Yuan et al., 
2009). 
 
 
Figure 1. 1: Structure of human CD1d with αGalCer.  
Extracted from (Koch et al.  2005) (a) interaction  of  CD1d  with αGalCer (α1–α3 
domains, blue; b2M, yelow) with bound αGalCer (orange) (b) chemical structure of 
αGalCer. 
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Several atempts  have  been  undertaken to  discover the self-ligands for  CD1d and 
many glycosphingolipids have been implicated as possible self-ligands. Several lipids 
were claimed to  be the self-lipids for  CD1d, including lysophospholipids and 
sphingomyelin (Yuan et al.,  2009). An initial study suggested that β-linked 
glycosphingolipids could  be a self-glycolipid ligand for  NKT cels (Stanic et al., 
2003).  A subsequent study  pointed to isoglobotrihexosylceramide (iGb3) as a self-
lipid antigen that  was recognised  by iNKT cels (Zhou et al.,  2004). It  was also 
discovered that mice with β-hexoaminidase enzyme deficiency have a defect in iNKT 
cel development, supporting the hypothesis that iGb3 is a key self-ligand for iNKT 
cels (Zhou et al., 2004). However subsequent studies reported that the distributions, 
development and function of iNKT cels were normal in the case of iGb3 deficiency 
(Porubsky et al., 2007). 
 
The finding that iGb3 cannot be detected using mass spectrometry in lymphoid tissue 
has strengthened the conclusion that iGb3  might  not  be a self-ligand for  NKT cel 
development (Van Kaer and Joyce, 2010). These data showed that several self-lipids 
could stimulate iNKT cels but there is no evidence for the involvement of self-lipids 
in the thymic selection of CD1d restricted T cels. 
 
Two other  glycosphingolipids in addition to iGb3,  namely ganglioside (GD3) and 
sulfatide, can also  be recognized  by  CD1d and  have  been  demonstrated as  potential 
natural ligands for iNKT (Blomqvist et al.,  2009).  Glycosphingolipids, in  particular 
sulfatide,  may  have a  major role as antigenic targets in autoimmune  disorders 
including  MS since sulfatide-reactive CD1-restricted  T cels  occurs (De  Libero and 
Mori, 2007;  Halder et al.,  2007; Venkataswamy and  Porceli,  2010). Sulfatide is a 
major component of CNS myelin, which has been found to be recognized by a major 
subset  of CD1d-restricted type I  NKT cels (Jahng et al.,  2004; Ambrosino et al., 
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2007;  Arenberg et al.,  2010). Sulfatide-reactive  T cels  were  detected in the  CNS 
tissue  during  EAE and treatment  of  wild-type  mice  with sulfatide  was shown to 
prevent antigen-induced  EAE (Jahng et al.,  2004). Additionaly, lipid  microaray 
studies  demonstrated that lipid-specific antibodies against sulfatide are  detected in 
CSF derived from MS patients and also in mice with EAE (Kanter et al., 2006). They 
further revealed that immunization  of  mice  with sulfatide  with  myelin  peptides 
exacerbated EAE (Kanter et al., 2006). The specific implications of these findings for 
iNKT cel antigen recognition and function in MS are, as yet, largely unkown. 
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1.4 Invariant NKT cels 
	  
1.4.1 Overview of invariant NKT cels 
	  
iNKT cels uniquely express phenotypic and functional characteristics of both CD1d-
restricted αβ T cel receptor (TCR) and NK cel markers including NK1.1 or (CD161) 
(Bendelac et al., 1995a; Exley et al., 1998). The expression of CD161 is mostly found 
on resting and mature iNKT cels (Godfrey et al., 2004). They also express other NK-
cel markers such as CD94, NKG2D, IL2Rβ (CD122), Ly49A and Ly49C (Bix et al., 
1995;  MacDonald et al.,  1995;  Exley et al.,  1998;  Brigl and  Brenner,  2004). In 
addition to  NK-cel  markers, iNKT cels also express  very early activation  markers 
such as CD69 and costimulatory molecules of memory phenotype including CD62L 
(L-selectin) and  CD44 (MacDonald et al.,  1995;  Cui et al.,  1997;  Bendelac et al., 
1997; Kawano et al., 1997; Hayakawa et al., 2001; Wilson et al., 2002; Kronenberg, 
2005). 
 
Diferent  methods  were  originaly  used to classify iNKT cels.  Firstly, T cels  were 
characterised  using complementary suppressor  T cel  mouse  hybridoma systems, 
which identified a conserved  Vα14-Jα18  TCR (Sumida et al.,  1984;  Sumida and 
Taniguchi, 1985; Imai et al., 1986). Subsequent studies have demonstrated a subset of 
double  negative (CD4-CD8-) thymocytes,  which express  predominantly Vβ8  gene 
with the same Vα14-Jα18 sequence (Budd et al., 1987; Fowlkes et al., 1987). Finaly, 
the invariant Vα24 chain paired to Vβ11 T cels was established in humans in 1994 
(Delabona et al., 1994). 
 
iNKT cels in mouse express an invariant TCRα chain (Vα14-Jα18) associated with a 
limited  number  of β chains (Vβ8.2,  Vβ2 or  Vβ7) (Koseki et al., 1991;  Arase et al., 
1992; Lantz and  Bendelac  1994; Makino et al., 1995; Bendelac et al., 1997). In 
humans, iNKT cels express a  highly conserved  TCR repertoire expressing an 
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invariant Vα24 rearangement (Vα24-Jα18), paired with Vβ11 (Porceli et al., 1993; 
Delabona et al., 1994; Lantz and Bendelac 1994; Exley et al., 1997). 
 
They  develop in the thymus and  have a specific tissue  distribution. iNKT cels are 
believed to be memory, activated and non-naïve when they emerge from the thymus, 
unlike  other  T cels.  Although they represent  only  0.2%  of the  peripheral  T cel 
population in  humans, they  have  been implicated in the regulation  of autoimmunity 
(Linsen et al., 2005; Molano and Porceli, 2006). They can rapidly secrete a variety of 
cytokines including IL-2, IL-4, IL-5, IL-13, IL-10, IFN-γ, Tumour Necrosis Factor-α 
(TNF-α) and transforming  growth factor-β (TGF-β)  within  minutes  of activation 
(Takahashi et al.,  2000;  Linsen et al.,  2005).  This can in turn lead to secondary 
activation of a variety of innate and adaptive immune cels including DCs, NK cels, 
B cels and modulation of Th cel responses (Linsen et al., 2005; Molano and Porceli, 
2006). 
 
1.4.2 Tissue distribution of invariant NKT cels  
	  
NKT cels have a specific tissue distribution. In mice, they are found predominantly 
in thymus, spleen, liver and  bone  marow and  with reduced frequencies in the 
peripheral blood (Eberl et al., 1999a). The frequency of iNKT cels varies widely in 
diferent tissues.  For example, in  mice, they represent 30-50%  of  T lymphocytes in 
the liver and 20% of T cels in bone marow. iNKT cels only represent about 2-5% of 
splenic T lymphocytes. Surprisingly, in the thymus where they develop and mature, 
iNKT cels only represent 0.3-0.5% of thymocytes (Godfrey et al., 2000). iNKT cels 
are extremely rare in peripheral lymph nodes and gut (Bendelac et al., 1994; Bendelac 
et al., 1997; Godfrey et al.,  2000;  Matsuda et al., 2000). In  humans, iNKT cels are 
not as frequent as mouse iNKT cels and most studies have been limited to peripheral 
blood.  A  much lower frequency  of  Vα24 iNKT cels are found in the  human liver 
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compared to mice (Doherty et al., 1999). They have been found in human peripheral 
blood lymphocytes (0.1-0.2%) and  hepatic  T cels (0.5%) (Exley et al., 2002; 
Gumperz et al.,  2002;  Lee et al.,  2002;  Kenna et al., 2003;  Montoya et al.,  2007; 
Brennan et al., 2013). The distribution of iNKT cels in other human tissues has not 
been as extensively studied as in mice and remains to be determined. 
 
1.4.3 Subsets of invariant NKT cels 
	  
Both  humans and  mice  have similar iNKT cels characteristics (Table  1.3). iNKT 
cels are  divided  mainly into  CD4+  CD8־ and  CD4־  CD8־ (double  negative,  DN) cel 
subsets (Godfrey et al., 2000; Linsen et al., 2005; Sakuishi et al., 2010). Studies have 
identified  CD8+ iNKT cels in  wild type  mice and  humans,  which  produced 
predominantly IFN-γ and less IL-4 upon αGalCer stimulation (Takahashi et al., 2002; 
Lee et al.,  2009). In  humans, a  number  of iNKT cels express  CD8α  but  barely 
express CD8β (Linsen et al., 2005;  Sakuishi et al., 2010) and  40 to  60%  of   iNKT 
cels are CD4+ (Linsen et al., 2005; Sakuishi et al., 2010). The CD4+ subsets are able 
to produce Th1 (TNF-α and IFN-γ) and Th2 (IL-4, IL-5, IL-10 and IL-13) cytokines 
(Bendelac et al.,  1997; Chen and  Paul,  1997; Wilson et al.,  1998).  The  DN subset 
produces  only  Th1 cytokines (Exley et al.,  1997; Gumperz et al.  2002;  Lee et al. 
2002; Sakuishi et al., 2010). Moreover, CCR4 chemokine receptors are expressed on 
CD4+ NKT cels but CCR6, CCR1 and CXCR6 on DN NKT cels (Kim et al., 2002a; 
Linsen et al., 2005; Sakuishi et al., 2010). 
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Characteristic Mouse iNKT cels Human iNKT cels 
Major Subset CD4
+/DN 
CD8+ 
CD4+/DN 
CD8+ 
T cel receptor Vα14/ Vβ8, Vβ7 or Vβ2 
Vα24/Vβ11 
 
Accessory molecules (NK 
associated) 
NK1.1 
CD122 
Ly 49 
NKR-P1 
CD122 
Restriction element CD1d CD1d 
Antigen Glycolipids Glycolipids 
Cytokine production CD4
+ produce Th1 and Th2/ 
DN and CD8+ produces Th1 
CD4+ produce Th1 and Th2/ 
DN and CD8+produces Th1 
Frequency (PBL) 1% 0.1-0.5% 
Table 1.3: iNKT cels features in mouse and human.  
Extracted from Bendelac et al., 1997; Chen and Paul, 1997; Exley et al., 1997; Wilson 
et al., 1998; Godfrey et al., 2000; Takahashi et al., 2002; Lee et al., 2009; Sakuishi et 
al., 2010. 
 
 
1.4.4 Development of invariant NKT cels 
	  
iNKT cels develop in the thymus as per other T lymphocytes (Bendelac et al., 1995b; 
Eberl et al., 1999a; Tiloy et al., 1999; Pelicci et al.,  2002; Benlagha et al., 2002). 
Moreover, Vα14 TCR gene rearangements can develop in bone marow, foetal liver 
and intestine (Makino et al., 1994; Shimamura et al., 1997). 
 
iNKT cels originate mainly in the thymus where they undergo positive and negative 
selection.  The  positive selection requires the  presence  of  CD1 cortical thymocytes, 
which  gives rise to  CD4+  or  DN iNKT cels (Bendelac,  1995b;  Coles and  Raulet, 
2000;  Gapin et al., 2001). The  negative selection  of iNKT cels contributes to the 
interaction  of  CD8  with  CD1d,  which increase avidity  of immature iNKT cels for 
CD1d (Bendelac et al., 1994; Bendelac et al., 1997). 
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There are two  proposed  models that explain the  possible  mechanisms  of iNKT cel 
thymic development. The mainstream model suggests that iNKT cels arise after TCR 
expression and interaction with CD1d iNKT cel ligand (Bendelac et al., 1997). The 
double-positive (DP) precursors with randomly rearanged Vα14 TCR α and β chains 
alows interaction with CD1d ligands expressed by cortical thymocytes before lineage 
commitment, and down regulate CD4 and CD8, arising as either CD4+ or CD4-CD8- 
mature iNKT cels (Lantz and Bendelac 1994; Bendelac et al., 1995b; Pelicci et al., 
2002). After positive selection, DP immature cortical thymocytes are CD44low NK1.1–
, and do not yet appear to express NK receptors (Gapin et al., 2001). During further 
development and maturation they progress to CD44high NK1.1– then CD44high NK1.1+ 
and  by acquiring the  NK  markers they turn into  mature Vα14+ T cels (Gapin et al, 
2001; Benlagha et al., 2002; Matsuda and Gapin, 2005). 
 
By contrast the  pre-commitment  model, suggests that iNKT cels  diferentiate from 
commited precursor cels that are discrete from conventional T lymphocytes before 
TCR expression. This model requires that iNKT precursor cels subsequently express 
the invariant TCR to be selected by CD1d for maturation (Bendelac et al., 1997; Sato 
et al., 1999; Kronenberg, 2005; Bendelac et al., 2007). 
 
1.4.5 Invariant NKT cels homing and migration 
	  
Studies tracking iNKT cel  development  process  with  CD1d tetramers  have 
demonstrated that iNKT cels develop in the thymus and are absent at birth (Matsuda 
et al., 2000; Gapin et al., 2001; Benlagha et al., 2002; Pelicci et al., 2002; Matsuda 
and  Gapin, 2005). In  mice, iNKT cels  gradualy accumulate in several  peripheral 
organs and reach a  plateau  by  6-8  weeks  of age (Bendelac et al.,  1994;  Ohteki and 
MacDonald,  1994; Pelicci et al.,  2002).  Once they reach these  organs they  may 
possibly migrate to inflamed tissue or diferent organs. The circulation and migration 
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of iNKT cels is regulated by adherence molecules or by chemokines (Ohteki et al., 
1999). It  has  been  demonstrated that  Leukocyte  Function-Associated  Antigen-1 
(LFA-1) has an essential role in accumulation of iNKT cels in the liver (Emoto et al., 
1999a). Moreover, it has been shown that Macrophage Inflammatory Protein-2 (MIP-
2) can recruit iNKT cels to the splenic  marginal zone  during tolerance induction 
(Faunce et al., 2001). Furthermore, Monocyte Chemotactic Protein-1 (MCP-1) led to 
the accumulation  of iNKT cels in a  MCP-1-dependent  manner in the lung after 
cryptococcal infection and  played a crucial role in the  production  of  Th1 cytokines 
and resistance to this fungal infection (Kawakami et al., 2001). 
 
1.4.6 Factors influencing the development of invariant NKT cels 
	  
The expressions  of several transcription factors are required for iNKT cel 
development including NF-κB1, RelB and κB inhibitor gene (Sivakumar et al., 2003; 
Schmidt-Supprian et al.,  2004).  Moreover it  has  been identified that T-bet, a  T-box 
transcription factor is required for Th1 cel diferentiation, also has an important role 
in the terminal maturation and peripheral homeostasis of iNKT cels (Townsend et al., 
2004). Other studies  demonstrate a critical role  of  GATA-3, a  T cel-specific 
transcription factor in the development, survival, activation and efector functions of 
iNKT cels (Kim et al.,  2006a).  The transcription factor Promyelocytic  Leukaemia 
Zinc  Finger (PLZF)  may control the  development  of  CD1d-restricted iNKT cels 
(Savage et al., 2008; Kovalovsky et al., 2008). Mice lacking PLZF have a substantial 
reduction in iNKT cel  numbers  with the residual iNKT cels failing expansion and 
efector diferentiation, displaying a naïve phenotype (Savage et al., 2008). 
 
Other studies  demonstrated that c-Myc is another transcription factor,  which is 
required for iNKT cel development (Dose et al., 2009; Dose and Gounari, 2009). It 
has been shown that c- Myc is required for iNKT cel proliferation (Dose et al., 2009). 
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The signaling lymphocytic activation molecule (SLAM) family  of receptors are 
known to  be associated  with  SLAM-associated  protein (SAP)  which  have a crucial 
role in iNKT cel development, Th2 cel priming and NK cels activation (Veilete, 
2006). The  SLAM family consists  of  nine  members  named SLAM1,  SLAM8, 
SLAM9, 2B4, CD319, CD84, NTBA and Ly9 (Veilete et al., 2006; Godfrey et al., 
2010). iNKT cels are dependent on the interaction between SLAM proteins with the 
SAP family through tyrosine-based motifs compared to other T cel subsets (Sayos et 
al.,  1998;  Godfrey et al.,  2010).  Phosphorylation events  occur folowing the  SAP-
SLAM interaction, alowing the recruitment of FYN to the TCR complex (Latour et 
al., 2001). Studies have demonstrated that iNKT cels are extremely reliant on signals 
provided by the SLAM proteins. Mice lacking SAP have shown severe deficiency in 
iNKT cels as seen in  patients  with  X-linked lymphoproliferative (XLP)  disease 
secondary to SAP mutation (Gadue et al., 1999; Chung et al., 2005; Nicholas et al., 
2005;  Pasquier et al.,  2005). It  has  been  demonstrated that  Slamf1 (SLAM) and 
Slamf6 (Ly108) are essential for iNKT cel lineage  development (Griewank et al., 
2007). Another study showed that Fyn-deficient mice have reduced numbers of iNKT 
cel and transgenic expression  of the canonical Vα14-Jα18 TCR α chain resulted in 
restoration  of iNKT cel  development, suggesting that  Fyn acts at early stage  of 
development before alpha-chain rearangement (Gadue et al., 2004). 
 
1.4.6.1 Cytokine and chemokine support for invariant NKT cel development 
	  
It is  most likely that the  mechanisms through  which transcription factors  have an 
efect on the development of iNKT cels are associated with the presence of diferent 
cytokine and chemokines. It has been shown that TGF-β receptor deficiency resulted 
in blockage in iNKT cel development (Marie et al., 2006). In mice deficient in genes 
encoding IL-2R  beta/IL-15 receptor  beta chain, the frequency  of iNKT cels is 
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significantly  decreased,  demonstrating that components  of the IL-15  pathway 
including IL-15, IL-15Rα, and IL-2/15Rβ plays a vital role in iNKT cel development 
(Ohteki et al.,  1997). Interferon regulatory factor  1 (IRF-1) is required for the 
development of iNKT cels via regulating IL-15 gene expression (Ohteki et al., 1998). 
Also it has been revealed that the Src protein tyrosine kinase Fyn is required for iNKT 
cel  development (Eberl et al.,  1999b).  These cytokines including IL-2, IL-7, IL-15 
and IL-21 are known to be important in the proliferation and survival of iNKT cels 
(Vicari et al., 1994; Ohteki et al.,  1997; Coquet et al.,  2007). IL-18 and IL-12 can 
augment the kiling activity of iNKT cels via perforin-dependent pathway (Dao et al., 
1998; Papamichail et al., 2004). 
 
The requirements for costimulation in the activation  of iNKT cels and cytokine 
production have been investigated. Studies have demonstrated that blockade of CD28-
CD80/CD86 signals by anti-CD80 and anti-CD86 antibodies inhibited IFN-γ and IL-4 
production  by  NKT cels,  while  blockade  of CD40-CD154 signals  by anti-CD154 
antibody inhibited  only IFN-γ production (Hayakawa et al.,  2001; Uldrich et al., 
2005). More recently, the co-stimulartory  molecule  Glucocorticoid-induced  TNF 
receptor (GITR) was found to co-stimulate iNKT cel activation (Kim et al., 2006b). 
 
1.4.7 Invariant NKT cels activation and downstream events 
	  
Several mechanisms  have  been  proposed for iNKT cel-mediated regulation  of 
autoimmunity. In general, CD1d/glycolipid complexes are exported to the cel surface 
by the support  of lipid transfer  proteins as saposins and interact  directly  with iNKT 
cels, leading to Th1 and  Th2 cytokine  production  by these cels (Bendelac et al., 
1997;  Mars et al.,  2004;  Bendelac et al.,  2007;  Wu et al.,  2009).   Some studies  of 
iNKT regulation of autoimmunity in the NOD diabetes model and EAE reported that 
Th2 cytokine  production including IL-4 and IL-10  via activated iNKT cels is 
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protective,  while  Th1 cytokines such as IFN-γ exacerbate the  disease (Hammond et 
al.,  1998;  Pal et al.,  2001;  Miyamoto et al.,  2001;  Sharif et al.,  2002).  However, 
Furlan et al., (2003) showed a protective efect of IFN-γ by activated iNKT cels in 
EAE. It was also found that antigen-stimulated iNKT cels resulted in early activation 
of B cels through IL-4 production and upregulation of the activation marker CD69 on 
B and  NKT cels (Kitamura et al.,  2000).  Activated iNKT cels induce  other cels 
including  NK cels,  CD4+  T cels,  CD8+  T cels,  B cels and  macrophages  by 
cytokines  production  or influence these cels  directly through receptor interactions 
(Nishamura et al.,  2000;  Mars et al.,  2004).  Moreover, it  was  demonstrated that as 
early as  90  min folowing in  vivo  with αGalCer stimulation, the cytokine storm 
released  by activated iNKT could activate  NK cels through IFN-γ  production and 
CD69 induction (Carnaud et al., 1999).  
 
They  may also influence the  maturation and  diferentiation  of  DCs resulting in 
tolerogenic  DCs (Vincent et al.,  2002;  Fuji et al.,  2003a). Upon activation  by 
αGalCer, CD4+ NKT cels upregulate their  CD40 ligand expression,  which engages 
CD40 on APC and stimulates the production of IL-12 (Tomura et al., 1996). Another 
proposed  mechanism is that activated iNKT cels are able to kil autoreactive 
lymphocytes by Fas and perforin dependent mechanisms (Nicol et al., 2000; Kaneko 
et al.,  2000). Additionaly, iNKT cels can  migrate to the site  of the infection in 
tissues  because they express  diferent adhesion  molecules and chemokine receptors 
(CCR1, CCR6, CCR4, and CXCR6) (Kim et al., 2002a; Kim et al., 2002b; Gumperz 
et al.,  2002; Thomas et al.,  2003). For that reasons, iNKT cels influence the innate 
and the adaptive immune responses and contribute to  host  defence, anti-tumour and 
imune regulation (Figure  1.3) (MacDonald et al., 1995;  Schaible and Kaufmann, 
2000b; Brutkiewicz and Sriram, 2002; Gumperz et al., 2002). 
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1.4.8 Functions of invariant NKT cels 
	  
1.4.8.1 Antiviral functions of invariant NKT cels 
	  
iNKT cels are known to play a critical role against bacterial, viral, fungal, as wel as 
parasitic infections. Several studies  have focused  on the relationship  between  viral 
load and iNKT cels.  Many studies  have  demonstrated  decreased  numbers  of iNKT 
cels in the  peripheral  blood  of  human subjects  with  viral infection (Tessmer et al., 
2009). CD1d-restricted human iNKT cels were markedly decreased in the peripheral 
blood of HIV-1 infected individuals and this might be due to the high expression of 
co-receptors CCR5 and CXCR6 on iNKT cels making the CD4 iNKT cels directly 
targeted by HIV-1 (van der Vliet et al., 2002; Motsinger et al., 2002). In hepatitis B 
virus (HBV) transgenic  mice, injection  with αGalCer inhibited  virus replication in 
vivo  by activating iNKT and  NK cels to secrete antiviral cytokines (Kakimi et al., 
2000). Moreover, significant reduction in iNKT cel numbers with no variation in T, 
B and  NK cels  numbers  was  demonstrated in  EBV associated  X-linked 
lymphoproliferative disease (Rigaud et al., 2006). 
Figure 1.2: How NKT cels influence the immune response. 
Extracted from Godfrey et al., 2004. 
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1.4.8.2 Invariant NKT cels in anti-microbial and anti-parasite immunity 
 
Several studies  have thoroughly addressed the  participation  of iNKT cels in anti-
microbial responses. iNKT cels are thought to  be involved in  direct  microbial 
recognition,  mediate cytotoxicity, and they can  modulate immune responses  by 
influencing  NK cels (Skold and  Behar,  2003). Microbial glycolipds are found in 
Sphingomonas spp,  which, can  be recognized as antigens  by the iNKT cels (Kinjo 
and  Kronenberg,  2005). On the  other  hand, some  microbes such as extracelular 
bacteria Salmonela spp. and E.coli cannot  be recognized  by iNKT cel,  but they 
activate NKT cels through DC maturation and production of cytokines such as IL-12 
(Brigl et al., 2003; Tupin et al., 2007). It has been demonstrated that IFN-γ production 
by  CD4+  NKT through IL-12 induction  may contribute to  host resistance against 
Mycobacterium  bovis (Emoto et al., 1999b). Moreover,  during Toxoplasma  gondi 
infection, CD4+ NKT cels initiate Th2 responses through IL-4 secretion and also play 
a role in the  generation  of  CD8+ efector function mediating  host resistance to 
infection (Denkers et al., 1996). In experimental models of Cryptococcus neoformans, 
activation of CD1d restricted iNKT cels resulted in IFN-γ secretion, induction of Th1 
response and local  host resistance (Kawakami et al., 1994;  Kawakami et al., 2001). 
Furthermore, CD1d-restricted NKT cels promote Th2 immune responses through B 
cel  proliferation resulting in malarial splenomegaly and enhance  parasite antibody 
production against Plasmodium berghei infection (Hansen et al., 2003). 
 
1.4.8.3 Invariant NKT cels and anti-tumour responses 
	  
Apart from  protection against  microorganisms and autoimmunity, a  potentialy 
important protective role for iNKT cels was shown in surveilance of cancers. iNKT 
cels are reduced in cancer-bearing humans and mice (Tahir et al., 2001; Dhodapkar et 
al., 2003). Multiple mechanisms contribute to iNKT cels deficiency. The glycolipid 
antigen αGalCer was firstly recognized by iNKT cels while screening for anticancer 
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agents (Kobayashi et al., 1995; Motoki et al., 1995). iNKT cels can atain a protective 
efect in tumour responses either through the recognition  of self  glycolipid antigens 
presented  on  CD1 tumours  or  via the secretion  of cytokines and chemokines,  which 
activate DC, NK cels and cytotoxic T cels (Nishimura et al., 2000; Metelitsa et al., 
2001; Hayakawa et al., 2002; Baxevanis et al., 2003; Gilessen et al., 2003). Activated 
iNKT cels  produces large amount  of cytokines including IFN-γ,  which is, required 
for the initiation  of anti-tumour  Th1 responses. The  vital role  of IFN-γ has  been 
demonstrated in iNKT cel  deficient and IFN-γ  deficient  mice  demonstrating that 
IFN-γ  production  by iNKT cels  was absolutely required to reconstitute the anti-
metastatic activity after adoptive transfer  of αGalCer  primed cels (Smyth et al., 
2002). Adoptive transfer of iNKT cels to NKT deficient mice demonstrated a critical 
role for iNKT cels in tumour immunosurveilance against  methylcholanthrene 
(MCA)-induced sarcomas (Crowe et al.,  2002).  Other studies  have also  discovered 
that iNKT cels are required for IL-12-mediated rejection  of tumours (Cui et al., 
1997). It  was also reported in the  B16  melanoma  mouse  model  where  mice  were 
injected  with dendritic cels  pulsed  with αGalCer, antitumor cytotoxic activity  was 
induced, resulting in inhibition of tumour metastasis (Toura et al., 1999). 
 
Sustained expansion  of iNKT cels  was  demonstrated in advanced cancer  patients 
after injection with  monocyte  derived  mature  DCs that  were loaded  with αGalCer 
(Chang et al., 2005). iNKT cels activation was associated with increase secretion of 
IL-12 and IFN-γ suggesting that iNKT activation  might enhance adaptive  T cel 
immunity. In  prostate cancer and  diferent solid form cancer  patients, it  has  been 
shown that the number of iNKT cels and the amount of IFN-γ production is markedly 
decreased even  with αGalCer stimulation (Tahir et al.,  2001; Yanagisawa et al., 
2002). Also, studies have shown that patients with myelodysplastic syndrome (MDS) 
have  marked  deficiency in iNKT cels (Fuji et al.,  2003b). More recently, it  was 
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suggested that circulating myeloid dendritic cels in patients with advanced melanoma 
and renal cel cancer resulted in reduced iNKT cels activation and  Th1 cytokine 
production (Van  der  Vliet et al.,  2008). In contrast, it  was found that the frequency 
and function of iNKT cels are preserved in patients with glioma (Dhodapkar et al., 
2004).  Expanded iNKT cels using autologous  mature  dendritic cels loaded  with 
αGalCer from patients with glioma were found to exhibit antitumour lytic activity and 
mediate direct cytotoxicity (Dhodapkar et al., 2004). In colorectal carcinoma patients, 
an increased intratumour number of iNKT cels were observed, with patients having 
high iNKT cels infiltration showing a  higher  overal  disease free survival rate 
(Tachibana et al., 2005). In conclusion, studies have shown that iNKT cels in cancer 
patients  have  variable functional and  numerical  defects  depending  on the tumour 
models, stage and type. 
	  
1.4.8.4 Relevance of invariant NKT cels to autoimmune diseases 
	  
Systemic Lupus Erythematosus (SLE) 
Studies reported a reduction in invariant  Vα14  NKT cels in  mice  preceding the 
development of autoimmune manifestations in in the hydrocarbon oil-induced model 
of lupus nephritis (Mieza et al., 1996; Yang et al., 2003). In the study by Yang et al., 
(2003), CD1d deficient mice developed severe lupus nephritis suggesting that CD1d 
may play a role in the development of lupus. Conversely, iNKT cel stimulation with 
αGalCer  protects against  SLE autoimmunity  development in  mice  but aggravates 
atherosclerosis (Major et al.,  2006).  Other studies  have shown that iNKT cels 
increase in aging  NZB/W  mice and  promote the  production  of anti-DNA antibodies 
by B cels resulting in disease exacerbation (Zeng et al., 2003; Forestier et al., 2005). 
These conflicting results may suggest a protective role for iNKT cels before disease 
onset  but exacerbation  of  disease  once established (Mars et al.,  2004). Studies  have 
demonstrated reduced levels  of iNKT cels in  peripheral  blood  of  SLE and  RA 
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patients (Kojo et al., 2001; Van der Vilet et al., 2001).  
 
Diabetes Melitus (DM) 
In the  NOD  mouse  model,  numericaly and functionaly  deficient iNKT cels  have 
been found to corelate with enhanced disease (Gombert et al., 1996; Hammond et al., 
1998). It has also been shown that the activation of iNKT cels with glycolipid ligands 
such as αGalCer  prevents the  development  of  diabetes in  mice (Hong et al.,  2001; 
Sharif et al., 2002). Adoptive transfer of NKT thymocytes or transgenic expression of 
CD1d  molecules prevented insulin  dependent  diabetes  melitus in  NOD  mice 
(Hammond et al.,  1998;  Sharif et al.,  2001;  Hong et al.,  2001;  Sharif et al.,  2002). 
This  protection is associated  with stimulation and  proliferation  of  CD1-dependent 
NKT cels to  produce IL-4 and IL-10 and in vivo  blockade  of IL-10 abrogated this 
protective efect (Sharif et al., 2002). Reduced numbers and functions of iNKT cels 
were also  demonstrated in  diabetic  patients (Wilson et al.,  1998). These findings 
suggest that the  development  of SLE and  DM in  human and  mice  models is 
associated with defects in iNKT cels number and function. 
 
The role  of iNKT cels in  MS  has  been already  discussed in (section 1.1.8.7).  The 
regulatory function  of activated iNKT cels  has  been implicated in the regulation  of 
autoimmunity in  MS, especialy  by extrapolation from  EAE  models.  However, the 
detailed mechanisms of immune regulation remain to be identified. 
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1.5  Receptors expressed  on invariant  NKT cels and shared with 
other lymphocyte populations 
 
1.5.1 CD62L (L-selectin) 
	  
CD62L is a  key cel adhesion  molecule  belonging to the selectin family  of 
adhesion/homing  proteins that  have an essential role in lymphocyte endothelial cel 
interactions (Wedepohl,  2012).  L-selectin acts as a lymphocyte  homing receptor 
which  mediates the  migration  of leukocyte from the  peripheral  blood to secondary 
lymphoid organs via binding to their ligands (addressins) on high endothelial venules 
(HEV) (Nakache et al., 1989; Picker and Butcher, 1992; Mebius and Watson, 1993; 
Springer, 1994; Wedepohl, 2012). 
 
The creation of murine antibodies to HEV and chimeric human L-selectin- IgG fusion 
protein  has  permited the discovery of three sulphated  L-selectin ligands,  Sgp50, 
Sgp90 and Sgp200, that bind specificaly to L-selectin  (Streeter et al., 1988; Berg et 
al.,  1989; Watson et al.,  1990; Imai et al.,  1991;  Lasky et al.,  1992;  Briskin et al., 
1993).  MAdCAM-1 is another ligand  not specific for  L-selectin (Berg et al.,  1993), 
but acting as a ligand for α4β7-integrins (Hamann et al.,  1994). It  has  been 
demonstrated that α4β7-integrins have an important role in lymphocyte migration to 
mucosal sites (Hamann et al., 1994). 
 
In MS, the mechanism which alows mononuclear cel infiltration to the CNS requires 
adherence  between cel surface  molecules  on endothelium and leukocytes. Onset, 
relapse or remission of MS likely depend on recruitment of lymphocytes into the CNS 
as a result  of alterations in leukocyte  binding to endothelial cels at the  BBB and 
changes in the expression of adhesion molecules and activation markers.  
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Interactions between leukocyte and endothelium are mediated by adhesion molecules, 
including integrins (VLA-4,  CD11 and  CD18), selectins (L,  E and  P) and 
immunoglobulin family (ICAM-1 and VCAM-1) (Cronstein and Weissmann, 1993). 
On the  basis  of the  observation  of integrins and  vascular addressins  on endothelial 
cels  within  CNS tissue in  MS, it  was suggested that endothelial adhesion  molecule 
up-regulation is a  pathogenetic  process that  might  be fundamental to immune-
mediated  demyelination in  MS  pathology (Raine et al.,  1990). The expression  of 
lymphocyte/endothelial cel adhesion  molecules  was also increased  during  EAE 
(Raine et al., 1990). Another study demonstrated that blood mononuclear cels from 
MS  patients  were extensively  more adherent to cytokine-treated endothelial 
monolayers compared to healthy controls and this enhanced adhesion was property of 
CD4+ cels (Vora et al.,  1996).  Flow cytometry analysis  of cel adhesion  molecules 
revealed that the percentage of CD4+ and CD8+ lymphocytes expressing CD62L was 
significantly increased in MS patients peripheral blood compared to healthy controls, 
but the level of CD62L expression was decreased (Vora et al., 1996). 
 
1.5.2 CD25 
	  
The alpha chain  of the IL-2 receptor is known as  CD25. It is a cel surface  marker 
used to diferentiate between regulatory, activated and naïve CD25 T cels in humans 
(Thornton and Shevach, 2000; Dieckmann et al., 2001). 
 
Matesanz and coleagues investigated the involvement of SNPs at positions 384 and 
114 in IL-2  with  MS and  demonstrated that the Il-2  gene is associated  with 
susceptibility to SPMS (Matesanz et al., 2001). Mutation of the IL2RA/CD25 results 
in human immune aberation characterised by reduced frequency and abnormal 
proliferation of  peripheral  T cels (Sharfe et al.,  1997).  Furthermore, massive 
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lymphocytic infiltration, tissue atrophy and inflammation of  multiple tissues  were 
demonstrated (Sharfe et al., 1997). 
 
The notion that IL-2 mediate T-cel immunity was chalenged by the idea that mice 
lacking interleukin-2 receptor  have  normal immune responses,  however IL-2  was 
found to regulate the size and content of the peripheral lymphoid tissues and prevent 
autoimmunity (Kundig et al.,  1993;  Wilerford et al.,  1995;  Suzuki et al.,  1995). 
Subsequent studies  discovered a  vital role for IL-2 signaling in apoptosis,  which 
regulate  T cel  proliferation and predispose  T lymphocytes to Fas-mediated 
activation-induced cel  death (Lenardo et al.,  1991;  Van  Parijs et al.,  1999).  These 
studies highlighted an important role for IL-2 in immune regulation observed in IL-2 
deficient mice where they developed T-cel expansion and autoimmunity. 
 
Humans  with CD25  deficiency also  developed severe immune  dysregulation, 
lymphoproliferation, chronic inflammation and autoimmunity (Sharfe et al.,  1997; 
Roifman, 2000; Caudy et al., 2007). These findings demonstrated that the role of IL-2 
in immunity is extremely complicated and contains  both immune-stimulatory and 
immune-regulatory properties. 
 
The vital role of CD25 is evidenced by the utilisation of CD25 targeting therapies for 
prevention of alogeneic immune rejection after transplantation, chronic inflammation 
and autoimmune  diseases (Waldmann and  O'Shea,  1998;  Waldmann et al.,  2002). 
Daclizumab is a  humanized  monoclonal antibody targeting IL-2α receptor (CD25) 
designed to selectively inhibit activated  T cels and stimulates immune regulatory 
CD56bright NK cels (Quee et al., 1989). 
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It was reported that daclizumab therapy resulted in 78% reduction in MRI activity and 
sustained clinical improvement in MS patients failing clinicaly and radiologicaly to 
respond to IFNβ (Bielekova et al., 2004; Rose et al., 2004). Daclizumab monotherapy 
was found to  be efective in  most  MS  patients after  6  months  of IFNβ/Daclizumab 
combination therapy (Bielekova et al.,  2009).  Recent studies  demonstrated that 
daclizumab  monotherapy led to an  87.7% reduction in  MRI  brain  CELs and 
stabilized/improved clinical disease activity in  untreated  RRMS  patients  which is 
associated  with the expansion  of CD56bright NK cels in  CSF and  peripheral  blood 
(Bielekova et al., 2011). 
 
In conclusion,  daclizumab treatment  has an exclusive  mechanism  of action that  has 
multifactorial immunomodulatory  properties that result in inhibition  of  MS 
inflammation. Genetic association between IL-2Rα (CD25) and several autoimmune 
disorders such as MS and type 1 diabetes has established the vital involvement of IL-
2 in the regulation of the immune responses (Hafler et al., 2007; Lowe et al., 2007; 
Maier et al., 2009).  
 
1.5.3 CD161  
	  
CD161 is a  marker  of lymphocyte activation expressed  on NK cels, CD4+ T cels, 
CD8+ T cels and NKT cels. It has been demonstrated that CD161 act as a marker for 
Th17 cels in the  peripheral  blood and in inflamed tissues since IL-17  producing 
CD4+  T cels from  psoriatic  patient’s skin and from the  gut  of  patients  with  Crohn 
disease  were contained  by the  CD161+ fraction (Cosmi et al.,  2008).  CD161 is the 
equivalent of murine NK1.1 and was discovered to be one of the main up-regulated 
genes in human Th17 clones compared with Th1 and Th2 clones (Cosmi et al., 2008).  
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It has been found that IL-12 induces Th1 development and IL-23 is involved in Th17 
development,  but they  vary  due to the existence  of the  p35 (IL-12)  or  p19 (IL-23) 
chain. Some studies found that  EAE, colagen induced arthritis and  bowel 
inflammatory disorders was improved in mice deficient in the p19 (IL-23) gene, while 
the autoimmune  disease increased in severity in  p35 (IL-12) deficient  mice (Cua et 
al., 2003; Murphy et al., 2003). 
 
IL-17  has  been  detected in active lesions  of  MS by in situ  hybridization and 
immunohistochemistry suggesting an important role for IL-17 in  MS  pathogenesis 
(Tzartos et al., 2008). Furthermore, the expression of IL-17 and IL-22 receptors has 
been observed on BBB endothelial cels in MS lesions promoting BBB tight junctions 
disruption and CNS inflammation through CD4+ lymphocyte infiltration (Kebir et al., 
2007). O’Keefe and coleagues  demonstrated that the  percentage  of  T cels 
expressing CD161 was significantly decreased in the peripheral blood of MS patients 
compared to healthy controls (O’Keefe et al., 2008). 
 
1.5.4 CD69 
	  
CD69 is one of the earliest cel surface activation markers expressed by T cels upon 
activation (Ziegler et al., 1994). CD69 is a type I C-lectin, which upon activation acts 
as a co-stimulatory  molecule influencing  T cel activation and  proliferation (Alari-
Pahissa et al., 2012). In addition, CD69 is expressed by mature thymocytes, NK cels, 
B cels, neutrophils, eosinophils, monocytes, and platelets (Ziegler et al., 1994). The 
majority  of  C-type lectin receptors are expressed abundantly  by  dendritic cels and 
langerhans cels and regulate the maturation and migration of dendritic cels through 
influencing  Tol-like receptors (TLR) (Figdor et al.,  2002;  van  Vliet et al.,  2008). 
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Stimulation of CD69 induces lymphocyte proliferation through IL-2, CD25 and IFN-γ 
gene expression (Testi et al., 1989). 
 
Expression  of  CD69  has  been  widely reported in  various infections (Bohleret al., 
1999;  Vega-Ramos et al.,  2010) and autoimmune  diseases (Iannone et al.,  1996; 
Portales-Perez et al.,  1997; Ishikawa et al.,  1998;  Atzeni et al.,  2004) and  human 
cancers (Esplugues et al., 2003). Spontaneous and PHA-induced CD69 expression on 
CD4+ and CD8+ T cels increased with increasing viral load from peripheral blood of 
HIV-1-infected paediatric  patients (Bohleret al.,  1999). Listeria  monocytogenes 
infected CD69 deficient mice displayed increased apoptosis of splenocytes, liver and 
spleen  damage and  higher susceptibility to infection compared to controls (Vega-
Ramos et al., 2010). 
 
Up-regulation  of  CD69 expression in the synovial fluid  of  patients  with rheumatoid 
arthritis corelated  with  disease activity (Iannone et al.,  1996).  Also, it  has  been 
demonstrated that CD69 expression is significantly increased on peripheral blood and 
synovial fluid  neutrophils from patients  with rheumatoid arthritis compared  with 
control  neutrophils (Atzeni et al.,  2004).  PMA-induced  CD69 expression  was 
significantly decreased in T cels from patients with SLE (Portales-Perez et al., 1997). 
Moreover, in murine lupus model, CD69+CD4+ T cels were significantly increased in 
peripheral lymphoid tissues, kidney and lung through abnormal regulatory efects on 
IL-2, IL-3, and IL-4 cytokine production (Ishikawa et al., 1998). 
 
Significant reduction in tumour  growth  was  observed in tumour-bearing  CD69 
deficient  mice compared to  wild-type  mice (Esplugues et al.,  2003). The  negative 
regulatory role for  CD69  was  mediated  by  NK and  T cels and  was also related to 
increased chemokine  production, reduced  TGF-β  production and  diminished 
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lymphocyte apoptosis (Esplugues et al.,  2003). Also in vivo treatment  with the anti-
CD69 antibody therapy reproduced the phenotype of the CD69 deficient mice where 
it antagonized tumour  growth and  metastasis and increased autoimmune and 
inflammatory responses (Esplugues et al., 2005; Sancho et al, 2003). 
 
1.5.5 CD195 
	  
Chemokines are low molecular  weight cytokines that stimulate the recruitment  of 
leukocytes to inflamed tissue (Luster, 1998). Chemokine receptor type 5, also known 
as CCR5 or CD195, is expressed on Th1 efector cels (Moser and Loetscher, 2001; 
Rot and von Andrian, 2004). 
 
The frequency of CD4+ CCR5+ T cels was found to be increased in peripheral blood 
of MS patients but Fas expression was significantly decreased in these cels compared 
to healthy controls, making them resistant to apoptosis and favouring their migration 
into the CNS (Julia et al., 2006). It was found that CCR5+ T cels were increased in 
peripheral  blood  of  progressive  MS  patients  producing large amounts  of IFN-γ 
(Balashov et al., 1999). In the brain, CCR5-expressing cels and its ligand MIP-1alpha 
infiltrated  MS lesions (Balashov et al.,  1999).  Another study  detected  CCR5  on T 
cels, microglia and macrophages in active MS brain lesions (Sorensen et al., 1999). 
Increased expression of CCR5 on CSF T cels compared to circulating T cels has also 
been demonstrated in MS patients (Sorensen et al., 1999). 
 
Elevated levels of CCR5 expression by peripheral blood T cels has been reported in 
untreated  MS  patients compared to  healthy controls (Teleshova et al.,  2002). 
Interestingly, a longitudinal study found that  management  with IFNβ-1a  did  not 
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reduce the expression CCR5  on  T cels  during the first  12  months  of treatment in 
patients with the first demyelinating atack (Kivisakk et al., 2003). 
 
Based  on these results, in  MS  patients,  T cel  populations expressing  high levels  of 
chemokine receptor CCR5 and reduced expression  of apoptotic  markers led to 
resistance  of these cels to apoptosis and  persistence in the circulation and  potential 
migration to the  CNS.  Moreover, these  observations support the  development  of 
CCR5 inhibitors as a therapeutic approach for MS. 
 
1.6 Kiler cel immunoglobulin-like receptors 
	  
KIR molecules are membrane bound receptors that recognize the classical MHC class 
I molecules (Parham, 2005). They are transmembrane glycoproteins that belong to the 
immunoglobulin superfamily expressed mainly on NK, as wel as some iNKT and T 
cels (more often CD8 T cels with memory phenotype) (Vilches and Parham, 2002; 
van Bergen et al., 2004; Parham, 2005; Lanier, 2005). The human KIR gene family is 
clustered in the leukocyte receptor complex (LRC) on chromosome 19q13.4 (Suto et 
al.,  1996;  Wende et al.,  1999;  Martin et al.,  2000;  Wilson et al.,  2000;  Trowsdale, 
2001). These  genes are extremely  polymorphic, found in  humans and  primates, but 
missing in the  mouse  genome (Parham et al.,  2012). Fifteen expressed  genes  have 
been recognized in the KIR locus (KIR2DL1, KIR2DL2L3, KIR2DL4, KIR2DL5A, 
KIR2DL5B,  KIR2DS1–5,  KIR3DL1S1,  KIR3DL2–3),  with two  pseudogenes 
(KIR2DP1 and KIR3DP1) (Suto et al., 1996; Wende et al., 1999; Martin et al., 2000; 
Wilson et al., 2000; Trowsdale, 2001; Wiliams et al. 2005). 
 
The complexity of KIRs comprises a high degree of diversity at both the haplotye and 
alelic levels (Hsu et al.  2002; Shiling et al.,  2002;  Khakoo and  Carington  2006). 
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Two distinct  groups  of haplotypes  have  been suggested,  which  were shown to  have 
potential associations  with risk  of  disease and reproductive eficiency (Khakoo and 
Carington 2006; Jiang et al., 2012). 
 
Group A haplotypes comprises of two activating genes (KIR2DS4 and KIR2DL4) and 
five inhibitory  genes (KIR3DL1,  KIR3DL2,  KIR3DL3,  KIR2DL1 and  KIR2DL3) 
(Uhrberg et al.,  1997;  Khakoo and  Carington  2006). KIR2DS4 is supposedly 
activating but is inactivated by a 22-base pair deletion in exon 5 on 80% of European 
Americans, suggesting that they are expressed in a minority of individuals with group 
A  haplotype (Hsu et al.,  2002;  Maxwel et al.,  2002).  The  other activating  KIR  on 
group  A  haplotypes is  KIR2DL4,  which resides in the endosomal compartment and 
have very low expression  on the surface  of NK cels (Rajagopalan et al.,  2006; 
Khakoo and Carington, 2006). 
 
In contrast,  Group  B  haplotypes encompasses al remaining  haplotypes containing 
more activating receptor  genes including (KIR2DS1,  KIR2DS2,  KIR2DS3, 
KIR2DS5, KIR3DS1) (Uhrberg et al., 1997; Khakoo and Carington, 2006). 
 
These  haplotypes  had similar frequencies,  however  diferent  populations  have 
considerable  variations in these frequencies (Khakoo and  Carington,  2006). 
Haplotypes  A and  B  present equaly among amongst  Caucasians (Uhrberg et al., 
2002).  However they  varied significantly  within  other ethnic  groups such as 
Australian  Aborigines and the Japanese (Keicho et al.,  1998;  Wit et al.,  1999; 
Norman et al., 2001; Yawata et al., 2002). 
 
KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 framework genes were shared in al 
individuals tested and were found to be present in al haplotypes (Wilson et al., 2000; 
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Khakoo and Carington, 2006). The framework loci are KIR3DL3 at the centromeric 
end, KIR3DL2 at the telomeric end and KIR3DP1-KIR2DL4 are placed centraly in 
the middle of the KIR region (Pyo et al., 2010; Jiang et al., 2012). 
 
1.6.1 KIR structure 
 
The first description of the genomic organization of a human KIR receptor gene was 
demonstrated in  1997 (Wilson et al., 1997).  The specific  gene examined  was a 
member  of the  NKAT-2 family  of  KIRs curently  known as  2DL3 (Wilson et al., 
1997). The KIR gene consists of nine exons. The leader sequence is encoded by the 
first two exons.  The immunoglobulin  domains are encoded  by exons  3 to  5 and the 
linker and transmembrane regions are encoded  by exons  6 and  7,  while, the 
cytoplasmic domain is encoded by the final exons 8 and 9 (Carington and Norman, 
2003). The extracelular region of the KIR receptors is comprised of two (KIR2D) or 
three (KIR3D) immunoglobulin domains (Carington & Norman, 2003). 
 
The cytoplasmic tails of KIR genes can be either long or short but of similar sequence 
length (Carington & Norman, 2003). The variation occurs due to diferences in the 
location  of the stop codon  or  more  often  due to  nucleotide substitutions. KIR  genes 
are classified according to the structure  of the  protein they encode.  They can  have 
either two (KIR2D)  or three extracelular immunoglobulin-like  domains (KIR3D) 
with long cytoplasmic tails represented as (L) in the gene name or short-tailed KIRs 
denotes as (S) in the  gene  name (Carington and  Norman,  2003;  Parham,  2004). In 
general,  KIR  proteins  with long cytoplasmic tails contain an immunoreceptor 
tyrosine-based inhibitory  motif (ITIM) and transduces inhibitory signals (Fry et al., 
1996; Jiang et al.,  2012), KIRs  with short cytoplasmic tail  have an immunoreceptor 
tyrosine-based activating  motif (ITAM) and transduce activating signals (Olcese et 
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al., 1997; Lanier et al., 1998). 
 
KIR2D proteins are divided into two groups based on the conformation of the proteins 
in the extracelular  domains (Vilches and  Parham,  2002).  Type I  KIR2D  genes 
(KIR2DL1,  KIR2DL2,  KIR2DL3,  KIR2DS1,  KIR2DS2,  KIR2DS3,  KIR2DS4 and 
KIR2DS5) have two extracelular domains with a D1 and D2 conformation (Vilches 
et al.,  2000a). Type I  KIR2D  genes (KIR2DL4 and  KIR2DL5) encodes two 
extracelular  domains  with a  D0 and  D2 conformation,  while the three extracelular 
domains  of type II  KIR3D  gene (KIR3DL1-3 and  KIR3DS1) are  D0,  D1 and  D2 
(Vilches et al., 2000b; Vilches and Parham, 2002). Some pseudo-exons do not have 
fundamental structural abnormalities and the reading frame is conserved suggesting 
that diferent mechanisms are responsible for the malfunction of transcription such as 
a nucleotide substitution that possesses a single base pair deletion or premature stop 
codon initiating diferential splicing of exon. 
 
The inhibitory  KIRs consist  of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, 
KIR2DL5, KIR3DL1, KIR3DL2 and KIR3DL3, while the activating KIRs comprise 
of KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1.  KIR2DL4 
has been found to be activating and inhibitory (Table 1.4). 
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Anti-KIR  monoclonal antibodies  have  been  used to characterize the surface 
expression of KIRs on cels. However some antibodies can bind to both activating and 
inhibiting  markers  due to the  high  degree  homology  of these receptors in the 
extracelular domain.  
Receptor Location Family Ligand (MHC class1) Function 
KIR2DL1 HLA-C group 2 Inhibitory 
KIR2DL2 HLA-C group 1 Inhibitory 
KIR2DL3 HLA-C group 1 Inhibitory 
KIR2DL4 HLA-G Activating and inhibitory 
KIR2DL5 Unknown Inhibitory 
KIR3DL1 HLA-Bw4 Inhibitory 
KIR3DL2 HLA-A3, HLA-A11 Inhibitory 
KIR3DL3 Unknown Inhibitory 
KIR2DS1 HLA-C group 2 (low affinity) Activating 
KIR2DS2 HLA-C group 1 (low affinity) Activating 
KIR2DS3 Unknown Activating 
KIR2DS4 Unknown Activating 
KIR2DS5 Unknown Activating 
KIR2DS6 Unknown Activating 
KIR3DS1 HLA-Bw4 Activating 
KIR3DP1 Unknown Pseudogenes 
KIR2DP1 
Leu
koc
yte 
Rec
ept
or 
Co
mpl
ex 
(L
RC
) 
Hu
man
 ch
ro
mos
om
e 9
 
Ig 
su
per
fa
mil
y 
Unknown Pseudogenes 
Table  1.4: Overview  of activating and inhibitory  KIRs (chromosomal location, 
family, function and known ligand). 
 
 
1.6.2 Two domain KIRs 
	  
KIR2DL1 and KIR2DS1 
KIR2DL1 is a type  1 inhibitory  KIR receptor and a  member  of  group  A  haplotype, 
which is the  most common  haplotype  present in nearly al individuals (Wit et al., 
1999).  KIR2DL1 and the activating  KIR2DS1 are recognized  by the same 
monoclonal antibodies anti-CD158ah (clone  EB6B). Based  on  diferent immune-
based strategies, Inhibitory  KIR2DL1 and activating  KIR2DS1 share ligand 
specificity for group 2 HLA-C aleles (Winter et al., 1998). 
 
Sequencing of the KIR gene with genotyping the KIR populations demonstrated that 
KIR  genes are  highly  polymorphic (Wagtmann et al.,  1995;  Shiling et al.,  1998; 
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Rajalingam et al., 2001; Shiling et al., 2002). Diferent aleles have been sequenced 
for the  KIR2DS1  gene, showing the  highly  polymorphic  nature  of these  genes 
(Biassoni et al., 1996; Valiante et al., 1997a; Wilson et al., 2000; Rajalingam et al., 
2001). 
 
It  has  been  demonstrated that activating receptor  KIR2DS1 (p50  molecule)  bound 
weakly to Cw4 transfectants, while the inhibitory receptor KIR2DL1 (p58 molecule) 
bound  with  high afinity (Biassoni et al.,  1997). Moreover, substitution  of lysine at 
position 70 with threonine by site-directed mutagenesis led to a dramatic increase in 
the  binding afinity  of activating  KIR2DS1 (p50  molecule) to Cw4 (Biassoni et al., 
1997). However, substitution  of threonine at  position  70  with lysine abolished the 
binding  of inhibitory  KIR2DL1 (p58  molecule) (Biassoni et al.,  1997). This 
demonstrated that a single amino acid mutation at position 70 greatly influenced the 
KIR2DL1 (p58  molecule) and  KIR2DS1 (p50  molecule) binding afinity for their 
HLA-Cw4 ligand.  Also, direct  binding  of KIR2DL1 (p58  molecule) inhibitory 
receptor to HLA-Cw4  was  detected  by  native  gel electrophoresis (Fan et al., 2001). 
The activating KIR2DS1 (p50 molecule) and the inhibitory KIR2DL1 (p58 molecule) 
have  highly  homologous extracelular  domains but show  diferent functions and 
diferential  binding to HLA-Cw7  molecule (Vales-Gomez et al.,  1998).   The 
KIR2DL1 (p58  molecule)  binds  very rapidly to  HLA-Cw7  while  KIR2DS1 (p50 
molecule) bind very weakly (Vales-Gomez et al., 1998). 
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KIR2DL2/L3 
When KIR2DL2 and  KIR2DL3  were  originaly identified, they were treated as 
separate  genes. However, several functional and  molecular studies have concluded 
that they react in an essentialy alelic fashion since they are  not  on the same 
haplotype. KIR2DL2 and KIR2DL3 are identified by the same monoclonal antibody 
anti-CD158b (clone DX27 or GL183) and both recognize HLA-C group 1 alotypes 
with asparagine at position 80 (Colonna et al., 1993; Wagtmann et al., 1995). 
 
 
1.6.3 Three domain KIRs 
	  
KIR3DL1 and KIR3DS1 
KIR3DL1 is an inhibitory  KIR receptor recognizing HLA-B alotypes that  have the 
Bw4 serological motif, which represents around 40% of the known HLA-B alotypes 
(Cela et al., 1994; Gumperz et al., 1995; Uhrberg et al., 1997). The human NK cel 
receptor (NKB1),  now  known as  KIR3DL1, was first identified and characterized 
using the  DX9  monoclonal antibody (Litwin et al.,  1994). The  DX9  mAb  was 
subsequently used to compare KIR3DL1 surface expression by NK and T cels from 
peripheral  blood lymphocytes  of  203  HLA-typed  donors  using flow cytometry 
(Gumperz et al., 1996). Extensive heterogeneity in the frequency and level of NK and 
T cels  binding to  DX9 antibody  was  observed among individuals (Gumperz et al., 
1996).  Moreover,  within this  population the  NKB1 receptor expression  were 
geneticaly controled, but  not corelated  with  HLA type (Gumperz et al.,  1996). 
Successful  molecular cloning  of  NKB1 receptor for  HLA-B alotypes  was reported 
(D’Andrea et al., 1995). KIR3DL1 proteins are relatively polymorphic at the level of 
cel surface expression with diferent aleles having diferent cel surface expression 
levels except for  KIR3DL1*004 alele, which is  not expressed  on the cel surface 
(Gardiner et al., 2001; Pando et al., 2003). 
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Trundley and coleagues (2007) showed that the  Z27 antibody is able to recognize 
both activating  KIR3DS1 and inhibitory  KIR3DL1 receptors  but  DX9 antibody 
demonstrated  monoclonal specificity for  KIR3DL1 receptor  only. KIR3DS1was 
initialy identified  by sequence analysis  of  human  NK cels (Dohring et al.,  1996). 
KIR3DL1 and KIR3DS1 are inhibitory and activating receptors respectively and were 
originaly considered separately to be of diferent genes (Valiante et al., 1997b), but 
now KIR3DS1 segregates as an alele of the KIR3DL1 gene even with the associated 
ITIMs and without a long cytoplasmic tail (Gardiner et al., 2001; Car et al., 2007). 
KIR3DL1 and  KIR3DS1 share around  97% amino acid sequence  homology in the 
extracelular  domains (Car et al.,  2007). However, these  diferences are in the 
extracelular Ig-like  domains and are expected to afect the  binding. Car and 
coleagues reported that DAP12 adaptor molecule is critical for the surface expression 
of functional KIR3DS1 (Car et al., 2007). 
 
1.6.4 KIR expression on T cels  
 
1.6.4.1 KIR expression on CD8+ T cels 
 
Inhibitory  natural  kiler receptors (NKRs) such as  KIRs  were found expressed  on a 
subset of peripheral blood αβ T cels in humans (Mingari et al., 1998; Speiser et al., 
1999).  Evidence exists that the  majority  of  KIR+  T cels are  CD8+ and these cels 
express a  memory  phenotype  CD45R0+  CD29+  CD28–CD45RA– (Mingari et al., 
1996).  Likewise, a  population  of  mouse  memory  CD8+  T cels expressed inhibitory 
Ly49 molecules (Coles et al., 2000). Several in vitro experiments using human T cel 
clones  have  proposed that  up-regulation  of inhibitory  NKRs  on  T cels could act as 
inhibitors  of  T cels efector functions (Mingari et al.,  1995;  Mingari et al.,  1996; 
Mingari et al.,  1998;  Speiser et al.,  1999).  Ugolini and coleagues  generated 
transgenic mice (KIR-HLA Tg) expressing human inhibitory KIR3DL2 and its HLA-
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Cw3 ligand and reported that recognition  of  MHC class I  molecules  by inhibitory 
KIR3DL2 resulted in accumulation and diferentiation of a subset of memory CD8+ T 
cels (Ugolini et al., 2001). Moreover, the expansion of CD8+ T cels in KIR-HLA Tg 
mice  was restricted to a  population expressing IL-2Rβ+ cels indicating  T cel 
activation and  KIR-induced  T cel survival  which, corelates  with chronic antigenic 
exposure (Ugolini et al.,  2001). By analyzing cultures  of  melanoma-primed  CD8+ T 
cels, inhibitory  KIRs suppressed efector functions (cytotoxicity and IFN-γ 
production)  of these  CD8+  T cels (Huard  &  Karisson,  2000).  Another study 
demonstrated that inhibitory  KIR2DL2/L3  was confined to a  population  of  CD8+ T 
cels  with  high constitutive expression  of  granzyme  B and few cels expressed the 
activating KIR2DS2 in the absence  of the inhibitory  KIR2DL2/L3 (Arletaz et al., 
2004). 
 
1.6.4.2 KIR expression on CD4+ T cels 
 
KIR expression  has  been firmly established on TCR γδ+ T cels and  CD8+ cels  but 
relatively litle is known about KIR expression by CD4+ T cels (Mingari et al., 1996; 
Batistini et al.,  1997;  van  Bergen et al., 2004).  KIR receptors  were frequently 
detected  on  CD4+CD28nul  T cels in  patients  with rheumatoid arthritis and acute 
coronary syndromes (Namekawa et al., 2000; Nakajima et al., 2003). In rheumatoid 
arthritis, the expansion  of  CD4+CD28nul  T cels corelated  with  disease severity 
(Martens et al.,  1997). CD4+CD28nul  T cels isolated from rheumatoid arthritis 
patients  with  vasculitis expressed activating  KIR2DS2  molecule compared  with 
CD28- CD4 T cels from healthy controls (Yen et al., 2001). Using flow cytometry, 
van Bergen and coleagues confirmed that most healthy individuals have KIR+ CD4 T 
cels and these increase with age. RT-PCR analysis supported the expression of KIR 
expression  on  T cel clones (van  Bergen et al., 2004).  Moreover, upon stimulation 
with  plate-bound anti-CD3, it  has  been  demonstrated that KIR+ CD4  T cels  were 
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biased toward a Th1 cytokine profile since the production of Th2 cytokines IL-4, IL-
5, IL-10 and  CCR4  was significantly lower (van  Bergen et al., 2004).  Also, it  has 
been shown that CD4+  KIR+  T cels are associated  with a late  memory surface 
phenotype (CD28-),  which constituted a  high frequency  within  CMV-specific cels 
(van  Bergen et al.,  2009). In addition,  blocking the inhibitory interaction  between 
KIR2DL3 and its HLA-C ligand  using anti-HLA class I antibody,  drasticaly 
increased the  CMV-specific  proliferation  of  CD4+  KIR+T cels (van  Bergen et al., 
2009).  Although engagement  of inhibitory KIR2DL3 significantly reduced the 
proliferative response of the CMV-specific CD4+ KIR+ T cels, no detectable efect on 
cytokine profile was revealed  between  diferent subsets (van  Bergen et al.,  2009). 
This indicated an important role of inhibitory KIRs on CD4 efector functions. 
	  
1.6.4.3 KIR expression on CD1d restricted invariant NKT cels 
	  
The role  of  KIR  on iNKT cels is less clear. Paterson and coleagues investigated 
KIR expression  on ex vivo  or in vitro αGalCer-expanded iNKT cels and iNKT cel 
clones  using flow cytometry (Paterson et al.,  2008).  Staining  with CD1d/αGalCer 
tetramer and the  pan-anti-KIR2D (CD158abjhi) antibody, a smal  proportion  of 
polyclonal ex vivo  or in vitro αGalCer-expanded iNKT cels expressed  KIR at a 
frequency similar to that of conventional T cels and KIR expression on iNKT cels 
was variegated compared with the expression patern on NK and conventional T cels 
(Paterson et al.,  2008). On the  other  hand, KIR expression  on resting iNKT cel 
clones was detectable but significantly lower compared to NK and T cels (Paterson 
et al.,  2008). Expression  of  KIR (KIRDL4,  KIR3DL2 and  KIR2DL1)  by iNKT cel 
clones at the  mRNA level has  been confirmed by  RT-PCR (Paterson et al.,  2008). 
Furthermore,  KIR expression  on iNKT cels clones  has  been	  confirmed by 
immunobloting  using the  pan-anti-KIR2D (Paterson et al.,  2008). Upon alogeneic 
activation  of iNKT cels, up-regulation  of  KIR  was  demonstrated in the first  6  h 
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folowed by down-regulation to baseline levels suggesting a dynamic process of KIR 
expression on iNKT cels (Paterson et al., 2008).	  	  
	  
1.6.5 Association of KIR with disease  
	  
There is mounting evidence that reported genetic associations between KIR and HLA 
aleles and susceptibility to HIV, hepatitis C, cancer, autoimmune diseases and solid 
organ transplantation (Table  1.5) (Parham,  2005;  Khakoo and  Carington,  2006; 
Boyton and Altmann, 2007; Jiang et al., 2012). 
 
Peter Parham addressed the interactions between activating KIR2DS2 and KIR2DS1 
with  HLA-C and related the  presence  of  genes encoding  KIR2DS1 in  C1/C1 
homozygous individuals to activation and autoimmunity (Parham,  2005).  When the 
activating  KIR2DS1 is expressed along  with the inhibitory  KIR2DL1 in  C1/C2 
heterozygous individuals, this  may result in tolerance  or anti-inflammatory 
mechanisms, inhibitory signals overcoming the activating ones (Parham, 2005). 
 
Carington and Khakoo suggested that AA KIR haplotypes and C1/C1 ligands were 
associated with enhanced activation and several autoimmune diseases, while BB KIR 
haplotypes along with C2/C2 ligands were related to severe inhibition and was linked 
to infectious diseases (Carington and Khakoo, 2003). 
 
Fusco and coleagues investigated KIR and HLA genotypes in Italian RRMS patients. 
Genotyping  of  HLA -A, -B, -Cw, -DRB1 and  KIRs loci in  RRMS  patients and 
healthy controls suggested that the strong interaction  of activating KIR2DS1  gene 
together  with their  HLA ligands resulted in a  protective efect in  MS (Fusco et al., 
2010). 
 
The presence of HLA-Bw4, a ligand of the inhibitory KIR3DL1 receptor, was found 
to  be  protective against  MS (Lorentzen et al.  2009; Fusco et al.,  2010; Jelcic et al., 
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2012; Garcia-Leon et al.,  2011). On the  other  hand,  MS  patients carying the 
inhibitory KIR2DL2 appear to acquire a more severe form of the disease (Lorentzen 
et al., 2009). The inhibitory KIR2DL3 gene frequency was significantly decreased in 
CIS and  MS  patients, and the lack  of  KIR2DL3  gene  was associated  with the 
development of CIS and MS in patients carying HLA-C1 aleles (Jelcic et al., 2012). 
 
Disease KIR association Observation Reference 
Psoriatic arthritis 
Presence of KIR2DS1 
and/or KIR2DS2 in the 
absence of HLA-Cw 
group ligand 
increase KIR2DS1 
Susceptibility 
Martin et al., 2002; 
Nelson et al., 2004 
 
 
 
Wiliams et al., 2005 
Type 1 diabetes 
increased KIR2DS2 
and HLA-C1 
 
decrease in inhibitory 
KIR-HLA genotype 
combinations 
 
KIR2DS2 and 
KIR2DL2 in the 
presence of MICA 
alele 5 
Susceptibility 
Van Der Silk., et al 
2003 
 
Van Der Silk., et al 
2007 
 
Nikitina-Zake et al., 
2004 
Scleroderma 
the presence of the 
activating KIR2DS2 
and the absence of the 
inactivating KIR2DL2 
Susceptibility Momot et al., 2004 
Rheumatoid arthritis 
with vasculitis 
the presence of the 
activating KIR2DS2 in 
the absence of 
opposing inhibitory 
receptors 
Susceptibility Yen et al., 2001 
Table  1.5:  Examples  of  HLA-C  and  KIR  association  with susceptibility to 
diseases.  
Extracted from (Boyton and Altmann, 2007). 
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1.7 Aims of the thesis 
	  
The rationale behind this  PhD  project is that  MS susceptibility, severity  or relapse 
may  be associated  with  qualitative  or  quantitative abnormalities in the  number  or 
function of iNKT cels. In order to study this I looked at the folowing: 
 
a) Evaluate  quantitative  diferences in the frequency  of iNKT cels in  peripheral 
blood from  healthy controls,  CIS and  MS  patients  using  multiparameter flow 
cytometry. 
 
b) Evaluate the presence and distribution patern of iNKT cels in brain tissue of MS 
cases and healthy controls from UK MS Tissue Bank donors. 
 
c) Investigate a  qualitative alteration in iNKT cels from  healthy controls and  MS 
patients with particular reference to the TCR sequence. 
 
d) Investigate the expression of specific receptors such as KIRs on iNKT cels using 
multiparameter flow cytometry. 
 
e) Investigate the role  of  diferent  molecules involved in  homing,  maturation, 
activation, diferentiation and immune regulation of peripheral lymphocytes, such 
as CD25, CD62L, CD69, CD161 and CD195 on lymphocyte populations like NK, 
NKT and iNKT cels.  
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2. Methods  
 
2.1 Blood colection and patient recruitment 
 
Blood samples were colected in sodium heparin vacutainers (Becton Dickinson, UK) 
folowing informed consent as approved  by the Imperial  Colege  Ethic  Board 
Commitee (Ethical  Approval  n.05/MRE12/8).  Randomly selected  healthy  donors 
were recruited  within Imperial  Colege  London;  Hammersmith and  St  Mary’s 
Campuses. Blood from MS and  CIS  patients were recruited  with the  help  of  our 
neurology consultants (Dr Richard Nicholas, Dr Omar Malik and Dr Paolo Gianneti) 
from the MS Clinic at Charing Cross Hospital, London. 
 
2.2 Isolation of peripheral blood mononuclear cels  
 
Peripheral  Blood  Mononuclear  Cels (PBMCs)  were isolated  by  Histopaque  density 
gradient centrifugation (Sigma  Aldrich,  UK).  Peripheral  blood  was colected in 
heparinised vacutainer (Becton Dickinson, UK). Blood samples were then diluted at 
1:1 ratio with sterile Phosphate Bufered Saline (PBS) (Invitrogen, UK) and layered 
carefuly  over  15ml  of  pre-warmed Histopaque (Sigma,  UK). The  PBMCs  were 
colected from the inter-phase using a sterile pasteur pipete after centrifuging at 800g 
for  20  minutes at  24°C.  The isolated cels  were washed three times in PBS  via 
centrifugation at (350g, 300g and 200g) for 10 minutes at 24°C. The supernatant was 
discarded and the cel pelet was washed with cell washing buffer containing PBS + 
10%  heat-inactivated  Foetal  Calf  Serum (FCS) (Biosera,  UK).  Finaly, to count the 
cels, 10µl of the cel suspension was diluted at 1:5 ratio with 0.4% Trypan Blue dye 
(Sigma-Aldrich,  UK)  using a  disposable haemocytometer (Hycor  Biomedical Inc., 
U.S.A.).  10µl  of the cel suspension  was loaded in a  haemocytometer chamber and 
cels  were counted  using a light  microscope.  Cel concentration (cels/ml)  was 
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determined using the formula: average number of cels over the four corners squares 
of the counting chamber x dilution factor (5) x total volume (10) x volume conversion 
factor to  1  mL (104). In  order to  build  up a library  of lymphocytes from  diferent 
healthy controls and  MS  patients for future  use,  PBMCs  were cryopreserved at 
maximum 10x106 cels per  ml in cold freezing  medium containing  10%  dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich,  UK) and  90%  FCS and then transfered into 
1.5ml cryovials (VWR International, Luterworth, UK). Cryovials were then moved to 
the freezing container  Mr  Frosty (Nalgene®,  Thermo  Fisher  Scientific, 
Loughborough,  UK).  The freezing container  with the  vials  were  placed in an -80°C 
freezer for at least 48 hours before long-term storage in liquid nitrogen tanks. 
 
2.3 Immunophenotyping of iNKT cels  using  multiparameter flow 
cytometry 
 
The immunophenotyping of iNKT cels was caried out on fresh PBMCs. In order to 
identify the  percentage  of iNKT cels,  3x106 cels  were added in each  wel  of  V-
botomed 96-wel plates (Sarsted, UK). The cels were blocked for 20 minutes on ice 
using  FACS  blocking  bufer (PBS containing  10%  human serum and  1%  Bovine 
Serum Albumin (BSA, Sigma-Aldrich, UK). After the incubation time the plate was 
centrifuged for 10 minutes at 300g, the supernatant was removed and the cels were 
stained  with the folowing anti-human antibodies (Table  2.1) and incubated for  45 
minutes on ice in the dark. After the incubation, cels were washed three times with 
FACS  washing  bufer (PBS containing  1% BSA) and fixed  with  200µl  of  1% 
paraformaldehyde (PFA, Sigma-Aldrich,  UK). Fluorescence  Minus  One (FMO) 
controls and appropriate isotype controls were used for al experiments to determine 
positive populations. Cels were then analysed using FACS Aria I SORP cel sorter 
(Becton  Dickinson,  Mountain  View,  CA)  with at least  500,000 events counted for 
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each sample.  Compensation  was  done  using Comp  Beads (anti-mouse Ig,k/negative 
control compensation  particles set, Becton  Dickinson,  Oxford,  UK) and  was 
subsequently analysed using BD Diva Software (Becton Dickinson, Mountain View, 
CA).  Al statistical analysis  was  performed  using  GraphPad  Prism  5  Software and 
Microsoft Excel (Microsoft Ofice, UK). 
 
The  patients included in  our study  were  divided into  5  groups:  RRMS  untreated 
patients (RRMS),  RRMS  patients  on  Natalizumab treatment (RR-NatAb),  RRMS 
patients on Interferon treatment (RR-IFNb), progressive MS patients (PMS) and CIS 
patients (Table 2.2). PBMCs from this study were frozen and stored in liquid nitrogen 
until  used for the immunophenotyping cel surface  markers experiments in (Section 
2.5). 
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Table 2. 1: Antibodies used for PBMC Staining in order to identify the frequency 
of iNKT cels. 
Antibody Specificity Clone Fluorochrome Company 
Anti-CD3 Mouse Anti-human UCHT1 V450 BD Bioscience 
Anti-CD4 Mouse Anti-human RPA-T4 V500 BD Bioscience 
Anti-CD8 Mouse Anti-human RPA-T8 AlexaFluor® 700 BD Bioscience 
Anti-CD56 Mouse Anti-human B159 AlexaFluor® 647 BD Bioscience 
Anti-TCR Vα24 Mouse Anti-human C15 PE Beckman Coulter 
Anti-TCR Vβ11 Mouse Anti-human C21 FITC Beckman Coulter 
 
 
 
 
Table  2. 2: Characteristics  of immunophenotyping study  population (expressed 
as mean). 
Diagnosis Number Female/Male Age  
Healthy controls 22 (14/8) 37 (25-53) 
Progressive MS 9 (5/4) 56 (51-66) 
RRMS/untreated 11 (8/3) 44 (34-65) 
RRMS/on Interferon 8 (6/2) 36 (26-44) 
RRMS/on Natalizumab 10 (6/4) 45 (28-61)  
CIS 10 (7/3) 41 (30-48) 
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2.4  KIR expression  on iNKT,  NKT  and  NK cels  using 
multiparameter flow cytometry 
 
Al experiments in this section  were caried  out  on fresh  PBMCs and the  patient 
populations used were distinct from those used in (Section 2.3). In order to evaluate 
KIR expression  on iNKT cels,  peripheral  blood from  33  healthy controls,  15  CIS 
patients and  51  MS  patients  divided into  5  groups according to  disease type and 
treatment (Table  2.3) were colected and isolated  using  Histopaque  protocol as 
described in Methods (Section 2.1 and 2.2). The PBMCs staining procedure used was 
identical to those described in (Section 2.3) using a variety of antibodies (Table 2.4). 
Cels  were then analysed  using  FACS  Aria I  SORP cel sorter (Becton  Dickinson, 
Mountain  View,  CA)  with at least  500,000 events counted for each sample. 
Compensation  was  done  using Comp  Beads (anti-mouse Ig,k/negative control 
compensation  particles set, Becton  Dickinson,  Oxford,  UK) and  was subsequently 
analysed  using  BD  Diva  Software (Becton  Dickinson,  Mountain  View,  CA).  Al 
statistical analysis  was  performed  using  GraphPad  Prism  5  Software and  Microsoft 
Excel (Microsoft Ofice, UK). Al healthy controls and patients were genotyped by Dr 
James Traherne in Professor John Trowsdale’s group at University of Cambridge with 
the aim of marying up the genetic data with surface expression. 
 
Table  2.3:  Characteristics  of KIR expression study  population (expressed  as 
mean). 
 
Diagnosis Number Female/Male Age  
Healthy controls 33 19/14 45 (25-60) 
Progressive MS 11 6/5 51 (32-62) 
RRMS/untreated/stable 8 7/1 47 (34-62) 
RRMS/untreated/active 10 7/3 41 (16-58) 
RRMS-on Interferon 10 10/0 40 (27-57) 
RRMS-on Natalizumab 12 8/4 40 (25-52)  
CIS 15 8/7 41 (30-50) 
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Table  2. 4:  Antibodies  used for  PBMC staining for  KIR expression  on iNKT, 
NKT and NK Cels.  
 
Antibody Specificity Clone Fluorochrome Company 
Anti-CD3 Mouse Anti-human SK7 APC-H7 BD Bioscience 
Anti-CD4 Mouse Anti-human RPA-T4 V500 BD Bioscience 
Anti-CD8 Mouse Anti-human RPA-T8 AlexaFluor® 700 BD Bioscience 
Anti-CD56 Mouse Anti-human B159 PE-Cy7 BD Bioscience 
Anti-CD158a/h 
(KIR2DL1/S1) Mouse Anti-human 11PB6 VioBlue Miltenyi Biotec 
Anti- CD158e 
(KIR3DL1) Mouse Anti-human DX9 APC Miltenyi Biotec 
Anti- CD158b 
(KIR2DL2/L3) Mouse Anti-human DX27 PerCP Miltenyi Biotec 
Anti-TCR Vα24 Mouse Anti-human C15 PE Beckman Coulter 
Anti-TCR Vβ11 Mouse Anti-human C21 FITC Beckman Coulter 
	  
	  
	  
2.5  Evaluation  of  activation / migration / differentiation  markers 
expression  on iNKT,  NKT  and  NK cels  using  multiparameter flow 
cytometry 
 
Al experiments in this section  were caried  out  on frozen  PBMCs from  5 healthy 
controls and  21  MS  patients  divided into  4  groups according to  disease type and 
treatment (Table 2.5). PBMCs for this study were frozen from January 2010 to May 
2010. The  patient  populations  used in this section  overlapped  with those  used in 
(Section 2.3). Only 2-3 vials were thawed at a time in a pre-warmed 37°C water bath. 
The entire content from the vials was transfered slowly to a 15ml falcon tube (BD, 
UK) containing pre-warmed complete medium containing Pen Strep, RPMI 1640 and 
5ml L-glutamine (Gibco, Invitrogen, UK). The tubes were centrifuged at 1500rpm for 
10 minutes at room temperature. The cels were washed twice to eliminate debris and 
dead cels. After the final washing step, the supernatant was discarded, cel pelet was 
	   95	  
re-suspended in  10ml  media and cels  were counted as  described in (Section  2.2) 
using  Trypan  Blue exclusion in  order to  determine cel recovery and  viability after 
thawing. Cels were re-suspended at 10x106 cel per ml in complete media and left in 
a  humidified incubator at 37°C and  5%  CO2.   After incubation  FACS staining  was 
caried  out as  described in (Section  2.3)  using a  variety  of antibodies (Table  2.6). 
Cels  were then analysed  using  FACS  Aria I  SORP cel sorter (Becton  Dickinson, 
Mountain  View,  CA)  with at least  500,000 events counted for each sample. 
Elimination  of  dead cels from  our experimental analysis  was caried  out  using 
Live/Dead  Fixable  Violet  Dead cel  Stain  Kit (Molecular  Probes, Invitrogen,  UK). 
Compensation  was  done  using Comp  Beads (anti-mouse Ig,k/negative control 
compensation particles set, Becton Dickinson, Oxford, UK) and ArCTM reactive beads 
(Molecular  Probes, Invitrogen,  UK) and  was subsequently analysed  using  BD  Diva 
Software (Becton  Dickinson,  Mountain  View,  CA).  Al statistical analysis  was 
performed using GraphPad Prism 5 Software and Microsoft Excel (Microsoft Ofice, 
UK). 
 
 
 
Table 2.5: Characteristics of activation/migration/ diferentiation markers study 
population (expressed as median). 
 
Diagnosis Number Female/Male Age  
Healthy controls 5 4/1 39 (29-40) 
Progressive MS 5 3/2 53 (51-62) 
RRMS/untreated 6 4/2 36 (34-45) 
RRMS/on interferon 5 4/1 37 (26-59) 
RRMS-on Natalizumab 5 1/4 39 (28-49)  
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Table 2.6: Antibodies used for PBMC staining for activation/ migration/ 
diferentiation markers expression on iNKT, NKT and NK cels. 
	  
Antibody Specificity Clone Fluorochrome Company 
Anti-CD3 Mouse Anti-human SK7 PerCP BD Bioscience 
Anti-CD4 Mouse Anti-human RPA-T4 V500 BD Bioscience 
Anti-CD8 Mouse Anti-human RPA-T8 AlexaFluor® 700 BD Bioscience 
Anti-CD56 Mouse Anti-human B159 PE-CF594 BD Bioscience 
Anti-CD62L Mouse Anti-human DREG-56 FITC BD Bioscience 
Anti-CD25 Mouse Anti-human M-A251 APC-H7 BD Pharmingen 
Anti-CD195 Mouse Anti-human 2D7/CCR5 APC BD Pharmingen 
Anti-CD161 Mouse Anti-human HP-3G10 PerCPcy5.5 eBioscience 
Anti-CD69 Mouse Anti-human FN50 PE-Cy7 eBioscience 
CD1d loaded with 
PBS57 (tetramer) Human  PE NIH 
 
 
 
2.6 Analysis of iNKT cels in Line 7 mice  
 
2.6.1 Assessment of disease in Line 7 mice 
 
 
Line 7 mice experiments were caried out in accordance with the guidelines detailed 
in  Professor  Danny  Altmann  Home  Ofice  Project  Licence (PPL  70/6939,  19b8; 
Spontaneous  MS  Model).  From the  development  of the first sign  of  paralysis,  mice 
were scored twice a  week.  Then they  were scored every  other  day  upon reaching 
score 3 and scored twice every day upon reaching score 4. For our experiments, mice 
scoring  between 0 and  3, aged  between  67 and  69 weeks  were  used for  our 
experiments (Table 2.7). The grading system for clinical assessment of Line 7 mice is 
summarized in (Table  2.8). Dr  Durenberger  was scoring the  mice and  Dr  Chong 
helped in culing the mice. For immunephenotyping by flow cytometry, splenocytes 
and thymocytes  were extracted from freshly  dissected spleens and thymuses.
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2.6.2 Isolation of splenocytes and thymocytes 
 
Line  7  mice  were culed; spleens and thymuses  were  harvested and  placed into 
complete RPMI-1640 medium (Gibco, Invitrogen, UK). Lymphocytes were extracted 
from each spleen and thymus  using 1ml syringe  needles, then colected in a  15ml 
falcon tube and centrifuged for 5 minutes at 1500rpm and supernatant was discarded. 
Red blood cels were lysed using 5ml red blood cel lysis bufer and incubated for 5 
minutes with cel suspension. 
 
Table 2.7: Characteristics of DR15 controls and Line 7 mice (expressed as 
median). 
 
Diagnosis Number Female/Male Age (weeks) Score 
DR15 controls 2 2/0 16 (16) - 
Line 7 mice 7 3/4 68 (67-69) 2 (0-3) 
 
 
Table 2.8: Grading system for clinical assessment of Line 7 mice  
	  
Grade Clinical sign 
0 Normal mouse 
1 Limp tail 
2 Waddling gait 
3 Partial hind limb paralysis 
4 Complete hind limb paralysis 
5 Total limb paralysis 
6 Moribund state; death by disease 
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2.6.3 Analysis of iNKT cels in Line 7 mice splenocytes and thymocytes by means 
of flow cytometry 
 
Cels were washed twice with cold FACS bufer (PBS + 10% FCS). Surface staining 
was caried out on 1x106 cels after blocking with FACS bufer for 20 minutes on ice 
and then incubated  with the relevant antibodies indicated in (Table  2.9) for  45 
minutes at 4°C in the dark. Cels were washed twice with FACS bufer and then fixed 
in  200µl  of  1%  PFA.  FMO and isotype controls  were  used for al experiments to 
determine accurate gating of positive populations. Compensation was done via Comp 
Beads (anti-rat and  hamster Ig,k/negative control compensation  particles set  BD, 
Oxford,  UK).  Samples  were run  on a  FACS  Aria I  SORP flow cytometer (Becton 
Dickinson,  Mountain  View,  CA),  with at least  250,000 events counted for each 
sample and analysed  using  BD  Diva  Software (Becton  Dickinson,  Mountain  View, 
CA).  Al statistical analysis  was  performed  using  GraphPad  Prism  5  Software and 
Microsoft Excel (Microsoft Ofice, UK).  
 
Table 2.9: List of antibodies used in order to identify the frequency of iNKT cels 
in Line 7 mice. 
 
Antibody Specificity Clone Fluorochrome Company 
Anti-CD3 Hamster Anti-mouse 145-2C11 FITC BD Bioscience 
CD1d loaded with 
PBS57 (tetramer) Mouse - PE 
NIH Tetramer 
Facility USA 
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2.7 Immunofluorescence  
 
MS and control  brain tissue sections  were  obtained from the  UK  Multiple  Sclerosis 
Tissue  Bank (Wolfson  Neuroscience  Laboratories, Imperial  Colege  Faculty  of 
Medicine, Hammersmith Campus). Serial sections (10µm) with previously identified 
area  of  demyelination in the  white  mater from  5  MS  donors and from  5  non-
neurological controls were used in this study. Basic clinical and demographic details 
of control and  MS cases can  be found in (Table  2.10).  Tonsil tissue  was  provided 
from the Human Biomaterials Resource Centre (Hammersmith Hospitals NHS Trust, 
Hammersmith Hospital, London). Tissue sample was taken from a 19 year-old female 
that underwent tonsilectomy due to reactive lymphoid hyperplasia. 
 
Table 2.10: clinical and demographic details of control and MS cases. 
	  
Total Sex 
Age at 
death 
(years) 
Cause of death Post-mortem delay (hours) 
Type 
of MS 
Disease 
duration 
(years) 
MS01 F 49 Bronchopneumonia, multiple sclerosis 7 SPMS 23 
MS02 F 44 
Aspiration 
pneumonia, 
multiple sclerosis 
18 SPMS 16 
MS03 F 35 Multiple sclerosis 9 SPMS 5 
MS05 M 45 Multiple sclerosis 7 SPMS 16 
MS07 F 46 Multiple sclerosis 10 SPMS 25 
C01 M 75 Aspiration pneumonia 17 NA NA 
C02 F 88 Bronchopneumonia 20 NA NA 
C03 F 86 Cerebrovascular accident 29 NA NA 
C04 M 75 Metastatic renal carcinoma 18 NA NA 
C05 F 69 Lung cancer 33 NA NA 
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Tetramer staining was achieved folowing protocols previously described in Reynolds 
et al. (2009); snap frozen sections were fixed in 4% PFA for 3 minutes and washed in 
PBS. 20% donkey serum in PBS was added to each slide for 20 minutes to prevent 
non-specific  binding.  Then slides  were rinsed in  PBS.  15µl  human  CD1d tetramer 
loaded with PBS57 (NIH Tetramer Core Facility, USA) in PBS was applied at 200µl 
per slide and left to incubate at room temperature overnight. Slides were rinsed with 
PBS and  were incubated in  4%  PFA for  20  minutes to fix tetramer  binding.  Slides 
were rinsed in PBS and polyclonal rabbit serum against streptavidin (Sigma-Aldrich, 
UK) was applied at 1:800 dilution for 45 minutes. Slides were rinsed with PBS and 
1/500  polyclonal  goat anti-rabbit (Alexa  Fluor®  488 goat anti-rabbit IgG from 
Invitrogen, UK) was added and left to incubate for 30 minutes. Slides were rinsed in 
PBS.  Coverslips  were applied to slides  with fluorescent  mounting  media containing 
DAPI and slides were left to dry under pressure. The coverslips were sealed onto the 
slides  with  nail  polish and  kept at 4 °C  until  needed. Slides  were  viewed  under a 
Nikon  Eclipse  E1000M  microscope. Images  were captured  using a Nikon  Eclipse 
E1000M microscope digital camera, and processed using ImagePro7 software (Media 
Cybernetics,  Bethesda,  MD,  USA) as  wel as ImageJ software (Rasband,  W.S). 
Negative controls included  unloaded  CD1d tetramer (NIH  Tetramer  Core  Facility, 
USA). 
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2.8 Human TCR Vα24/ Vβ11 CDR3 analysis 
 
2.8.1 Healthy controls and MS patients recruitment 
 
Blood samples were colected folowing informed consent and ethical approval from 
4  healthy controls from Imperial  Colege  London,  Hammersmith  Campus and  3 
untreated  RRMS  patients from  Charing  Cross Hospital (Table  2.11). Samples  were 
processed within four hours of colection. 
 
 
Table  2.11:  Characteristics  of  human  TCR  Vα24/  Vβ11 CDR3  analysis study 
population (expressed  as  median). 
	  
Diagnosis Number Female/Male Age  
Healthy controls 4 3/1 44 (41-50) 
RRMS/untreated 3 3/0 30 (25-33) 
 
2.8.2 FACS sorting of iNKT cels 
 
Al experiments in this section  were caried  out  on fresh  PBMCs and the  patient 
populations used in this section were distinct from those used in (Section 2.3 and 2.4). 
PBMCs  were isolated using  Histopaque  density  gradient centrifugation as  described 
in (Section 2.2). PBMCs were counted using Trypan Blue exclusion as described in 
(Section 2.2) and transfered to a 15ml Falcon tube and centrifuged at 1500rpm for 10 
minutes at room temperature.  The supernatant  was  discarded, cel  pelet  was re-
suspended in  1ml  PBS and were stained  with anti-human antibodies indicated in 
(Table  2.12).  Cels  were then incubated for  45  minutes on ice in the  dark.  After 
incubation, cels  were  washed twice  with  PBS at  1500rpm to eliminate  debris and 
dead cels. After the final washing step, the supernatant was discarded and cel pelet 
was re-suspended in  3ml  PBS and filtered into  FACS tubes. The iNKT cels  were 
sorted using FACS Aria I SORP flow cytometer (Becton Dickinson, Mountain View, 
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CA) with at least 2000 events sorted for each sample. Compensation was done using 
Comp  Beads (anti-mouse Ig,k/negative control compensation  particles set, Becton 
Dickinson,  Oxford,  UK). The iNKT cels were sorted directly into  FACS tubes 
containing cel lysis  bufer (Stratagene,  UK).  Before freezing  0.7µl β-
mercaptoethanol (β-ME,  Stratagene,  UK) and  100µl  of lysis  bufer  was added for 
each sample of up to 1x104 cels. The iNKT cels were then kept frozen at -80ºC until 
RNA extraction was performed. 
 
 
Table 2.12: Antibodies used for iNKT cels sorting 
	  
Antibody Specificity Clone Fluorochrome Company 
Anti-CD3 Mouse Anti-human UCHT1 V450 BD Bioscience 
Anti-TCR Vα24 Mouse Anti-human C15 PE Beckman Coulter 
Anti-TCR Vβ11 Mouse Anti-human C21 FITC Beckman Coulter 
 
 
2.8.3 RNA extraction 
 
Total RNA was prepared from sorted iNKT cels using Absolutely RNA Nanoprep kit 
(Stratagene, UK). Each sample of up to 1x104 cels was homogenized in 100µl lysis 
bufer containing  0.7µl  of β-ME and stored at -80°C  until ready for  use.  An equal 
volume  of  70% ethanol was added to the cel lysate and  mixed thoroughly for  5 
seconds using a vortex. The mixture was transfered to RNA-binding nano-spin cup 
from the  kit and centrifuged for  60 seconds at >12,000g.  The filtrate  was  discarded 
and 300µl of 1X Low Salt Wash Bufer (Stratagene, UK) was added to the spin cup 
and centrifuged for 60 seconds at >12,000g. The filtrate was discarded and spun for 2 
minutes at >12,000g to dry the fibre matrix. DNase solution was prepared via gentle 
mixing of 12.5µl DNase digestion bufer (Stratagene, UK) with 2.5µl of reconstituted 
	   103	  
RNAse-free  DNase I (Stratagene,  UK), and the solution  was added  onto the fiber 
matrix. The sample was then incubated for 15 minutes at 37°C. After the incubation, 
300µl of 1X High Salt Wash bufer (Stratagene, UK) was added to the spin cup and 
centrifuged at  12,000g for  60 seconds. The filtrate  was  discarded and 300µl  of 1X 
Low Salt Wash Bufer was added and spun at 12,000g for 60 seconds. A second wash 
with 1X Low Salt Wash Bufer was performed and folowed by centrifugation for 3 
minutes at 12,000g to dry the fiber matrix. Then the spin cup was transfered to a new 
2ml colecting tube from the kit. Finaly, 10µl of elusion bufer (Stratagene, UK) was 
added to the fiber  matrix and  was incubated for  2  minute at room temperature.  The 
samples were then centrifuged at 12,000g for 5 minutes and purified RNA was in the 
colection tube. Extracted  RNA  was  quantified  using  Nanodrop  ND-1000 
spectrophotometer (Thermo Scientific, USA). Total RNA was stored at -20°C. 
 
2.8.4 cDNA synthesis 
 
cDNA synthesis was caried out using reagents provided in Superscript® II Reverse 
Transcriptase  kit (Invitrogen,  UK).  RNA  was first  mixed  with  1µl  deoxynucleotide 
triphosphates (dNTPs;  10mM;  Amersham  Bioscience,  UK) and  1µl random  primers 
(50ng/µl; Invitrogen) and  made  up to total  volume  of  13 µl  by adding  RNase free 
water (Sigma-Aldrich, UK). The mixture was incubated for 5 minutes at 65˚C before 
being placed on ice for one minute. cDNA was synthesized in a final volume of 20µl 
including the  13µl  mixture  described  previously  with  4µl  5X first strand  bufer 
(Invitrogen,  UK),  1µl  SuperScript® II  Reverse  Transcriptase (SSII, Invitrogen, 
UK),  1µl  dithiothreitol (DTT; Invitrogen) and  1µl  RNAse  out inhibitor (Invitrogen, 
UK).  The reaction  was incubated at  25˚C for  5  minutes,  50˚C for  60  minutes and 
finaly 70˚C for 15 minutes. cDNA was stored at -20˚C. 
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2.8.5 Primer design 
 
TCR  Vα24 and  Vβ11  CDR3 regions  were amplified  using appropriate  primers 
designed by Dr Catherine Reynolds (Table 2.13). Primers (Sigma-Aldrich, UK) were 
prepared in molecular grade water (Invitrogen, UK) and stored at -20˚C. Primers were 
tested using diferent concentrations of Magnesium chloride (1.5mM, 1.75mM, 2mM, 
2.25mM, 2.5mM) and diferent annealing temperatures (55-60˚C). 
 
 
Table 2.13: List of primers used for amplifying TCR Vα24/ Vβ11 CDR3 region  
	  
 Forward (sense) primer Reverse (antisense) primer 
Vα24 (PCR1) CTGCACTCTTCAATGCAAT TCGGTGAATAGGCAGACAGA 
Vβ11 (PCR1) GAAGATCACTCTGGAATG CCTTTTGGGTGTGGGAGAT 
Vα24 (PCR2) CTGCACTCTTCAATGCAAT GTCACTGGATTTAGAGTCT 
Vβ11 (PCR2) GAAGATCACTCTGGAATG CACAGCGACCTCGGGTGGG 
 
2.8.6 Polymerase Chain Reaction (PCR) 
 
TCR  Vα24 and  Vβ11  CDR3 regions in iNKT cels  were amplified  using a  nested 
PCR strategy as starting quantities of cDNA, particularly in MS patient samples, were 
very low. PCR reactions were prepared on ice in a total volume of 25µl (Table 2.14). 
The PCR cycle included an initial denaturation step of 95˚C for 5 minutes folowed 
by 37 cycles of denaturation at 95˚C for 1 minute, annealing at 60˚C for 1 minute, and 
elongation at 72˚C for  1  minute  before a final elongation step at  72˚C for  8 minute 
and stored at  8˚C.  Each reaction  was run  on a  1% agarose  gel  made  with  1X  TAE 
bufer (Bioline  Ltd,  UK) containing 5µl  Sybr-safe (Invitrogen,  UK). 2µl  of  10X 
loading  bufer (Bioline,  UK)  was added to  15µl  PCR  product and  were loaded into 
the gel along with 5µl of hyperladder Ι (Bioline, UK). PCR products were separated 
at  120V for  45  minute and  visualized  under  UV light  with  Labworks  Software and 
expected patern of PCR product size determined from the DNA ladder. 
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Table 2.14: Master-mix for 1 PCR reaction. 
	  
PCR component Volume (µl) 
Molecular Biology H2O (Sigma-Aldrich, UK) 8.375 µl 
10x bufer (Bioline Ltd, UK) 2.5 µl 
MgCl2 (7.5mM) (Bioline Ltd, UK) 5 µl 
dNTPs (1mM) (Invitrogen, UK) 5 µl 
Forward primer (100µg/ml) (Sigma-Aldrich, UK) 1.25 µl 
Reverse primer (100µg/ml) (Sigma-Aldrich, UK) 1.25 µl 
cDNA 2.5 µl 
BIOTAQ polymerase (Bioline Ltd, UK) 0.125 µl 
 
 
2.8.7 Gel extraction 
 
The PCR product from the agarose gel was excised using a clean scalpel under UV 
light and weighed. Purification of the PCR product was performed using QIAquick® 
Gel  Extraction  Kit (Qiagen,  UK).  Three  volumes  of  bufer  QG  was added to  1  gel 
volume of each PCR product and incubated for 10 minutes at 50˚C. After the gel slice 
has completely  dissolved  one  volume  of isopropanol  was added to the sample and 
mixed.  The sample  was transfered to a QIAquick spin column  within a  2ml 
colection tube and centrifuged ful speed for  1  minute.  The flow-through  was 
discarded and  0.5ml  Bufer  QG  was added to the column and centrifuged for  1 
minute.  The filtrate  was  discarded.  After that  0.75ml  bufer  PE  was added and 
centrifuged for 1 minute and filtrate was discarded. The column was left to stand for 
2-5 minutes folowed by centrifuging the column for 1 minute at 13000rpm to remove 
remaining  washing  bufer.  Then the spin column  was  placed into a fresh  1.5ml 
microcentrifuge tube.  Finaly,  DNA  was eluted  by adding  30µl  Bufer  EB to the 
centre  of the column and incubated for  4  minutes folowed  by centrifugation for  1 
minute.  
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2.8.8 TA Cloning 
 
 
2.8.8.1 Ligation  
 
Ligation  of  PCR  product into  pCR2.1 cloning  vector  was caried  out  using the 
pCR®2.1 TA Cloning Kit (Invitrogen, UK). Al ligations were performed in a total 
volume of 10µl consisting of 6.5µl PCR product, 1.5µl pCR®2.1 vector, 1µl ligation 
bufer, 1µl DNA ligase (Invitrogen, UK). Reactions were incubated at 16˚C overnight 
before transformation the folowing day. 
 
2.8.8.2 Transformation of X-L10 Gold competent cels 
 
TA cloning ligations  were transformed  using  XL-10  Gold  Ultracompetent cels 
(Stratagene, UK). One 50µl vial of frozen competent cels was thawed on ice. 10µl of 
ligation reaction  was added  directly to the  vial  of competent cels and incubated  on 
ice for  20  minutes.  The cels  were  heat shocked at  42˚C for  45 seconds and 
immediately  placed  on ice.   250µl  of room temperature  S.O.C  medium (Invitrogen, 
UK) was added to each ligation reaction and reactions were incubated horizontaly in 
a shaking incubator at 37˚C for 1 hour. The transformations were briefly centrifuged 
to pelet bacteria and the pelets re-suspended in a smal volume of media to spread on 
top  of  LB agar  plates containing  50µg/ml ampicilin.  Plates  were  pre-prepared  by 
spreading  with  4µl  of  200mM IPTG (isopropyl β-D-1-thiogalactopyranoside) 
(Sigma,-Aldrich,  UK) and  40µl  of  40mg/ml  X-GAL (5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside)(Bioline,  UK) for  blue/white colony screening.  Finaly, the 
plates  were incubated at  37˚C  overnight and stored at  4˚C to alow  proper colour 
development. 
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2.8.8.3 Plasmid extraction of successful transformants 
 
Transformed white colonies were picked using sterile pipete tips and cultured in 5ml 
LB broth containing 50µg/ml ampicilin (Sigma-Aldrich, UK) overnight at 37˚C in a 
shaking incubator. Plasmid was extracted and purified using a plasmid Miniprep kit 
(Sigma-Aldrich,  UK).  Overnight cultures  were centrifuged at 3000g for  10  minutes 
and the supernatant was discarded. Cels were re-suspended in 200µl of resuspension 
solution folowed by addition of 200µl of lysis solution and samples mixed by gentle 
inversion. Then 350µl of neutralization solution was added to the mixture, mixed by 
inversion and centrifuged for  10  minutes at  maximum speed.  The supernatant  was 
transfered to a  binding column in a colecting tube  previously  prepared  by adding 
500µl  of column  preparation solution and spun at  >12,000g for  1  minute  before 
discarding supernatant.  Next,  750µl  of  wash solution  was added to the column and 
centrifuged at  maximum speed for  1  minute.  The flow through  was  discarded.  A 
second spin was caried out for 1 minute to dry the column. Finaly to elute purified 
plasmid  DNA, the column  was transfered to a  new colecting tube and  50µl  of 
elution solution  was added and centrifuged for  1  minute.  The  purified  plasmid  was 
stored in -20˚C. 
 
2.8.8.4 Digestion of plasmid with EcoR1 
	  
Plasmids containing the  PCR  product  were screened  using restriction  digest. 
Reactions were caried out in a total volume of 20µl containing 5µl purified plasmid 
DNA,  2µl  of  10X reaction  bufer (Invitrogen,  UK),  0.5µl  of  EcoRI enzyme 
(Invitrogen, UK) and 12.5µl of molecular biology water. Reactions were incubated at 
37˚C in an incubator for 1 hour. Digests were run on 1% agarose gel alongside DNA 
hyperladder Π. 
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2.8.9 CDR3 sequencing and analysis 
	  
Plasmids containing inserts after digestion with EcoRI were sent for sequencing at the 
Natural  History  Museum  DNA  Sequencing service (London,  UK)  using the  M13 
primer (5’-  CTGGCCGTCGTTTTAC-  3’).  Sequence  data  was analysed  using 
GeneJockey Π software (Biosoft, UK). The identity of CDR3 region was determined 
using the International Immunogenetics (IMGT) information system  database 
(htp:/imgt.cines.fr/). 
 
2.9 Statistical analysis 
 
GraphPad  Prism5  Software (GraphPad  Software Inc,  USA) was  used for statistical 
analysis of the samples. Non-parametric Mann-Whitney statistical test was caried out 
to compare quantitative data obtained for healthy donors, CIS and MS patients as data 
points  did  not folow  normal  Gaussian  distribution.  A  one-tailed test  was  used as I 
was looking for an increase  or  decrease in the  parameter. Statisticaly significant 
diferences are indicated  on each figure  with the coresponding significance level; 
*p<0.05, **p<0.01, ***p<0.001. Moreover, other statistical test was performed such 
as parametric 1-Way ANOVA analysis to look at more than two groups of data and 
compare them and to test three or more means at one time by using variances. Since 
absolute numbers and MFI of flow cytometric data were not included in our analysis, 
1-Way ANOVA was not considered. For line 7 mice experiments, statistical analysis 
was not valid since only two DR15 controls were used and this is an extremely smal 
number.  
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3. Frequency of iNKT cels in MS patients  
	  
	  
A  decreased frequency  of iNKT cels  has  been reported in several autoimmune 
diseases including SLE (Yang et al.,  2003;  Kojo et al.,  2001;  Van  der  Vilet et al., 
2001), type 1  diabetes (Hong et al.,  2001;  Sharif et al.,  2001;  Wang et al.,  2001; 
Naumov et al., 2001) and MS (Ilés et al., 2000; Araki et al., 2003; Van der Vilet et 
al., 2001) compatible with the idea of a protective efect of iNKT cels opposing these 
immune diseases. 
 
Alterations in iNKT cels number and function have been reported in MS (Ilés et al., 
2000; Van der Vliet et al., 2001; Araki et al., 2003; Demoulins et al., 2003). A marked 
reduction  of iNKT cels frequency in the  peripheral  blood  of  MS patients  has  been 
demonstrated  using flow cytometry (Van  der  Vilet et al.,  2001; Araki et al.,  2003). 
O’Keefe and coleagues reported that iNKT cels from MS patients failed to expand 
and  produce IFN-γ  upon αGalCer stimulation, suggesting a  possible  defect in the 
efector functions  of this subset  during  disease (O’Keefe et al,  2008). Using the 
SSCP technique, Ilés and coleagues showed a decreased Vα24 mRNA levels in the 
peripheral  blood  of  MS  patients compared to  healthy controls (Ilés et al.,  2000). 
Moreover, It has been demonstrated with the use of polymerase chain reaction (PCR)-
based technology (immunoscope) and DNA sequencing, that the peripheral blood of 
relapsing  MS  patients exhibited a significant reduction in the levels  of  Vα24+ 
transcript (Demoulins et al., 2003). 
 
My initial aim was to see if I could shed further light on iNKT cel subset alterations, 
analysing a cohort of donors recruited at Charing Cross Hospital MS Clinic. 
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3.1 Frequency of iNKT cels in MS patients and healthy controls 
 
 
In  order to evaluate any  qualitative and  quantitative  diferences in the frequency  of 
iNKT cels in  MS  patients compared to  healthy controls,  peripheral  blood from  22 
healthy controls and  38  MS  patients  was colected and isolated  by  Histopaque 
centrifugation as  described in (Chapter  2, Section  2.2). Information related to age, 
gender and EDSS for al donors participated is summarized in (Table 3.1). 
 
Briefly,  8x106 cels were stained  on the same  day for flow cytometry  based 
immunophenotyping.  The antibody  panel  used for this study  was as  described in 
(Chapter  2, Section  2.3).  The folowing antibodies  were  used:  Anti-CD3 (V450), 
Anti-CD4 (V500),  Anti-CD8 (AlexaFluor  700),  Anti-CD56 (AlexaFluor 647), anti-
Vβ11 (FITC) and anti-Vα24 (PE).  Each sample  was run alongside its isotype and 
FMO controls.  
 
In order to identify iNKT cels, anti-Vα24 and anti-Vβ11 monoclonal antibodies were 
used.  Lymphocyte  populations  were  gated  on forward  versus side scater (Figure 
3.1A).  Doublets  were excluded from the analysis (data  not shown),  gating then  on 
CD3+ cels (Figure 3.1B). iNKT cels were identified as a double positive population 
by ploting Vα24 versus Vβ11 (Figure 3.1C). As iNKT cels can be defined as having 
either a CD4+CD8-, CD4-CD8- (DN), CD4+CD8+ (DP) or CD8+ phenotype, I assessed 
CD4+, DN, DP or CD8+ subpopulations using a gate based on CD4 and CD8 staining 
(Figure 3.1D). The percentages of CD4+, DN, DP and CD8+ iNKT cels so obtained 
were used for further statistical analysis. The data colected using Diva Software 6.0 
(BD,  Mountain  View,  CA)  was  processed for statistical analysis  using GraphPad 
Prism  5  Software. A  one-tail  Mann  Whitney test  was  used.  P  values  <  0.05  were 
considered significant. Figure  3.1 shows a representative imunophenotyping 
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experiment  by  means  of flow cytometry  performed  on a healthy control (E1), a 
treated  RRMS (E2) and a  PMS  patient (E3) (Figure  3.1). The  gating strategy and 
percentage of iNKT cels are indicated.      
 
 
Table  3.1: Characteristics  of immunophenotyping study  population (expressed 
as mean). 
	  
Diagnosis Number Female/Male Age EDSS 
Healthy controls 22 (14/8) 37 (25-53) - 
Progressive MS 9 (5/4) 56 (51-66) 6 (3-7) 
RRMS/untreated 11 (8/3) 44 (34-65) 2 (0-4.5) 
RRMS/on Interferon 8 (6/2) 36 (26-44) 2 (1-6) 
RRMS/on Natalizumab 10 (6/4) 45 (28-61)  3 (1-6) 
CIS 10 (7/3) 41 (30-48) 2 (0-4) 
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Figure 3.1: Frequency of iNKT cels in MS patients and healthy controls.  
Representative  of flow cytometry  dot  plots showing immunophenotyping and  gating 
strategies. Briefly, PBMCs were identified on the basis of forward and side scater (A), 
and then gated on CD3+ cels (B). iNKT cels were selected on the basis of Vα24 (PE) 
and Vβ11 (FITC) (C). Cels were then gated for CD4+, CD4-CD8-, CD4+CD8+ and CD8+ 
iNKT cels (D). iNKT cels  were  measured as a  percentage  of the  gated  population. 
These plots show representative analysis for  1  healthy control (E1),  1  RRMS treated 
patient (E2) and 1 progressive MS patient (E3). The same FACS data analysis was done 
for al healthy and MS patients. FACS analysis was caried out using BD Diva Software. 
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There was a striking diference between healthy controls and MS patients with respect 
to frequency of iNKT cels, the later group showing a significant decrease in iNKT 
cels (***p<0.001) (Figure 3.2A). 
 
Disease modifying treatments  may afect iNKT cels frequency and function. Gigli 
and coleagues  demonstrated that interferon therapy significantly increased the 
frequency of iNKT cels in PBMCs of MS patients and enhanced the secretion of IL-
4, IL-5 and IFN-γ  upon activation, suggesting that iNKT cel frequency can  be a 
corelate of response to treatment (Gigli et al., 2007). 
 
 
I therefore decided to investigate whether disease type or treatment had an efect on 
iNKT cel  number.   MS  patients  were  divided into subgroups  of  RRMS  patients 
treated  with IFNβ (RR-IFNb),  RRMS  untreated  patients (RRMS),  RRMS  patients 
treated with Natalizumab (RR-NatAb) and progressive MS patients (PMS). 
 
 
The frequency of iNKT cels was significantly increased in healthy controls compared 
to  untreated  RRMS  patients and  PMS  patients (**p<0.01, Figure  3.2B).  However, 
RRMS receiving IFNβ  or  Natalizumab showed a trend towards an increase in the 
iNKT cel  population, albeit  not reaching statisticaly significance.  A  potential 
confounder in this respect is that patients were recruited at diferent time point during 
the treatment course. To have an estimate of the number of iNKT cels in the samples, 
I  normalized al  data  using the folowing formula:  number  of iNKT events in the 
iNKT cels gate/ number of events of singlets x 100.  
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From the  diference in frequency  of iNKT cels  between  MS  patients and  healthy 
controls, I wondered whether iNKT cels are reduced at or before disease onset or 
become reduced as  disease  progresses and becomes  more severe.  To look at this I 
analysed  PBMC from  CIS  patients  who  had  presented  with  one symptomatic atack 
lasting for at least  24  hours.  Around 85%  of  MS  patients report  having initialy 
experienced a single, isolated atack, refered to as CIS (Miler et al., 2005). However, 
less than  50%  of  CIS  patients  wil  develop further symptoms  or  MRI evidence 
confirmatory of MS. By investigating iNKT alterations in CIS patients I hoped to gain 
insights into  distinguishing  between  high and low risk  patients for  development  of 
MS.  
 
iNKT cel frequency in  CIS samples appeared to  be intermediate  between  healthy 
controls and  MS  patients and there  was  no significant  diference  between  healthy 
control and CIS patients (Figure 3.2A). The frequency of iNKT cels was significantly 
decreased in  MS  patients compared to  CIS  patients (**p<0.01, Figure  3.2A). 
Moreover, the relative  percentage  of iNKT cels  was significantly increased in  CIS 
patients compared to untreated RRMS and PMS patients (*p<0.05, Figure 3.2B). 
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Figure 3.2: Diferences in frequency of iNKT cels in healthy controls, MS and CIS 
patients. 
iNKT cels  were identified in 22  healthy controls, 38  MS and  10  CIS  patients. iNKT 
cels  were  defined as those expressing Vα24 and  Vβ11 after  gated  on  CD3+ cels. (A) 
Comparison  between  healthy controls,  CIS and  MS  patients. (B)  Comparison  between 
CIS patients and MS patients divided into subgroups. Analysis was determined using BD 
Diva software and GraphPad Prism 5 Software. Statistical analysis caried out using the 
Mann-Whitney test: *p<0.05, **p<0.01, ***p<0.001. 
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3.2 Association between the percentage of iNKT cels and age in MS 
patients 
 
The efect of ageing process on peripheral iNKT cel numbers has only been assessed 
in limited number of studies, where iNKT percentages were shown to decrease with 
age in healthy donors (DelaRosa et al, 2002; Croug et al., 2004; Peralbo et al., 2006). 
The efect of age on iNKT cels numbers in MS patients has not been evaluated. In 
order to address  whether age  had an efect in  determining the reduced iNKT cel 
frequency observed in the older PMS patients, the corelation between age and iNKT 
cel  percentage  was calculated  using a  nonparametric  Spearman’s corelation 
coeficient. 
 
 
 
The  percentage  of circulating iNKT cels in  healthy controls,  RRMS and  PMS 
patients seemed to  decrease  with increasing age,  however this corelation  was  not 
significant (Figure 3.3). 
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Figure 3. 3: The degree of association between age and the percentage of iNKT 
cels.  
Lymphocytes from 22 healthy controls, 11 RRMS and 9 PMS patients were analysed. 
iNKT cels were identified based on the percentage of iNKT cels expressing Vα24 
and Vβ11. The association between the percentage of iNKT cels and age in healthy 
controls (A),  RRMS (B) and  PMS  patient (C). Analysis  was  determined  using BD 
Diva software and GraphPad Prism 5 Software. Statistical analysis caried out using 
nonparametric Spearman’s corelation coeficient. 
A 
B 
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3.3 Frequency of CD4+, CD8+, CD4-/CD8- and CD4+/CD8+ iNKT cels 
in MS patients 
 
 
Studies  by  Araki and coleagues reported that the reduction in iNKT cels  was 
restricted to CD4-/CD8- and CD8+ iNKT cels during remission in MS patients (Araki 
et al., 2003). Furthermore, CD4+ iNKT cels from MS patients were biased to a Th2 
profile in the remission state as they  produced  more IL-4,  which  may  be  protective 
during the remission state (Araki et al., 2003). Another study reported that CD4-/CD8- 
Vα24+  T cel clones from the  peripheral  blood  of  RRMS  patients  displayed lower 
frequencies of IL-4 than patients with progressive MS and controls (Gausling et al., 
2001). 
 
In my study, iNKT cels are initialy identified as Vα24+Vβ11+ double positive cels. 
However, they can  be further classified  by sub-dividing into  CD4+,  CD8+, 
CD4+/CD8+ and  CD4-/CD8- cels. I therefore looked at these subpopulations to 
investigate  whether the relative  proportion  of these subsets are afected  by  disease 
type and/or specific treatment.  
 
Statistical analysis  of lymphocytes from  untreated  RRMS  patients revealed an 
increase in circulating CD4+ iNKT cels when compared to healthy controls (*p<0.05, 
Figure  3.4A).  A trend towards a reduction in  CD4+ iNKT cels  was seen in  PMS 
patients with respect to al other type of donors (Figure 3.4A). Treatment with IFNb 
and  Natalizumab seems to  boost the level  of  CD4+ iNKT cels, albeit  not reaching 
statisticaly significance (Figure 3.4A). 
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Analysis  of  CD8+ iNKT cels showed  no significant  diferences  between  MS,  CIS 
patients and  healthy controls (Figure  3.4B).  However the trend is that  untreated 
RRMS and  PMS  patients  have a  decreased  proportion  of this subpopulation (Figure 
3.4B). 
 
A reduction in CD4-/CD8- iNKT cels was seen in untreated RRMS and PMS patients 
compared to healthy controls (*p<0.05, Figure 3.4C). Interestingly the levels of CD4-
/CD8- iNKT cels  were significantly increased in  RRMS  patients treated  with 
Natazilumab  with respect to  untreated  RRMS (*p<0.05, Figure  3.4C).  A trend 
towards an increase in  CD4+/CD8+ iNKT cels  was  observed in al  MS  patients 
compared to healthy controls (Figure 3.4D). 
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Figure 3.4: Frequency of CD4+, CD8+, DN and DP iNKT cels. 
Lymphocytes from  22  healthy controls,  38  MS and  10  CIS  patients were analysed. 
iNKT cels  were identified  based  on the  percentage  of iNKT cels expressing Vα24 
and Vβ11. Cels were then gated for CD4+ (A), CD8+ (B), DN (C) and DP (D) cels. 
Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5  Software. 
Statistical analysis caried  out  using Mann-Whitney test and represented as folows: 
*p<0.05. 
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3.4 Frequency of CD4+, CD8+, CD4-/CD8- and CD4+/CD8+ cels in MS 
patients: difference in T lymphocyte populations 
	  
I  wanted to investigate  whether there  was any significant  diference in the relative 
percentage  of  diferent lymphocyte  populations in  MS  patients compared to  healthy 
controls. Furthermore, I  wanted to examine if changes in  CD4+,  CD8+,  DN and  DP 
iNKT cels in MS patients were related to loss of specific lymphocyte population. To 
further characterise T lymphocyte subsets, I gated on CD3+ cels and then looked at 
the relative  percentage  of  CD4+ single  positive,  CD8+ single  positive,  CD4+CD8+ 
double positive (DP) and CD4-CD8- double negative (DN) cels. 
 
Flow cytometric analysis showed a significant reduction in the  percentage  of  CD8+ 
single  positive cels in PMS patients compared to  healthy controls and  CIS  patients 
(*p<0.05) and significant reduction  was  observed in  RR-NatAb  with respect to 
RRMS patients (***p<0.001, Figure 3.5A).  
 
There is a trend towards an increase in CD4+CD8+ cels in MS patients compared to 
healthy controls (Figure 3.5B).  
 
CD4-CD8- cels  were  decreased in  RRMS  patients compared to  healthy controls 
(*p<0.05) (Figure  3.5C) and significant reduction  was  observed in  RRMS patients 
with respect to RR-NatAb patients (*p<0.05, Figure 3.5C).  
 
There was no significant diference in the percentage of CD4+ cels between healthy 
controls and MS patients (Figure 3.5D). 
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Figure 3. 5: Relative percentage of CD4+, CD8+, DP and DN cels in MS patients. 
Lymphocytes from  22  healthy controls,  38  MS and  10  CIS  patients  were  gated  on 
CD3+ cels. Cels were then gated for CD8+ (A), DP (B), DN (C) and CD4+ (D) cels. 
Analysis  was  determined  using  BD  Diva software and  GraphPad  Prism  5  Software. 
Statistical analysis caried out using the Mann-Whitney test: *p<0.05, ***p<0.001. 
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3.5 Frequency of NKT cels in MS patients 
 
 
Diferent working definitions have been used for NKT cels; I have focused mainly on 
a wel-defined group of these cels that co-express Vα24 and Vβ11. Since the panel 
included CD3 and CD56 antibodies, I decided to investigate whether changes in NKT 
cels (defined as CD3+/CD56+ cels) were seen in MS and whether I could find any 
alteration  not specificaly related to iNKT (Vα24+/Vβ11+) cels  defined  on the  basis 
of TCR invariance.  
 
As shown in (Figure 3.6), I  did  not  observe any significant  diference in the 
percentage of CD3+/CD56+  NKT cels  between  MS  patients and  healthy controls, 
while the  percentage  of Vα24+/Vβ11+ iNKT cels  were significantly reduced in  MS 
patients compared to  healthy controls (***p<0.001, Figure 3.2A).   Thus, any 
functional  deficit in  MS  patients  must relate  not to  NKT cels per se,  but to the 
specific iNKT subset expressing their specific receptor. 
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Figure 3. 6: Frequency of NKT cels. 
Lymphocytes from  22  healthy controls and  38  MS  patients were analysed.  NKT cel 
were identified as CD3+/CD56+. Analysis was determined using BD Diva software and 
GraphPad  Prism  5 software.  Statistical analysis caried  out  using Mann-Whitney test 
and represented as folows: ***p<0.001. 
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3.6 Frequency of Vα24+ and Vβ11+ single positive cels in  MS 
patients 
 
 
In humans iNKT cels express a highly conserved TCR repertoire, which coresponds 
to the  gene  products  Vα24Jα18 and  Vβ11 (Porceli et al., 1993;  Delabona et al., 
1994; Lantz and Bendelac, 1994; Exley et al., 1997). Some previous studies have used 
Vα24 staining alone to define iNKT cels (O’Keefe et al., 2003; Valiante et al., 2000; 
Lucas et al.,  2003). It  has  been  demonstrated that the expression  of Vα24+/Vβ11+ 
cels  was around  1 log  higher than Vα24+ single  positive cels alone (Lucas et al., 
2003).  Therefore, I  wanted to investigate the relative  percentage  of single  positive 
Vα24+/ and Vβ11+ and verify whether there was any imbalance that might explain the 
dramatic decrease of iNKT cels in patients. 
 
Analysis  of lymphocytes from  RRMS  patients  on  Natalizumab therapy revealed a 
significant reduction in circulating Vα24+ single  positive cels when compared to 
untreated  RRMS (**p<0.01, Figure  3.7A).  The frequency  of Vα24+ single  positive 
cels was significantly increased in CIS patients compared to PMS patients (*p<0.05, 
Figure 3.7A).  
 
When looking at Vβ11+ single positive cels, a reduction in this population was seen 
in PMS (**p<0.01) and CIS (*p<0.05) patients compared to healthy controls (Figure 
3.7B). The cause for this variation within the Vβ11 single positive cels without great 
diferences within Vα24 single positive cels is not yet clear.  
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Figure 3. 7: Frequency of Vα24+ and Vβ11+ single positive cels. 
Lymphocytes from  22  healthy controls,  38  MS and  10  CIS  patients were analysed. 
Vα24+ single positive cels were identified as cels lying in the Vα24 single positive 
gate (A) Vα24+. Vβ11+ single positive cels were identified as cels lying in the Vβ11 
single positive  gate (B) Vβ11+.  Analysis  was  determined  using BD  Diva  Software 
and GraphPad Prism 5 Software. Statistical analysis caried out using Mann-Whitney 
test and represented as folows: *p<0.05, **p<0.01. 
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3.7 Comparison between Vα24+/Vβ11+ and CD1d-glycolipid 
tetramer staining 
 
 
iNKT cels can be detected in human peripheral blood using either Vα24 and Vβ11 
TCR specific antibodies or CD1d glycolipid tetramers (Karadimitris et al., 2001; Liu 
et al.,  2006). CD1d-αGalCer loaded tetramers  have  been  used as a sensitive tool to 
stain both mouse and human iNKT cels (Matsuda et al., 2000; Benlagha et al., 2000; 
Liu et al.,  2006). The readily available combination  of antibodies is  used  more 
frequently in phenotypic analysis. It has been demonstrated that Vα24+/Vβ11+ double 
positive iNKT cels overlap almost completely with CD1d-αGalCer tetramer positive 
cels (Karadimitris et al., 2001). The specificity of CD1d-αGalCer tetramer binding is 
further shown  by the ability  of  CD1d-αGalCer tetramers to expand cultures for the 
presence of Vα24+/Vβ11+ T cels (Karadimitris et al., 2001). 
 
To investigate the optimal methods for iNKT cels staining, I compared staining with 
TCR antibodies and  CD1d loaded  with  PBS-57 tetramer; PBS-57 is an analogue  of 
αGalCer complexed to  CD1d tetramers  developed  by the  NIH  Tetramer  Facility. 
Figure 3.8A shows a representative flow cytometry plot in which 0.4% of T cels co-
express Vα24+ and  Vβ11+ TCR.  Staining  of the same cels  with  CD1d loaded  with 
PBS-57 tetramer shows exactly the same frequency  of CD1d tetramer+ cels (Figure 
3.8B), verifying the ability of CD1d loaded with PBS-57 tetramer to stain Vα24+ and 
Vβ11+ cels.  Further experiments  were caried  out to confirm the specificity  of the 
tetramers. Figure  3.9A shows that Vα24+/Vβ11+ antibodies give similar  paterns  of 
staining when compared to CD1d glycolipid tetramers staining (Figure 3.9B) in MS 
patients and healthy controls.  
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It was noted that 1 healthy control, 1 CIS and 5 (2 PMS, 1 RR-IFNb, 2 RRMS) MS 
patients express double populations of iNKT cels as stained by either Vα24+/Vβ11+ 
antibodies (Figure 3.10A) or CD1d glycolipid tetramers (Figure 3.10B). This may be 
compatible with the notion of high and low receptor density cels, potentialy due to 
expression of dual TCRα chains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure  3. 8:  Comparison  between Vα24+/Vβ11+  and CD1d-glycolipid tetramers 
staining. 
Example  of flow cytometry  dot  plots showing iNKT cels using either  CD1d 
glycolipid tetramers  or  Vα24 and  Vβ11 antibodies  gating  on  CD3+ cels. 
Vα24+/Vβ11+ (A), and CD1d tetramer+ cels (B). Analysis was determined using BD 
Diva Software. 
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Figure  3. 9:  Comparison  between the frequency  of Vα24+/Vβ11+  and CD1d-
glycolipid tetramers. 
Lymphocytes from  15  healthy controls and  24  MS  patients were analysed.  The 
percentage of iNKT cels using either CD1d glycolipid tetramers or Vα24 and Vβ11 
was  gated  on  CD3+ cels. (A) Vα24+/Vβ11+ (B)  CD1d+.  Analysis  was  determined 
using BD Diva software and GraphPad Prism 5 Software. Statistical analysis caried 
out using Mann-Whitney test and represented as folows: *p<0.05. 
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Figure 3. 10: Double population of iNKT cels. 
Representative flow cytometry  dot  plot showing iNKT cels  with  double  population 
for 1 healthy control. Double populations similar to the ones showed in these pictures 
were seen for 1 CIS and 5 MS (2 PMS, 1 RR-IFNb, 2 RR) patients. iNKT cels were 
selected on the basis of Vα24 and Vβ11 or CD1d/ CD3+. (A) Vα24+/Vβ11+ (B) CD1d 
tetramer+ cels. FACS analysis was caried out using BD Diva Software. 
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3.8 Analysis of iNKT cels in Line 7 mice 
 
 
Being based in a lab that has emphasized the value of transgenic models humanized 
with respect to HLA and TCR for the modeling of spontaneous, MS-like disease, I 
speculated that such mice might aford an opportunity to explore the role of iNKT cel 
alterations in  pathogenesis.  The  Line  7  model is a  T cel  driven  disease  model, so I 
hypothesized that, if changes to the iNKT cel compartment were downstream of this 
pathological  process, the  model  might  be expected to show a similar  phenotype to 
human  patients.  This  would in turn  open  up the  possibility for  more  detailed 
longitudinal and mechanistic studies. 
 
Several studies  have shown that stimulation  of iNKT cels  with αGalCer  protects 
mice against  EAE (Singh et al.,  2001; Miyamoto et al.,  2001; Mars et al.,  2002; 
Furlan et al.,  2003). The  protective efect  of iNKT cels can  be atributed to their 
ability to secrete IL-4 and/or IL-10 (Godfrey et al., 2000; Pal et al., 2001; Singh et al., 
2001; Miyamoto et al., 2001).  
 
Animal models, and specificaly, EAE in mice and rats, are extensively utilized in MS 
research (Steinman and Zamvil, 2005; Steinman and Zamvil, 2006; Lassmann, 2007). 
I here used flow cytometry to investigate whether there was any diference in iNKT 
cels frequency in spleen and thymus of Line 7 mice. I used mice scoring between 0 
and 3 (see Chapter 2 for more details on the scoring process Table 2.8), while the age 
was between 67 and 69 weeks (Table 3.2).  
 
For these experiments, mice  were culed and spleen and thymus  were  harvested. 
DR15  mice  were  used as control. Briefly,  1x106 cels from  both spleen and thymus 
were stained on the same day for immunophenotyping by means of flow cytometry. 
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The antibody panel used for this study is described in (Chapter 2, Section 2.6.3). Anti-
CD3 (FITC) and CD1d tetramer loaded with PBS57 (PE) were used to gate on mouse 
iNKT cels both in spleen and thymus. Each sample was run alongside with its isotype 
and FMO controls.  
 
 
Table  3.2:  Characteristics  of  DR15 controls  and  Line  7  mice (expressed  as 
median). 
 
Diagnosis Number Female/Male Age (weeks) Score 
DR15 controls 2 2/0 16 (16) na 
Line 7 mice 7 3/4 68 (67-69) 2 (0-3) 
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Preliminary analysis revealed that the frequency of iNKT cels is reduced in both the 
spleen and the thymus  of Line  7  mice compared to control  mice (Figure  3.11A and 
B).  Since  only two  DR15 control  mice  were  used as control, i  did  not  perform any 
statistical analysis.  
 
 
 
 
 
Figure 3. 11: Frequency of iNKT cels in Line 7 mice. 
The percentage  of iNKT cels expressing  CD1d tetramer+ cels  was  gated  on  CD3+ 
cels. (A) Line 7 spleen (B); Line 7 thymus. Data analysis was caried out using BD 
Diva software.  Flow cytometry  data  were  processed  using GraphPad  Prism  5 
Software.  
(A) Line 7 spleen (A) Line 7 thymus 
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3.9 Optimization of a protocol for staining tissue bank brain sections 
with CD1d tetramer  
 
 
The data described in the preceding section raise a number of questions. The paucity 
of iNKT cels in the periphery of MS patients suggests either that, as cause or efect 
of the  disease they are absent,  or  possibly that as  part  of the  CNS inflammatory 
process they have migrated to that site. Elevated proportion of invariant Vα24 TCR 
was identified in inflammatory lesions of human diseases including periodontitis and 
chronic inflammatory demyelinating polyneuropathy lesions (Yamazaki et al., 2001; 
Iles et al.,  2003),  but it  was rarely expressed in  MS lesions  or in rheumatoid 
synovium (Iles et al.,  2003;  Maeda et al.,  1999). There  have  been relatively few 
studies involving the use of tetramers to stain human tissue sections (Reynolds et al., 
2009). In  order to conduct this study in  UK  MS  Tissue  Bank samples, it  was first 
necessary to optimize a staining protocol using human lymphoid tissue. 
 
	  
3.9.1 Tested protocol on positive control tissue (human tonsils) 
 
We evaluated iNKT cel staining in the  periphery using  CD1d loaded and  unloaded 
tetramers provided by the NIH Tetramer Facility. Figure 3.12 shows a representative 
experiment in which loaded and unloaded tetramers were used to stain tonsil sections. 
A positive signal were mostly observed cels in connective tissue rather than germinal 
centres (Figure  3.12A)  while  no signal  was  observed  with  CD1d  unloaded tetramer 
(Figure 3.12B). 
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3.9.2 Human brain tissue section staining 
 
Preliminary immunofluorescence staining  of control  brain tissue and  brain samples 
from MS cases from the UK MS Tissue Bank were evaluated for staining with CD1d 
tetramer (Figure 3.13). Staining revealed very few positive cels scatered throughout 
the white mater (WM) in 2 out of 5 MS cases (Figure 3.13B) compared to controls 
(Figure 3.13A).  The signal appeared to  be  on the cel surface  of cels  with 
lymphocytic  morphology, confirming the likely specificity (Figure 3.13C).  This 
preliminary observation is indicative of very few CD1d positive cels in post-mortem 
MS  brain sections.  However the  phenotype  of these cels remains to  be confirmed 
using additional markers such as CD3, CD4 and CD8. 
 
 
 
 
 
 
A 
Loaded  
	  
B 
Unloaded 
	  
Figure 3. 12: CD1d tetramer staining in positive control human tonsils. 
Control tonsil sections were stained with loaded and unloaded CD1d tetramer. Loaded 
CD1d tetramer showed a strong positive signal on tonsil sections (A) mostly on cels 
in connective tissue. As a negative control unloaded CD1d tetramer was used and no 
specific staining was observed (B). Magnification x20.	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Figure 3. 13: CD1d tetramer staining in MS and control white mater. 
MS and control  brain tissue sections  were stained for PBS-57 loaded and  unloaded 
CD1d tetramer.  Staining  of loaded  CD1d tetramer showed  no specific staining in 
control tissue (A) compared to  MS tissue (B).  Unloaded  CD1d tetramer showed  no 
specific staining.  A  negative control  used  unloaded  CD1d tetramer. Magnification 
x60.	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3.10 Discussion 
 
The data presented in this chapter demonstrate a significant reduction of iNKT cels in 
the periphery of MS patients compared to healthy controls. These results confirm and 
coroborate  previous findings reported  by  others  groups (Iles et al., 2000; Van  der 
Vilet et al., 2001; Araki et al., 2003). Because I wanted to have a beter understanding 
of the immunological significance  of iNKT cel changes in  MS, I aimed to  define 
iNKT subsets in  MS  patients of  diferent  disease types, CIS  patients as  wel as 
patients on diferent treatments, by multiparameter flow cytometry. 
 
Stratifying MS donors into RRMS, RR-IFNb, RR-NatAb and PMS, the frequency of 
iNKT cels was reduced in al groups compared to healthy controls. However, RRMS 
treated  with  both IFNβ and  Natalizumab showed a  mild increase in the iNKT cel 
population  with respect to  RRMS and  PMS, albeit  not reaching statistical 
significance.  This  might  be explained  with the fact that  patients  were recruited at 
diferent time points during treatments, as the aim of this study was not to conduct a 
systematic analysis of the efects of diferent drugs at diferent time points. While this 
indicated that iNKT cel reductions are somehow related to disease phenotype, it was 
not elucidated whether iNKT cels defects occurs prior to the development of MS and 
thus contribute to  disease  onset,  or they  may  be reduced as a consequence  of the 
disease, either through diferences in cytokine networks, in cel-turnover, proliferation 
and induction  of  programmed cel  death,  or  might  be sequestered in the  CNS. This 
might explain diferences iNKT cel defects observed by diferent studies, especialy 
as iNKT cels were investigated during diferent stages of the disease (Gausling et al., 
2001; Iles et al., 2000; Araki et al., 2003; Demoulins et al., 2003; Gigli et al., 2007; 
O’Keefe et al., 2008). To define the causes of the iNKT deficiency in MS patients, I 
investigated the role  of iNKT cels in CIS  patients, to  determine  whether iNKT 
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changes precede confirmed, overt disease and might guide us to distinguish between 
high and low risk  patients  of  developing  MS and  might  help in  making a  decision 
about early treating  CIS  patients at  higher risk. The  data showed that iNKT cel 
frequency appeared to be intermediate between healthy controls and MS patients and 
there  was  no significant  diference  between  healthy controls and  CIS  patients. 
However, the frequency of iNKT cels  was significantly  decreased in  MS  patients 
compared to  CIS  patients.  This suggests that iNKT cel changes  may indeed  have a 
role at disease onset. 
 
To investigate the possibility of impairment in maturation on iNKT cel was present 
in MS patients, subpopulations of iNKT cels were identified in al healthy controls, 
MS and CIS  patients:  CD4+,  CD8+,  CD4-/CD8- and CD4+/CD8+ iNKT cels. The 
results presented in this study showed a significant elevation in the frequency of CD4+ 
iNKT cels in  RRMS  patients compared to  healthy controls.  Treatment  with  both 
IFNβ and  Natalizumab increased the frequency  of  CD4+ iNKT cels, in line  with 
previous findings that interferon treatment increases the frequency  of iNKT cels in 
PBMCs of MS patients (Gigli et al., 2007). This further supports the notion that gross 
iNKT levels are a disease corelate and possibly that one mode of action of IFNβ may 
involve re-constitution of a regulatory iNKT compartment through the modulation of 
myeloid  DCs  via  up-regulation  of co-stimulatory  molecules including  CD1d,  CD80 
and CD40 (Gigli et al., 2007). The results are compatible with previous reports that 
CD4+ iNKT cels are  biased towards  Th2 cytokines  during remission,  proposed to 
have an immuno-regulatory role (Araki et al., 2003).  
 
The data also showed a significant reduction in CD4-/CD8- iNKT cels in RRMS and 
PMS patients when compared to healthy controls. This is in agreement with results by 
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Araki et al. (2003) that atributed the reduction of iNKT cels in MS patients mainly 
to changes in the CD4-/CD8- subset. Most of the iNKT cels in healthy controls are 
CD4-/CD8- and they are significantly higher in healthy controls than RRMS and PMS 
patients, thus suggesting a protective role of double negative CD4-/CD8- cels in the 
disease. The CD4-/CD8- subset has  been atributed  various  properties in  microaray 
analysis including enhanced cytotoxic functions as suggested  by  high  NCR3 
expression and homing to non-lymphoid tissue, suggested by CCR6 expression (Lin 
et al., 2006). This may perhaps suggest a role of this subset in healthy individuals in 
the regulation of autoreactive T cel clones via cytolysis. 
 
I found a trend towards a reduction in CD8+ iNKT cels in RRMS and PMS patients 
compared to healthy controls and CIS patients, in agreement with Araki et al., 2003. I 
also analysed the  proportion  of  CD4+/CD8+ iNKT cels in  our cohort.  Analysis  of 
CD4+/CD8+ iNKT cels showed no significant diferences between MS, CIS patients 
and  healthy controls.  However the trend is that all  MS  patients  have an increased 
proportion  of these subpopulations compared to  healthy controls and  CIS  patients. 
Decreased  proportion  of CD8+ subpopulation in  untreated  RRMS and  PMS  patients 
have raised the possibility that diferent iNKT cel subsets might undergo through a 
sort of accumulation in a specific maturation stage without being able to progress to 
the next step. 
 
This hypothesis cannot be easily verified in humans, but transgenic line of mice that 
spontaneously develop a disease similar to MS might be enlightening on this mater. 
There is compeling evidence that CD1d-restricted iNKT cels  have a  vital role in 
autoimmunity in transgenic  mice, in  which expansion  of iNKT cels through 
administration  of αGalCer (Hong et al.,  2001; Miyamoto et al.,  2001; Singh et al., 
2001; Sharif et al., 2001; Mars et al., 2002; Furlan et al., 2003) or by up-regulation of 
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CD1d expression  within the site  of autoimmunity (Falcone et al.,  2004)  provided 
protection against autoimmune  disease and controled  disease  progression in  pre-
clinical models of MS and type 1 diabetes. Moreover, deletion of the CD1 locus and 
lack  of iNKT cels  worsened autoimmune  diabetes in the  NOD  mouse (Shi et al., 
2001). Line 7 mice model represent a pathologicaly relevant model for human MS, 
which  provide a  unique  opportunity to elaborate  on the  utility  of functional and 
mechanistic studies  using the  mouse  model,  which  would  not  be  possible in the 
human system	  particularly celular interactions involved in disease onset since	  disease 
is spontaneous and  occurs in the absence  of adjuvants required to activate 
autoreactive  CD4  T cels.  My  preliminary analysis demonstrated a reduction in the 
frequency of iNKT cels in both the spleen and the thymus of Line 7 mice compared 
to control mice. However, limitations faced in the number of Line 7 and control mice 
used.  Therefore, greater experimental  numbers should  be considered to ensure 
statistical meaning. 
 
This  prompted  us to speculate a  diferent recruitment  of subpopulation  of cels in 
other compartments (e.g. the brain) and to investigate a diferent maturation pathway 
of  T cels in the  periphery. In  order to further investigate a  diferent recruitment  of 
subpopulation of cels in other compartment, namely the brain, we decided to evaluate 
the presence and distribution of iNKT cels in brain tissue sections from MS patients 
and  healthy controls. It  has  been speculated that iNKT cels  deficiency in the 
periphery might be as a consequence of iNKT cels traficking to lesions in the CNS, 
but this theory is not supported by the observation of a low percentage of iNKT cels 
in the  CNS (Iles et al., 2000). In this  preliminary study  we  used an IF staining 
method  using  CD1d tetramer loaded  with  PBS-57 to identify iNKT cels.  We 
validated  our staining  using tonsils and  were able to identify iNKT cels. It  was 
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noteworthy that  MS  brain tissue sections revealed  very few  positive cels scatered 
throughout the  WM compared to controls and then  only in  2  out  of  5 cases, while 
unloaded  CD1d tetramer showed  no specific staining compared to the  CD1d loaded 
tetramer staining of MS cases confirming specificity. This preliminary observation is 
indicative  of  very few  CD1d  positive cels in  post-mortem  MS  brain sections. 
However the phenotype of these cels remains to be confirmed and it does not seem 
that iNKT cels have migrated from the periphery to the CNS. The assumption must 
be that the reduction in  peripheral iNKT cels in  MS  patients is absolute rather a 
reflection of migration to another site. From the animal models one can speculate that 
this  peripheral  deficiency in some  way alows the exacerbation  of autoimmunity, 
either through the loss  of anti-inflammatory cytokines  or the loss  of a function in 
cytolysis of autoreactive T cels.  
 
I then  hypothesised that selective expression  of specific  TCR  or receptors  on the 
iNKT cel surface  might  be important in  defining  whether a  defined  phenotype  of 
iNKT cels is predominant in MS. 
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4. TCR Vα24 and Vβ11 CDR3 region analysis in iNKT cels 
of MS patients 
 
iNKT cels were defined on the basic of expression of a CD1d-restricted, invariant, αβ 
TCR and  NK cel  markers including  NK1.1  or (CD161)  (Delabona et al., 1994; 
Exley et al.,  1997;  Exley et al.,  1998). iNKT cels in  mouse express an invariant 
TCRα chain (Vα14-Jα18) associated  with a limited  number  of β chains (Vβ8.1, 
Vβ8.2, Vβ8.3, Vβ2 or Vβ7) (Koseki et al., 1991; Lantz and Bendelac 1994; Makino et 
al., 1995; Bendelac et al., 1997; Apostolou et al., 2000). These Vβ chains are highly 
diverse, in particular in their  CDR3 and Jβ segment  usage (Behar et al.,  1999; 
Apostolou et al., 2000; Matsuda et al., 2001). In humans, iNKT cels express a highly 
conserved TCR repertoire expressing an invariant Vα24 rearangement (Vα24-Jα18), 
paired  with  Vβ11 (Porceli et al., 1993;  Delabona et al., 1994;  Lantz and  Bendelac 
1994;  Exley et al., 1997;  Exley et al.,  1998). Structural studies  of iNKT  TCR 
interactions  with  CD1d reveal  diferences from classical  TCR/MHC class I 
interaction.  The invariant iNKT TCR adopts a  unique, paralel docking  mode to the 
CD1d-glycolipid complex (Koch et al., 2005; Borg et al., 2007). The crystal structure 
of CD1d–αGalCer in complex with the iNKT Vα24Vβ11 TCR was reported in 2007 
(Borg et al.,  2007).  According to this structure, CDR1α and  CDR3α loops  of the 
invariant TCRα were found to be responsible for the binding with αGalCer and CD1d 
molecules. Docking  of the  TCRβ chain  was limited to the  CDR2β loop,  which also 
interacts  with αGalCer/CD1d  molecules (Malevaey et al.,  2009).  The  only  non-
germline encoded region of the iNKT TCR is CDR3β, which does not seem to make 
contact  with the antigen  directly.  Murine iNKT cels recognition  of αGalCer/CD1d 
complex  has  been shown to  be  mediated  via the  CDR2β and  CDR3β loops  of the 
iNKT TCR (Malevaey et al., 2009). The hypervariable CDR3β loop has a vital role 
in regulating the afinity  of the iNKT  TCR to CD1d (Matulis et al.,  2010).  Several 
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mechanisms  have  been  proposed to explain the  Vβ  bias in the iNKT cel repertoire 
including the efect of thymic selection during NKT cel development (Schumann et 
al.,  2006;  Wei et al.,  2006) or  preference for  pairing  with iNKT  TCRα chain 
(Degermann et al., 1999; Gui et al., 2001). 
 
Using  SSCP to examine  TCR repertoire, Ilés et al (2000) showed that  MS patients 
have  decreased levels  of  Vα24  mRNA in the  blood compared to  healthy controls. 
Démoulins and coleagues investigated the expression  of  Vα24+ T-cel repertoire in 
the entire  blood  of  MS  patients  during relapses  using  PCR-based technology 
(immunoscope) and extensive DNA sequencing. They observed a marked reduction in 
the  number and  diversity  of the  Vα24+ T-cel transcripts, suggesting that 
perturbations  of the  Vα24+ T-cel repertoire led to circulating iNKT cel  defects in 
MS (Démoulins et al., 2003).  
 
My aim  here  was to investigate  whether there is any  qualitative alteration in iNKT 
cels from  healthy controls and  MS  patients  with reference to  TCR sequence.  Since 
there have been some recent observations to the efect that the CDR3 regions of iNKT 
cels  may  be less invariant than  had  previously  been thought (Gadola et al.,  2002; 
Gadola et al., 2006; Sanderson et al., 2012), identification of changes in CDR3 usage 
relative to the canonical iNKT motif may be helpful in determining if there are likely 
to be disease-related changes in TCR specificity or afinity. 
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4.1 FACS sorting of iNKT cels  
 
 
In order to determine whether Vα24 and Vβ11 TCR CDR3 length and sequence has 
an impact  on the  TCR  of iNKT cels in  MS  patients compared to  healthy controls, 
peripheral  blood from  4  healthy controls and  3  untreated  RRMS  patients  were 
colected (Table 4.1) and isolated using Histopaque centrifugation as described in the 
(Chapter 2, Section 2.2). The 3 untreated RRMS patients had active disease and were 
about to start Natalizumab treatment. Briefly, 40 x 106 cels were stained on the same 
day  using a cocktail  of antibodies  described in (Section  2.8.2). iNKT cels  were 
analysed and sorted on the same day using a FACS Aria I SORP flow cytometer. The 
purity  of sorted iNKT cels  was >99%. In  order to identify iNKT cels,  both anti-
Vα24 and anti-Vβ11  monoclonal antibodies  were  used (Chapter  2,  Table  2.12). 
Lymphocyte  populations  were  gated  on forward  versus side scater (Figure  4.1A). 
Doublet events  were excluded from the analysis (data  not shown), then  gating  on 
CD3+ cels (Figure 4.1B). iNKT cels were identified as a double positive population 
by ploting Vα24 versus Vβ11 (Figure 4.1C).  
 
Table  4.1:  Summary  of  demographics  and clinical information (expressed  as 
median) related to age, gender and EDSS for al donors.  
 
Diagnosis Number Female/Male Age EDSS 
Healthy controls 4 3/1 44 (41-50) NA 
RRMS/untreated 3 3/0 30 (25-33) 2 (1.5-2) 
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Figure 4.1: FACS analysis of sorted iNKT cels from a healthy control sample. 
FACS  dot  plots showing immunophenotyping and  gating strategies  used in sorting 
iNKT cels. Briefly, PBMCs were identified on the basis of forward and side scater 
(A). Then  gated  on CD3+ cels (B). iNKT cels  were selected on the  basis  of  being 
Vα24 (PE) and  Vβ11 (FITC)  positive (C).  Plots  before (i) and after sorting (i) are 
shown. 
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Figure 4.2: FACS analysis of sorted iNKT cels from a MS patient sample. 
FACS  dot  plots showing immunophenotyping and  gating strategies  used in sorting 
iNKT cels.  Briefly,  PBMCs  were identified  on the  basis  of forward and sideward 
scater (A). Then gated on CD3+ cels (B). iNKT cels were selected on the basis of 
being Vα24 (PE) and Vβ11 (FITC) positive (C). Plots before (i) and after sorting (i) 
are shown. 
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4.2 PCR strategy 
 
 
RNA was extracted from sorted iNKT cels (Chapter 2, Section 2.8.3) and converted 
to cDNA (Chapter  2,  Section  2.8.4) to alow  TA cloning  of  TCR  CDR3 region 
sequences. Primers  were  designed to amplify  TCR  Vα24 and  Vβ11  CDR3 regions 
(Chapter  2, Section  2.8.5). To  optimise  PCR conditions,  primers  were tested  using 
diferent concentrations  of  magnesium chloride (1.5mM, 1.75mM,  2mM,  2.25mM, 
2.5mM) and  diferent annealing temperatures (55˚C-60˚C).  Amplicons  were 
successfuly  generated at  1.5mM  MgCl2 concentration and a  melting temperature  of 
55˚C (Figure 4.3B and C). TCR Vα24 and Vβ11 CDR3 regions in iNKT cels were 
amplified by two rounds of PCR using nested PCR strategy as starting quantities of 
cDNA, particularly in MS patient samples, were very low (Chapter 2, Section 2.8.5). 
Our nested PCR strategy involves one set of forward primer and two sets of reverse 
primers, used in two runs of PCR (Figure 4.3A). The DNA undergoes the first run of 
PCR with the forward primer and first set of reverse primers. The PCR product from 
the first reaction undergoes a second run with the second set of reverse primers. The 
reverse primers were located in the constant region to make sure we are amplifying al 
sequences and the J region can be variable. 
 
 
 
 
 
 
 
 
	   147	  
 
 
 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 4.3: Optimisation of Vα24 and Vβ11 primers.  
(A)  Schematic  diagram  of the nested  PCR strategy  used to clone  VJ region from 
iNKT cels. 1% agarose gel picture showing amplification using (B) Vα24 (C) Vβ11 
primers. (1) The first run of PCR using reverse primer 1. (2) The second run of PCR 
using reverse primer 2. The PCR was performed using 1.5mM MgCl2 concentration 
at 55°C. Hyperladder I was used. 
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4.3 Amplification of TCR Vα24/Vβ11 CDR3 regions 
 
Folowing optimisation of reaction conditions for the Vα24 and Vβ11 PCRs, cDNA 
from sorted iNKT cels from  4  healthy controls and  3  MS  patients  were  used.  PCR 
reactions  were  performed  using the  optimal MgCl2 concentration  of  1.5mM and 
optimal annealing temperature of 55˚C. PCR products coresponding to both α and β 
TCR chains  were separated  on  1% agarose  gels (Figure  4.4).  PCR  products  were 
excised from the  gel,  purified  by  gel extraction and then ligated into the  pCR2.1 
vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Amplification of Vα24 and Vβ11 regions in sorted iNKT cels.  
1% agarose gel picture of PCR products. Vα and Vβ CDR3 regions were successfuly 
amplified in sorted iNKT cels from  both  healthy control and  MS  patient samples. 
Hyperladder I was used. 
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4.4 TA cloning 
 
The ligation products were transformed into E. coli (XL-10 gold strain) and selected 
on  LB agar containing ampicilin.  At least twenty-four transformed  white colonies 
were  picked from each  plate folowed  by  plasmid extraction and  EcoR1 restriction 
digest to check for the presence of inserts. Figure 4.5 shows plasmids containing the 
Vα24 and  Vβ11 inserts. Plasmids containing insert  were sent for sequencing using 
the M13 primer (5’- CTGGCCGTCGTTTTAC- 3’) (Chapter 2, Section 2.8.9). 
 
 
 C 
A B 
D 
Figure  4.5: EcoR1 restriction  digests  of  plasmid from transformants in sorted 
iNKT cels. 
Agarose  gel  picture  of the  pCR2.1  plasmid and  PCR  products  digested  with  EcoR1 
enzyme. Plasmids were successfuly transformed. (A) Vα24 was amplified in sorted 
iNKT cels in healthy control; (B) Vβ11 was amplified in sorted iNKT cels in healthy 
control; (C) Vα24 was amplified in sorted iNKT cels in MS patient. (D) Vβ11 was 
amplified in sorted iNKT cels in MS patient. Hyperladder I was used. 
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4.5 CDR3 analysis in healthy donors and MS patients 
 
Sequence  data  was analysed  using  GeneJockey Π software in terms  of  V region, J 
region, length and sequence  of the  CDR3 for  both  TCRα24 and  TCRβ11 chains. V 
and J region aleles used in each individual sequence were identified using the IMGT 
website.  The identity  of  CDR3 region  was  determined according to the IMGT 
database. 
 
4.6 TCR Vα24 CDR3 analysis in healthy controls and MS patients  
 
Single amino acid variations of the invariant Vα24-Jα18 α chain of human iNKT-cel 
TCRs  have  been identified (Kent et al.,  1999;  Exley et al.,  2008).  Exley and 
coleagues reported that  4 to  30%  of  human iNKT cel clones expressed such 
variations  of the  Vα24-­‐Jα18 chain (Exley et al.,  2008).  Consistent  with this, 
Sanderson and coleagues found four diferent Vα24-­‐Jα18 variants (VVS-­‐DRG, VVT-
DRG, VVN-DRG and  VVI-DRG) with single amino acid  variations  namely serine 
(Ser93), threonine (Thr93), asparagine (Asn93)  or isoleucine (Ile93) within the 
Vα24-­‐Jα18 junction at the middle position of codon 93 (Sanderson et al., 2012). 
 
My analysis of TCR α chain sequences including V region, J region, CDR3 sequence 
and length  was caried  out in sorted iNKT cels from  healthy controls and  MS 
patients. Results of this analysis are shown in (Table 4.2: healthy controls and Table 
4.3: MS  patients).  Al  HC and  MS cases analysed expressed the same  CDR3, 
comprised of CVVSDRGSTLGRLYF and were 13 amino acids long.  
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Table 4.2: TCR α sequences obtained from TCR CDR3 analysis of sorted iNKT 
cels from healthy controls.  
TRAV and TRAJ are shown along with the amino acid sequence and the length of the 
CDR3 region. 
	  
Healthy 
control TRAV CDR3α region TRAJ 
CDR3α 
Length 
HC1/A4 10 CVVSDRGSTLGRLYF 18 13 
HC1/A5 10 CVVSDRGSTLGRLYF 18 13 
HC1/A6 10 CVVSDRGSTLGRLYF 18 13 
HC1/A7 10 CVVSDRGSTLGRLYF 18 13 
HC2     
HC2/A1 10 CVVSDRGSTLGRLYF 18 13 
HC2/A2 10 CVVSDRGSTLGRLYF 18 13 
HC2/A3 10 CVVSDRGSTLGRLYF 18 13 
HC2/A4 10 CVVSDRGSTLGRLYF 18 13 
HC2/A5 10 CVVSDRGSTLGRLYF 18 13 
HC3     
HC3/A1 10 CVVSDRGSTLGRLYF 18 13 
HC3/A2 10 CVVSDRGSTLGRLYF 18 13 
HC3/A3 10 CVVSDRGSTLGRLYF 18 13 
HC3/A4 10 CVVSDRGSTLGRLYF 18 13 
HC3/A5 10 CVVSDRGSTLGRLYF 18 13 
HC4     
HC4/A18 10 CVVSDRGSTLGRLYF 18 13 
HC4/A19 10 CVVSDRGSTLGRLYF 18 13 
HC4/A20 10 CVVSDRGSTLGRLYF 18 13 
HC4/A21 10 CVVSDRGSTLGRLYF 18 13 
HC4/A22 10 CVVSDRGSTLGRLYF 18 13 
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Table 4. 3: TCR α sequences obtained from TCR CDR3 analysis of sorted iNKT 
cels from MS patients.  
TRAV and TRAJ are shown along with the amino acid sequence and the length of the 
CDR3 region. 
	  
	  
MS 
patient TRAV CDR3α region TRAJ 
CDR3α 
Length 
MS1/A1 10 CVVSDRGSTLGRLYF 18 13 
MS1/A2 10 CVVSDRGSTLGRLYF 18 13 
MS1/A3 10 CVVSDRGSTLGRLYF 18 13 
MS1/A4 10 CVVSDRGSTLGRLYF 18 13 
MS1/A5 10 CVVSDRGSTLGRLYF 18 13 
MS2     
MS2/A18 10 CVVSDRGSTLGRLYF 18 13 
MS2/A19 10 CVVSDRGSTLGRLYF 18 13 
MS2/A20 10 CVVSDRGSTLGRLYF 18 13 
MS2/A21 10 CVVSDRGSTLGRLYF 18 13 
MS2/A22 10 CVVSDRGSTLGRLYF 18 13 
MS3     
MS3/A1 10 CVVSDRGSTLGRLYF 18 13 
MS3/A3 10 CVVSDRGSTLGRLYF 18 13 
MS3/A4 10 CVVSDRGSTLGRLYF 18 13 
MS3/A5 10 CVVSDRGSTLGRLYF 18 13 
MS3/A6 10 CVVSDRGSTLGRLYF 18 13 
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4.7 TCR β CDR3 analysis in healthy controls and MS patients 
 
Analysis of TCRβ chains included V region, J region, CDR3 sequence and length and 
was caried out in sorted iNKT cels from healthy controls and MS patients. Results 
of this analysis are shown in (Table 4.4: healthy controls and Table 4.5: MS patients). 
In al healthy controls and MS patients the clones showed variability in sequences and 
were heterogeneous (Table 4.4: healthy controls and Table 4.5: MS patients). Al four 
healthy controls expressed a TCRβ chain comprising of TRBV 25-1 TRBJ 1-5 which 
represented  14.5%  of al cDNA clones analysed from  55 clones in total.  The 
similarity was only in amino acid usage at the end of the sequence (the last five amino 
acids in each case). Also, the TCRβ chain comprising of TRBV 25-1 TRBJ 2-1 was 
expressed in three out of four healthy controls representing 20% of al cDNA clones 
analysed from 55 clones in total. Again the similarity was only in amino acid usage at 
the end of the sequence (last five amino acids in each case). This finding is consistent 
with Matulis and coleagues  who  demonstrated that  CDR3β sequences  were 
extremely variable since Vβ11 was rearanged with diferent Jβ families including (1-
1, 2-7, 1-3, 1-5 and 2-5) (Matulis et al., 2010). 
 
On the other hand, the clones showed less diversity in MS patients, with particular J 
regions being favoured in al patients including TRBJ 1-1, TRBJ 2-7, TRBJ 2-1 and 
TRBJ  2-2.  TRBJ  1-1  was expressed the  most representing  33%  of al cDNA clones 
analysed from 61 clones in total. The similarity was only in amino acid usage at the 
end of the sequence (last five amino acids in TRBJ 1-1 and TRBJ 2-2) but (last four 
amino acids in TRBJ 2-7 and TRBJ 2-1). 
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Interestingly, there  was  only  one repeated sequence (CATTSPGPGEKLFF) across 
two  healthy controls and  one  MS  patients  with the same amino acid length and J 
region. These two healthy controls and one MS patient (HC1, HC3 and MS2) share 
the same white ethnic background. Moreover, there was one particular J region (TRBJ 
2-1) favoured in  HC2,  HC4 and  MS3 and they share the same  non-white ethnic 
background.  
 
Over al, the mean CDR3β length (Figure 4.6) was significantly longer in clones of 
MS  patients (mean=13.39  ±  0.3311) compared to  healthy controls (mean=12.69  ± 
0.1974).  However, two  CDR3 sequences from  MS  patients  were included in the 
analysis,  which  had exceptional  CDR3 region length.  By excluding these  2  outliers 
from the analysis there  was  no significant  diference in the  mean  CDR3β length 
between healthy controls and MS patients. 
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Figure 4.6: Vβ CDR3 length in healthy controls and MS patients. 
The  variability in  Vβ  CDR3 length  between  healthy controls and  MS  patients. 
Analysis  was  determined  using  GraphPad  Prism  5  Software.  Statistical analysis 
caried out using the Mann-Whitney test: *p<0.05. 
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Table 4.4: TCR β sequences obtained from TCR CDR3 analysis of sorted iNKT 
cels from healthy controls.  
TRAV and TRAJ are shown along with the amino acid sequence and the length of the 
CDR3 region 
	  
	  
Healthy 
control TRBV CDR3β region TRBJ CDR3β Length 
HC1/B2 25-1 CASSDQVLSEQYF 2-7 11 
HC1/B13 25-1 CASSGRLAYEQYF 2-7 11 
HC1/B3 25-1 CASTLGQSSYEQYF 2-7 12 
HC1/B12 25-1 CASTLGQSSYEQYF 2-7 12 
HC1/B17 25-1 CASSEKGQGAYEQYF 2-7 13 
HC1/B6 25-1 CATTSPGPGEKLFF 1-4 12 
HC1/B8 25-1 CATTSPGPGEKLFF 1-4 12 
HC1/B11 25-1 CASSGTPATNEKLFF 1-4 13 
HC1/B14 25-1 CASSGTPATNEKLFF 1-4 13 
HC1/B16 25-1 CASSDPPRTGGDEKLFF 1-4 15 
HC1/B7 25-1 CASSESNNSNQPQHF 1-5 13 
HC1/B9 25-1 CASHPVGQGSRETQYF 2-5 14 
HC1/B15 25-1 CASSDSPGGSGNTIYF 1-3 14 
HC1/B5 25-1 CAGSTLAQGPNTGELFF 2-2 15 
HC2 TRBV CDR3β region TRBJ CDR3β Length 
HC2/B1 25-1 CASSDPAGLYNEQFF 2-1 13 
HC2/B10 25-1 CASSVGPGQGNEQFF 2-1 13 
HC2/B7 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC2/B8 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC2/B9 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC2/B13 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC2/B2 25-1 CASHGGGGQPQHF 1-5 11 
HC2/B3 25-1 CASHGGGGQPQHF 1-5 11 
HC2/B5 25-1 CASHGGGGQPQHF 1-5 11 
HC2/B11 25-1 CASHGGGGQPQHF 1-5 11 
HC2/B14 25-1 CASHGGGGQPQHF 1-5 11 
HC2/B12 25-1 CASSPQGSAKNIQYF 2-4 13 
HC3 TRBV CDR3β region TRBJ CDR3β Length 
HC3/B1 25-1 CASSDGYEQYF 2-7 9 
HC3/B18 25-1 CASTQTGTGELEQYF 2-7 13 
HC3/B22 25-1 CASSSSLPVGYEQYF 2-7 13 
HC3/B24 25-1 CASSSSLPVGYEQYF 2-7 13 
HC3/B2 25-1 CATTSPGPGEKLFF 1-4 12 
HC3/B11 25-1 CATTSPGPGEKLFF 1-4 12 
HC3/B15 25-1 CATTSPGPGEKLFF 1-4 12 
HC3/B20 25-1 CATTSPGPGEKLFF 1-4 12 
HC3/B5 25-1 CASSVRQETDTQYF 2-3 12 
HC3/B16 25-1 CASSVRQETDTQYF 2-3 12 
HC3/B17 25-1 CASSVRQETDTQYF 2-3 12 
HC3/B9 25-1 CASLSTGGYNEQFF 2-1 12 
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HC3/B7 25-1 CASSILNRGGSYNEQFF 2-1 15 
HC3/B12 25-1 CASSGTGGGTEAFF 1-1 12 
HC3/B8 25-1 CASSEVTGNTVNTEAFF 1-1 15 
HC3/B4 25-1 CASSDPGRGGSPLHF 6-2 13 
HC3/B10 25-1 CASSEGRQGNQPQHF 1-5 13 
HC3/B21 25-1 CASSELFEGTGPPGELFF 2-2 16 
HC4 TRBV CDR3β region TRBJ CDR3β Length 
HC4/B7 25-1 CASSLNTEAFF 1-1 9 
HC4/B11 25-1 CASSVGLSNTEAFF 1-1 12 
HC4/B3 25-1 CASSEGLVLNKEAFF 1-1 13 
HC4/B12 25-1 CASSIMSGGLNTEAFF 1-1 14 
HC4/B15 25-1 CASSGQGSYNEQFF 2-1 12 
HC4/B2 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC4/B16 25-1 CASSEAGQTSYNEQFF 2-1 14 
HC4/B1 25-1 CASSRDSSGNTIYF 1-3 12 
HC4/B4 25-1 CASSRQGSNQPQHF 1-5 12 
HC4/B10 25-1 CASSDQSTNYGYTF 1-2 12 
HC4/B14 25-1 CASSEYTSQGAVTGELFF 2-2 16 
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Table 4.5: TCR β sequences obtained from TCR CDR3 analysis of sorted iNKT 
cels from MS patients.  
TRAV and TRAJ are shown along with the amino acid sequence and the length of the 
CDR3 region 
	  
MS 
Patients TRBV CDR3β region TRBJ 
CDR3β 
Length 
MS1/B1 25-1 CASSREDTEAFF 1-1 10 
MS1/B2 25-1 CASSREDTEAFF 1-1 10 
MS1/B5 25-1 CASSEGLKGTEAFF 1-1 12 
MS1/B16 25-1 CASSEGLKGTEAFF 1-1 12 
MS1/B4 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B6 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B13 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B18 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B22 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B23 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B24 25-1 CASSGTGGDGTEAFF 1-1 13 
MS1/B9 25-1 CASSGPREGSYEQYF 2-7 13 
MS1/B10 25-1 CASSGPREGSYEQYF 2-7 13 
MS1/B21 25-1 CASSGPREGSYEQYF 2-7 13 
MS1/B14 25-1 CASSDRGQGAHEQFF 2-1 13 
MS1/B17 25-1 CASSDRGQGAHEQFF 2-1 13 
MS1/B8 25-1 CASSEGGIGSTDEQYF 2-1 14 
MS1/B20 25-1 CASSHTSGGNTGELFF 2-2 14 
MS1/B25 25-1 CASSAWGLGGTNTGELFF 2-2 16 
MS1/B12 25-1 CASSEGGIGSADTQYF 2-3 14 
MS1/B19 25-1 CASTEDGAGGIADTQYF 2-3 15 
MS1/B15 25-1 CASSESEGTGGNIQYF 2-4 14 
MS1/B3 25-1 CASSESEGTGGNIQYF 2-4 14 
MS2 TRBV CDR3β region TRBJ CDR3β Length 
MS2/B4 25-1 CASTGLGLNEQFF 2-1 11 
MS2/B6 25-1 CASTGLGLNEQFF 2-1 11 
MS2/B2 25-1 CASSDPAGLYNEQFF 2-1 13 
MS2/B9 25-1 CASSERSPREYALNNEQFF 2-1 17 
MS2/B3 25-1 CASSELPHLRERPTDGGPEAHNEQFF 2-1 24 
MS2/B7 25-1 CASSELPHLRERPTDGGPEAHNEQFF 2-1 24 
MS2/B12 25-1 CATTSPGPGEKLFF 1-4 12 
MS2/B15 25-1 CATTSPGPGEKLFF 1-4 12 
MS2/B18 25-1 CATTSPGPGEKLFF 1-4 12 
MS2/B24 25-1 CATTSPGPGEKLFF 1-4 12 
MS2/B21 25-1 CASSGTPATNEKLFF 1-4 13 
MS2/B1 25-1 CASGGNGPYEQYF 2-7 11 
MS2/B13 25-1 CASGGNGPYEQYF 2-7 11 
MS2/B19 25-1 CASGGNGPYEQYF 2-7 11 
MS2/B23 25-1 CASSGDRGLGYEQYF 2-7 13 
MS2/B5 25-1 CASSAWGLGGTNTGELFF 2-2 16 
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MS2/B16 25-1 CASSARGLGGTNTGELFF 2-2 16 
MS2/B20 25-1 CASSARGLGGTNTGELFF 2-2 16 
MS2/B22 25-1 CASSDPRQGSTGELFF 2-2 14 
MS2/B10 25-1 CAGGGTEAFF 1-1 8 
MS2/B11 25-1 CASSVAKQGEGTEAFF 1-1 14 
MS2/B8 25-1 CASSPIGTGLRNTEAFF 1-1 15 
MS3 TRBV CDR3β region TRBJ CDR3β Length 
MS3/B5 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B10 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B15 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B16 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B18 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B21 25-1 CASSEFGTGVGTEAFF 1-1 14 
MS3/B13 25-1 CASTLGTGELFF 2-2 10 
MS3/B20 25-1 CASSDPARNGGELFF 2-2 13 
MS3/B22 25-1 CASSDPARNGGELFF 2-2 13 
MS3/B14 25-1 CASSEGQGARRSYTGELFF 2-2 17 
MS3/B12 25-1 CASSFSSGGGEDEQFF 2-1 14 
MS3/B19 25-1 CASSFSSGGGEDEQFF 2-1 14 
MS3/B24 25-1 CASSFSSGGGEDEQFF 2-1 14 
MS3/B1 25-1 CASSEWEVGEQYF 2-7 11 
MS3/B23 25-1 CASSEWEVGEQYF 2-7 11 
MS3/B8 25-1 CASSPSESGETQYF 2-5 12 
	  
	  
 
We  wanted to  visualise  whether there  was any common feature among  healthy 
controls  or  MS  patients and  between healthy controls and  MS  patients. I therefore 
ploted a  pie chart  per  donor looking at the  percentages  of J regions  within the  Vβ 
sequences  obtained.  Despite the relatively smal  number  of clones analysed, the 
picture that emerges is that  MS  patients  have a restricted  TCR β repertoire (Figure 
4.7, botom panel), while healthy controls showed a higher variability within the same 
region analysed (Figure 4.7, Top panel). 
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Figure 4.7: Pie chart obtained from TCRb CDR3 analysis of sorted iNKT cels from 
healthy controls and MS patients.  
Data are expressed as percentage of the same amino acid sequences of the J region with 
respect to the total  number  of clones analysed from each  donor.  Top  panel:  healthy 
control. In healthy controls the highlighted J regions are the only shared regions. Botom 
panel: MS patient. In MS patients the highlighted J regions are the only unshared regions. 
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4.8 Discussion 
 
The  halmark  of  human iNKT cels is their  highly conserved and  unique  TCR 
repertoire expressing an invariant 11 amino acid rearanged CDR3 TCR Vα24-Jα18 
a-chain, paired with semi-invariant TCR Vβ11 chain (Porceli et al., 1993; Delabona 
et al., 1994; Lantz and Bendelac 1994; Exley et al., 1997; Exley et al., 1998; Bendelac 
et al.,  2001;  Kronenberg and  Gapin,  2002). CDR3β loop is the  only  hypervariable 
region and therefore the adaptive element in  human iNKT  TCRs,  which  may  be 
postulated to regulate the afinity of the iNKT TCR to CD1d (Matulis et al., 2010). 
iNKT cels rapidly secrete  diverse and abundant cytokines such as  IL-4 and IFN-γ 
upon  TCR engagement (Bendelac et al.,  1997;  Exley et al., 1997;  Chen and  Paul, 
1997).  The extent to  which  nuanced  diferences in  CDR3  usage  may impact  on 
afinity and thereby  on transcription  of efector cytokines is curently  uncharted. 
There are a  number  of studies reporting that  Vα24  NKT cels are  decreased in the 
peripheral  blood in several  human autoimmune  diseases in  which these cels are 
unable to counteract a Th1-polarized microenvironment (Sumida et al., 1995; Wilson 
et al., 1998; Oishi et al., 2001; Van der Vliet et al., 2001; Kojo et al., 2001).  
 
I therefore aimed to investigate  whether there is any  qualitative alteration in iNKT 
cels sorted from  MS  patients  with  particular reference to their  TCR sequence 
compared to healthy controls. 
 
For al healthy controls and untreated RRMS cases that analysed they expressed the 
same  CDR3α region and  were  13 amino acids in length: as expected  my TCR 
analysis showed that the CDR3 Vα region is highly conserved between MS patients 
and healthy controls. Gausling and coleagues demonstrated that the frequency  of 
CD4-CD8- Vα24+ cels  was constant in the  peripheral  blood  of  untreated  RRMS 
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patients and there was no significant difference between healthy controls and RRMS 
patients (Gausling et al.,  2001).  However, the  CD4-CD8- Vα24+  T cel clones from 
RRMS  patients produced less IL-4 than healthy controls (Gausling et al.,  2001).  On 
the  other  hand, Démoulins and coleagues  demonstrated,  with the  use  of 
immunoscope, a  PCR-based technology and extensive  DNA sequencing, that  MS 
patients during relapses presented with marked reduction in the number and diversity 
of Vα24+ transcripts and the presence of expanded CDR3 Vα24 chains (Démoulins et 
al., 2003). 
 
Analysis of TCRβ chain sorted from iNKT cels of control individuals showed a high 
level  of intra- and inter-individual  heterogeneity and  high  variability in  CDR3 
sequence, Jb segments and CDR3 sequence length. TRBJ 1-5 was the only shared J 
region between al four healthy controls. Consistent with this, Matulis and coleagues 
demonstrated that CDR3β sequences are extremely variable since Vβ11 can rearange 
with diferent Jβ families (Matulis et al., 2010). 
 
In contrast, iNKT cels from  RRMS  patients showed a  more restricted  Vβ11  TCR 
junctional  diversity, since  particular J regions  were favoured in al  RRMS  patients 
such as TRBJ 1-1, TRBJ 2-7, TRBJ 2-1 and TRBJ 2-2.  
 
This is the first report pointing out a possible reduction in the Vβ11 TCR repertoire 
related to  MS  pathology.  Moreover, there  was  only  one repeated sequence 
(CATTSPGPGEKLFF) with 12 amino acid length and TRBJ 1-4 across two healthy 
controls and  one  MS  patients  with the same  white ethnic  background. In addition, 
there was one particular J region (TRBJ 2-1) favoured in two healthy controls and one 
MS patients with the same non-white ethnic background. This observation would be 
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in favour  of the  hypothesis that suggests that  TCR rearangement can  be influenced 
by genetic background. 
 
A decrease in the diversity of the Vβ11+ T cel repertoire was observed in untreated 
RRMS  patients  during remission  with respect to controls. The reason  behind this 
diference is  unclear.  Since the  CDR3β loop is the  only  hypervariable region in 
human iNKT TCRs, vitality may have role in the function of human iNKT cels by 
regulating the afinity of the iNKT TCR to CD1d (Matulis et al., 2010). The fact that 
the iNKT TCRβ repertoire appears constrained relative to the pool of cels in healthy 
controls may indicate either that these cels in the patients have been selected on the 
basis  of  particular features  of afinity (conceivably associated  with a  disease-related 
cytokine profile) or that constraint is imposed by the target antigen. While there has 
been a reliance in the filed  on  model  glycolipid antigens  bound to  CD1d,  one  must 
assume that the importance  of iNKT cels in  MS relates to their  binding of some 
CD1d bound autoantigen, as yet undefined. 
 
 
 
	   163	  
5. Expression of activation, migration and differentiation 
markers on iNKT, NKT and NK cels 
 
	  
I next aimed to investigate the role of cel-surface lymphocyte molecules involved in 
homing,  maturation, activation,  diferentiation and immune regulation  of  peripheral 
lymphocytes, such as CD25, CD62L, CD69, CD161 and CD195 on iNKT, NKT and 
NK cels in peripheral blood of MS patients and healthy donors.  
 
The expressions of CD25, CD62L, CD69, CD161 and CD195 have been previously 
assessed in the context of MS (Vora et al., 1996; Teleshova et al., 2002; Kivisakk et 
al., 2003; Julia et al., 2006; O’Keefe et al., 2008; Bielekova, 2012). However, most 
studies have focused on just one or two markers at time and	  have not investigated the 
simultaneous expression of those molecules in diferent lymphocytes populations.	  	  	  	   
 
In order to evaluate the expression of these molecules on lymphocytes of MS patients 
compared to  healthy controls,  peripheral  blood from  5  healthy controls, 6 RRMS 
untreated patients (RRMS), 5 RRMS patients treated with IFNβ (RR-IFNb), 5 RRMS 
patients treated with Natalizumab (RR-NatAb) and 5 progressive MS patients (PMS) 
was colected and isolated using Histopaque centrifugation (Chapter 2, Section 2.5). 
A summary  of information related to age,  gender and  EDSS for al  donors 
participating in this study is summarized in (Table 5.1). 
 
Briefly,  3x106 cels were stained  on the same  day for  FACS  based 
immunophenotyping.  The antibody  panel  was as  described in the (Chapter, Section 
2.5). The folowing antibodies were used: anti-CD3 (PerCP), anti-CD56 (PE-CF594), 
anti-CD25 (APCH7), anti-CD62L (FITC), anti-CD195 (APC), anti-CD69 (PeCy7), 
anti-CD161 (PerCPCy5.5) and CD1d tetramer loaded with PBS57 (PE). Each sample 
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was run alongside with its isotype and FMO controls.  
	  
PBMCs for this study  were frozen from January  2010 to  May  2010 and stored in 
liquid  nitrogen  until  used for the immunephenotyping experiments. A live-dead 
marker (Live/Dead Fixable Violet Dead cel Stain Kit, Molecular Probes, Invitrogen, 
UK) was  used in  order to  determine cel recovery,  viability after thawing and 
eliminate dead cels from experimental analysis. Lymphocyte populations were gated 
first  on forward  versus side scater, then  doublet events  were excluded from the 
analysis, finaly  gating  on live cels  using the live-dead  marker.  The  percentage  of 
cels in the live-dead gate was comparable among HC, RRMS, RR-IFNb, RR-NatAb 
and PMS, with a non-significant trend towards reduction in live cels in MS patients 
compared to healthy controls (data not shown). 
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Table  5.1: Summary  of demographics  and clinical information (expressed  as 
median) related to  age,  gender  and  EDSS for  al  donors  participating in 
this study. 
 
Diagnosis Number Female/Male Age  EDSS 
Healthy controls 5 4/1 39 (29-40) 0 
Progressive MS 5 3/2 53 (51-62) 6.5 (6-7) 
RRMS/non- treated 6 3/2 36 (34-45) 1.5 (0-4) 
RRMS/on interferon 5 4/1 37 (26-59) 1.5 
RRMS-on Natalizumab 5 1/4 39 (28-49)  3 (2.5-4) 
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5.1 Analysis of CD62L expression on iNKT, NKT and NK cels 
	  
CD62L is a cel adhesion  molecule  belonging to the selectin family  of 
adhesion/homing  proteins,  with an essential role in lymphocyte endothelial cel 
interactions, critical in migration of leukocytes from the peripheral blood to secondary 
lymphoid  organs (Nakache et al.,  1989;  Picker and  Butcher,  1992;  Mebius and 
Watson,  1993;  Springer,  1994; Wedepohl,  2012). It  has long  been  proposed that 
endothelial adhesion molecule upregulation might be fundamental to CNS ingress and 
immune-mediated  MS  pathology (Raine et al.,  1990). Expression  of 
lymphocyte/endothelial cel adhesion  molecules is increased  during  EAE (Raine et 
al., 1990). 
 
NK and NKT cels expressing CD62L showed a trend whereby the expression in cels 
from  RRMS and  PMS  donors  was slightly  decreased compared to healthy controls 
(Figure  5.1A and  B).  However, expression  of  CD62L  on  NK cels is significantly 
higher in RR-IFNb compared to RRMS patients (*p<0.05, Figure 5.1A). 
 
iNKT cels showed a completely  diferent  phenotype,  where  MS  patients  have a 
higher frequency  of iNKT cels expressing CD62L compared to healthy controls 
(Figure  5.1C). iNKT cels expressing  CD62L are significantly  higher in  RRMS 
patients compared to healthy controls (*p<0.05, Figure 5.1C). 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 1: Relative percentage of CD62L expression in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5  RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed. Relative expression of CD62L (y axis) on NK (A), NKT (B) and iNKT (C) 
cels. Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5 
Software. Statistical analysis caried out using the Mann-Whitney test: *p<0.0. 
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5.2 Analysis of CD69 expression on iNKT, NKT and NK cels 
 
CD69 is one of the earliest cel surface activation markers expressed by T cels upon 
activation and is expressed  by  mature thymocytes,  NK cels,  B cels,  neutrophils, 
eosinophils, monocytes, and platelets (Ziegler et al., 1994). Up-regulation of CD69 on 
lymphocyte subsets is  often reported in autoimmune  diseases including  SLE and 
rheumatoid arthritis (Iannone et al., 1996; Portales-Perez et al., 1997; Ishikawa et al., 
1997; Atzeni et al., 2004).  
 
NK cels  of  MS  patients seem to  have  only a slightly  higher frequency  of  CD69 
expressing cels (Figure 5.2A). NKT cels displayed a lower level of CD69 expression 
in  RRMS patients compared to healthy controls and  PMS patients (Figure  5.2B), 
however iNKT cels showed the inverse trend,  whereby  PMS patients had lower 
frequency of CD69 expressing cels than RRMS patients and healthy controls (Figure 
5.2C). 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  	  
	   169	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 2: Relative percentage of CD69 expression in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5  RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed. Relative percentage of CD69 (y axis) on NK (A), NKT (B) and iNKT (C) 
cels. Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5 
Software. 	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5.3 Analysis of CD161 expression on iNKT, NKT and NK cels 
	  
CD161 is a  marker  of lymphocyte activation expressed  on  NK cels, CD4+ T cels, 
CD8+ T cels and NKT cels. It has been described as a key marker of Th17 cels in 
peripheral  blood and in inflamed tissues since IL-17  producing  CD4+  T cels  were 
found within the CD161+ fraction of cels in tissues from autoimmune disease patients 
(Cosmi et al.,  2008). IL-17  has  been  detected in active lesions  of  MS by in situ 
hybridization and immunohistochemistry, suggesting an important role for IL-17 in 
MS pathogenesis (Tzartos et al., 2008). Furthermore, the expression of IL-17 and IL-
22 receptors  has  been  observed  on  BBB endothelial cels in  MS lesions  promoting 
BBB tight junctions  disruption and  CNS inflammation through  CD4+ lymphocyte 
infiltration (Kebir et al.,  2007). O’Keefe and coleagues  demonstrated that the 
percentage of T cels expressing CD161 was significantly decreased in the peripheral 
blood of MS patients compared to healthy controls (O’Keefe et al., 2008). 
	  
The common feature for NK, NKT and iNKT cels is that RRMS and PMS patients 
showed a lower frequency  of  CD161  positive cels compared to healthy controls 
(Figure 5.3). This reaches statistical significance in the comparison between healthy 
controls and  RRMS patients in  NK cels  (*p<0.05,  Figure  5.3A); and  between 
healthy controls and PMS patients in iNKT cels (**p<0.01, Figure 5.3C). 
 
iNKT cels expressing CD161 are lower in PMS and RR-NatAb patients compared to 
RRMS patients (**p<0.01, Figure 5.3C).  
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 3: Relative percentage of CD161 expressing cels in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5 RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed. Relative percentage of CD161 (y axis) on NK (A), NKT (B) and iNKT (C) 
cels. Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5 
Software.  Statistical analysis caried  out  using the Mann-Whitney test:  *p<0.05, 
**p<0.01. 
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5.4 Analysis of CD195 expression on iNKT, NKT and NK cels 
 
Chemokine receptor type  5, also  known as CCR5  or CD195, is  preferentialy 
expressed  on  Th1 efector cels (Moser and  Loetscher,  2001; Rot and  von  Andrian, 
2004). A  number  of studies  have looked at the role  of  CCR5+ cels in  MS.  The 
frequency  of CD4+  CCR5+ T cels was increased in the  peripheral  blood  of  MS 
patients  but Fas expression  was significantly  decreased in these cels compared to 
healthy controls (Julia et al., 2006). Elevated levels of CCR5 expression by peripheral 
blood T cels has been reported in untreated MS patients compared to healthy controls 
(Teleshova et al., 2002). 
 
In this cohort of donors, NK, NKT and iNKT cels expressed a higher level of CD195 
in  MS  patients compared to healthy controls (Figure  5.4). NK cels  of  RR-IFNb 
patients seem to express  higher levels  of  CD195 compared to  RRMS  patients 
(*p<0.05, Figure 5.4A). 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 4: Relative percentage of CD195 expression in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5  RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed. Relative percentage of CD195 (y axis) on NK (A), NKT (B) and iNKT (C) 
cels. Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5 
Software. Statistical analysis caried out using the Mann-Whitney test: *p<0.05. 
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5.5 Analysis of CD25 expression on iNKT, NKT and NK cels 
	  
CD25 is the alpha chain  of the IL-2 receptor. It is a cel surface  marker  used to 
diferentiate  between regulatory, activated and  naïve  CD25  T cels in  humans 
(Thornton and Shevach, 2000; Dieckmann et al., 2001). Genetic association between 
IL-2Rα (CD25)  polymorphisms and several autoimmune  disorders such as type  1 
diabetes and  MS  have emphasised the importance  of  variations in IL-2/IL-2R 
interactions in the regulation of autoimmunity (Hafler et al., 2007; Lowe et al., 2007; 
Maier et al., 2009). Interestingly, the use of Daclizumab, an antibody against CD25, 
led to an 87.7% reduction in MRI brain CELs and stabilized/improved clinical disease 
activity in  untreated  RRMS  patients (Bielekova et al.,  2011;  Bielekova,  2012). It 
should  be  noted that, in the absence  of staining for intracelular  FoxP3, there  wil 
always  be an element  of ambivalence around interpretation  of  CD25 shifts,  which 
may indicate either simple lymphocyte activation with respect IL-2R expression, or at 
very high levels, may be a marker of CD4 Tregs (Hafler et al., 2007)  
	  
As shown in Figure 5.5, there is a clear trend towards increase of expression of CD25 
in MS patients compared to healthy controls (Figure 5.5). The diferential expression 
of CD25 between healthy controls and PMS patients is statisticaly significant only in 
NK cels (*p<0.05, Figure 5.5A).  
	  
iNKT cels expressing  CD25 showed a trend  whereby the expression in cels from 
RRMS patients was  higher than healthy controls and  PMS patients (statisticaly 
significant result only between healthy controls and RRMS patients (**p<0.01, Figure 
5.5C). 
	  	  
Also, there is a trend towards increase of expression of CD25 in diferent lymphocyte 
populations in MS patients receiving therapy (RR-IFNb and RR-NatAb) with respect 
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to  RRMS  patients (Figure  5.5). This reaches statistical significance  only in the 
comparison  between  RR-IFNb and  RRMS patients in  NK cels  (*p<0.05, Figure 
5.5A). 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 5: Relative percentage of CD25 expression in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5  RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed. Relative percentage of CD25 (y axis) on NK (A), NKT (B) and iNKT (C) 
cels. Analysis  was  determined  using BD  Diva software and GraphPad  Prism  5 
Software.  Statistical analysis caried  out  using the Mann-Whitney test:  *p<0.05, 
**p<0.01.	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5.6  Analysis  of  CD25  and  CD161 co-expression  on iNKT,  NKT and 
NK cels 
	  
	  
As expression of CD25 was found increased in MS patients, while the expression of 
CD161 on the same cels was decreased, I decided to investigate the co-expression of 
CD25 and CD161 on the same subset of cels. 
 
Figure  5.6 shows that the co-expression  of  CD161 and  CD25  positive lymphocyte 
population  mirors the trend for  CD25 single  positive cels, with PMS  patients 
showing significantly  higher expression  of CD25/CD161 in NK and  NKT cels 
compared to healthy controls (*p<0.05,  Figure  5.6A; **p<0.01, Figure  5.6B).  Also, 
NKT and iNKT cels  of RRMS  patients expressed a  higher frequency  of 
CD25/CD161 compared to healthy controls (*p<0.05, Figure 5.6B; **p<0.01, Figure 
5.6C). 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 5. 6: Relative percentage of CD25/CD161 expression in MS patients. 
Lymphocytes from  5  HC,  6  RRMS,  5  RR-IFNb,  5  RR-NatAb and  5  PMS  were 
analysed.  Relative  percentage  of  CD25/CD161 (y axis)  on  NK (A),  NKT (B) and 
iNKT (C) cels.  Analysis  was  determined  using  BD  Diva software and  GraphPad 
Prism  5  Software.  Statistical analysis caried  out  using the  Mann-Whitney test: 
*p<0.05, **p<0.01. 
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5.7 Discussion 
	  
Large-scale genomic analysis of MS susceptibility loci emphasises the importance of 
genes related to activation and maturation of T cels (Sawcer et al, 2011). Phenotypic 
analysis of MS patient PBMC have tended to focus on given celular subsets in MS in 
terms  of  maturation,  development, activation  or  homing  markers (Vora et al.,  1996; 
Teleshova et al., 2002; Kivisakk et al., 2003; Julia et al., 2006; O’Keefe et al., 2008; 
Bielekova,  2012). I therefore  designed a  panel for  multiparameter flow cytometry 
alowing investigation  of the simultaneous expression  of  diferent cel surface 
markers of activation, diferentiation and maturation, namely CD25, CD62L, CD69, 
CD161 and  CD195, al  markers that  have linked to  MS  pathology  on  diferent 
lymphocyte populations.  While some of the changes I detected in this phenotyping 
merely confirmed earlier studies,  others appeared rather  novel and indicate a route 
forward for future studies. 
 
Surface expression  of  diferent markers on lymphocyte can  provide  valuable 
information about cel surface functions,  diferentiation and activation. One  of the 
adhesion/homing markers  of lymphocytes is  CD62L,  which is recognised  by 
addressins,  being involved in lymphocyte migration from the  peripheral  blood to 
secondary lymphoid organs (Nakache et al., 1989; Picker and Butcher, 1992; Mebius 
and Watson, 1993). With the exception of iNKT cels, RRMS and PMS patients seem 
to  down-regulate the expression level  of  CD62L in  NK and  NKT cels. These 
findings could be explained by hypothesizing that lymphocytes with high expression 
of CD62L might have preferentialy migrated to sites of inflammation or lymphocytes 
have acquired other functional molecules, such as CD69 (Wedepohl et al., 2012). The 
fact that iNKT cels have a completely diferent phenotype, whereby the frequency of 
iNKT cels expressing CD62L is higher in the peripheral blood of MS patients, might 
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be  due to  migration into surounding tissues  during immune surveilance and 
inflammation or as result of acquiring more memory-type phenotype since iNKT cels 
can produce a large amount of cytokines. 
	  
CD69 is considered one  of the earliest cel surface lymphocyte activation  markers. 
Raised expression of CD69 is widely reported in autoimmune diseases; its expression 
on NK cels is associated with IFN-γ production and cytotoxic function of NK cels 
(Ziegler,  1994;  Giaverdoni et al,  2000). In  our experiments,  peripheral lymphocytes 
from MS patients do not seem to constitutively express more CD69 than the healthy 
controls, even NK cels in MS patients are not more activated than healthy controls. 
To confirm the  memory-like  phenotype  of iNKT cels, their expression  of  CD69 in 
healthy controls and RRMS patients is similar, and less activated in PMS patients. 
	  
CD195, also known as CCR5, is expressed on Th1 efector cels (Moser & Loetscher, 
2001;  Rot and  von  Andrian,  2004). Al lymphocyte  populations expressed a  higher 
level of CD195 in MS patients compared to healthy controls. Interestingly, NK cels 
of  RR-IFNb seem to express significantly  higher frequency  of CD195 compared to 
RRMS patients. Our data confirm a previous finding, which reported elevated levels 
of CCR5 expression in peripheral blood T cels in untreated MS patients compared to 
healthy controls (Teleshova et al., 2002). 
	  
CD161 is  widely expressed  on activated lymphocytes and  by almost al cels 
producing IL-17 (Maggi et al, 2012). I observed that in RRMS and PMS patients the 
level  of  CD161 expression  was lower than in healthy controls for NK,  NKT and 
iNKT cels. Without the addition of IL-17 ICCS into this panel, it is unclear whether 
CD161 staining in each of these cel types is a marker of IL-17 release. 
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PMS  patients  have fewer iNKT cels expressing  CD161 than  RRMS  patients, 
suggesting that the lymphocytes in the  periphery  of  PMS  patients are less able to 
regulate or maybe modulate the activity of other lymphocyte. This can be due to the 
recruitment of the highly activated regulatory cels to the brain, supported by previous 
findings,  where IL-17  was detected in active lesions  of  MS by in situ  hybridization 
and immunohistochemistry (Tzartos et al.,  2008) and  CD161high  CD8  T cels  have 
been thought to  be  potentialy  pathogenic in  MS (Annibali et al,  2011).  Another 
explanation is that  our  RRMS  patients are  not in relapse, therefore the expression 
level of IL-17 and CD161 is lower.  
 
CD25 is the alpha chain  of IL-2R.  CD25 used to  diferentiate  between regulatory, 
activated and  naïve  CD25  T cels in  humans (Thornton and  Shevach,  2000; 
Dieckmann et al., 2001). I observed that frequency of CD25 expression on NK, NKT 
and iNKT cels increased in MS patients compared to healthy controls. Interestingly, 
there is a clear trend towards increase expression of CD25 in MS patients receiving 
therapy (RR-IFNb and RR-NatAb). 
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As expression of CD25 was found increased in MS patients, while the expression of 
CD161 on the same cels was decreased, I decided to investigate the co-expression of 
CD25 and  CD161  on the same subset  of cels and whether it coresponds to 
functionality. Co-expression  of  CD25 and  CD161 is significantly  higher in  MS 
patients compared to  healthy individuals in NK,  NKT and iNKT cels,  while 
expression of CD161 alone is down-regulated in NK, NKT and iNKT cels. Franson 
and coleagues recently  demonstrated that  T cels  with regulatory  phenotype and 
lacking  CD25 expression are increased  during  MS relapses (Franson et al.,  2010), 
although our patients are in a non-relapse state. 
 
Table 5.2: Summary of the most important findings discussed in this chapter.  
 (Increase) or  (decrease) refers to percentage of positive cels. 
 
 NKT cels iNKT cels NK cels 
HC vs. RRMS CD25+/CD161+ 
CD62L+ 
CD25+ 
CD25+/CD161+ CD161
+ 
HC vs. PMS CD25+/CD161+ CD161+ CD25+ CD25+/CD161+ 
RRMS vs. PMS  CD161+  
RRMS vs. RR-IFNb   
CD62L+ 
CD195+ 
CD25+ 
RRMS vs. RR-NatAb  CD161+  
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6. KIR expression on iNKT, NKT and NK cels  
 
Relatively litle  has  been  published so far  on the  patern  of  KIR expression  on cel 
types  other than  NK cels  or  CD8 cels.  Extensive  genetic studies  have addressed 
associations  between specific  KIR  genotypes and  disease,  but  usualy  without 
phenotypic context about the cel-types, again  other than  NK cels, that  may  be 
implicated. 
 
The role of  KIR expression  on T cels is  not fuly  understood,  but it  has  been 
suggested that signaling through KIRs can inhibit T cel receptor mediated activation 
(Philips et al. 1995; Mingari et al. 1996; Anfossi et al. 2004; van Bergen et al. 2004). 
Others suggested that  KIR could act as co-stimulatory  molecule  promoting  T cel 
activation (Snyder et al., 2004). 
 
KIRs are  membrane  bound receptors, either activating  or inhibitory in their 
contribution to celular activation, which recognize classical HLA-B and C molecules. 
KIR expression has been described predominantly in NK cels and, to a lesser extent, 
T cels with a memory phenotype mainly TCR αβ+, CD8+ and TCR γδ+ modulating 
TCR-dependent activation (Vilches et al.,  2002; van  Bergen et al. 2004; Parham, 
2005; Lanier, 2005; Martinez-Rodriguez et al., 2010). It had been reported that KIRs 
were not expressed by CD4+ and CD4-CD8- (double negative) iNKT cels using flow 
cytometry (Exley et al., 1997; Lee et al., 2002). However, more recently Paterson and 
coleagues demonstrated that a smal  proportion  of iNKT cels expressed  KIR at a 
frequency similar to that of conventional T cels (Paterson et al., 2008). 
 
In this chapter I aimed to investigate the  patern  of  KIR expression  on iNKT,  NKT 
and  NK cels in  MS  patients,  with and  without treatment, compared to  healthy 
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controls and CIS donors. 
 
I characterized the expression of KIRs on iNKT, NKT and NK cels in order to have a 
more complete  overview  of  KIR  distribution  on innate and innate like cels in the 
periphery. Peripheral  blood from  33  healthy controls, 8 RRMS untreated 
patients/stable (RRMS-stable), 10 RRMS untreated patients/active (RRMS-active) 10 
RRMS  patients treated  with IFNβ (RR-IFNb),  12  RRMS  patients treated  with 
Natalizumab (RR-NatAb),  11  progressive  MS  patients (PMS) and  15  CIS  patients 
(CIS)  was colected and isolated  using  Histopaque centrifugation as  described in 
(Chapter 2, Section 2.4). For al RRMS untreated patients with active disease (RRMS-
active), blood was taken immediately before starting the first dose of Natalizumab. A 
summary of information on age, gender and EDSS for al donors participated in this 
study is summarized in (Table  6.1). Using flow cytometry, 3x106 cels were stained 
for cel surface markers to characterize each subset as shown in (Table 6.2) and co-
stained for  KIR expression (Chapter  2,  Section  2.4). Specificities  of the  KIR 
antibodies  used in these experiments are summarized in (Chapter  2,  Table  2.4). 
However,  because the  gold standard for  KIR studies is a  deep analysis at  genetic 
level, we decided to cary out KIR genotyping in a smaler cohort of donors. This wil 
give  us the  possibility to  make a  direct comparison  between  gene and cel surface 
expression in  MS.  To  our  knowledge this is the  only study combining  genetic and 
flow cytometry analysis in  diferent cel types in  MS.  Al  healthy controls and 
patients were genotyped by Dr James Traherne in Professor John Trowsdale’s group 
at University of Cambridge with the aim of marying up the genetic data with surface 
expression (Table 6.3). For data analysis, I considered only those individuals whose 
KIR surface expression  was above zero  value (to  preclude the  possibility  of 
incorporating data from individuals who lacked the given gene). 
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Table  6.1: Summary  of  demographics  and clinical information (expressed  as 
mean) related to age, gender and EDSS for al donors. 
	  
Diagnosis Number Female/Male Age  EDSS 
Healthy controls 33 19/14 45 (25-60) - 
Progressive MS 11 6/5 51 (32-62) 6 (5-6.5) 
RRMS/untreated/stable 8 7/1 47 (34-62) 2 (1.5-3) 
RRMS/untreated/active 10 7/3 41 (16-58) 3 (1-6) 
RRMS-on Interferon 10 10/0 40 (27-57) 3 (1.5-6) 
RRMS-on Natalizumab 12 8/4 40 (25-52)  4 (1.5-6) 
CIS 15 8/7 41 (30-50) 1 (0-2.5)  
 
 
 
 
 
 
Table 6.2: Cel surface markers used to identify lymphocyte subsets. 
	  
Lymphocyte subsets Cel surface markers 
NK cels CD3- CD56+ 
NKT cels CD3+ CD56+ 
iNKT cels CD3+ Vα24+ Vβ11+ 
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Table 6.3: KIR genotyping of 32 healthy controls, 33 MS and 6 CIS patients. 
	  
	  
 2DL1 2DS1 2DL2 2DL3 3DL1   2DL1 2DS1 2DL2 2DL3 3DL1 
HC1 + - + + +  MS0227 + - + + + 
HC2 + + - + +  MS0228 + - - + + 
HC3 + - - + +  MS0229 + - + + + 
HC4 + - - + +  MS0230 + - + + + 
HC5 + - + + +  MS0234 + - - + + 
HC6 + + + + +  MS0235 + - - + + 
HC7 + - - + +  MS0237 + - - + + 
HC8 - - + + +  MS0238 + - + + + 
HC9 + + + + -  MS0239 + - + + + 
HC10 + + + + +  MS0240 + + + + + 
HC11 + - + + +  MS0241 + - - + + 
HC12 + - + - +  MS0242 + - - + + 
HC13 + - - + +  MS0244 + - + + + 
HC14 + - - + +  MS0245 + - - + + 
HC15 + + - + +  MS0246 + - - + + 
HC16 + + + + -  MS0247 + + - + + 
HC17 + + - + +  MS0249 + + + + + 
HC18 + + + + +  MS0250 + - + + + 
HC19 + + - + +  MS0251 + - - + + 
HC20 + + + + -  MS0252 + - - + + 
HC21 + - - + +  MS0253 + + - + + 
HC22 + - + + +  MS0254 - - + - + 
HC23 + - - + +  MS0255 + + - + + 
HC24 + - - + +  MS0256 + + + + + 
HC25 + - + + +  MS0257 + - - + + 
HC26 + + - + +  MS0258 + - - + + 
HC27 + + - + +  MS0259 + - + - + 
HC28 + - + + +  MS0261 + + + + + 
HC29 + - + + +  MS0262 + - + + + 
HC30 + - + + +  MS0264 + - - + + 
HC34 + + + + +  MS0265 + + + + + 
HC36 + + + + -  MS0266 + - + + + 
       MS0268 + - - + + 
       CIS232 + - - + + 
       CIS260 + - - + + 
       CIS263 + + - + + 
       CIS270 + + + + + 
       CISP38 + - + + + 
       CISP51 + - + + + 
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Lymphocyte  populations  were  gated  on forward  versus side scater (Figure  6.1A). 
Doublets were excluded from the analysis (Figure 6.1B) and NK cels were identified 
as  having a  CD3- CD56+  phenotype (Figure  6.1C).  NKT cels  were identified as 
double  positive  population  by  ploting  CD3  versus  CD56 (Figure  6.2C). iNKT cels 
were identified as double positive population by ploting Vα24 versus Vβ11 of CD3+ 
cels (Figure  6.3C).  KIR expression  was evaluated  on  NK cels (Figure  6.1),  NKT 
cels (Figure  6.2) and iNKT cels (Figure  6.3). Each sample  was run alongside its 
isotype and  FMO controls.  The  data colected  using  Diva  Software  6.0 (BD, 
Mountain  View,  CA)  was  processed for statistical analysis  using GraphPad  Prism  5 
Software. One-tail  Mann  Whitney test  was  used.  p  values  <  0.05  were considered 
significant. 
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Figure 6.1: Analysis of KIR expression on NK cels.  
Representative flow cytometry  dot  plots and  histograms showing  gating strategies 
used in this study.  Briefly, lymphocytes  were identified  on the  basis  of forward and 
side scater (A). Doublet events were excluded from the analysis (B). NK cels were 
identified  on the  basis  of  CD56 expression  only (C).  Anti-KIR antibodies  used  were 
CD158b, CD158e and CD158a/h. Cels were gated for (C) CD56+CD3- NK cels and 
KIR expression was measured as percentage of gated population. Histograms showing 
KIR2DL2/L3 (D), KIR3DL1 (E) and KIR2DL1/S1 (F) expression on NK cels.  Each 
sample was run alongside with their isotype control (G), (H) and (I). These plots are 
representative of a healthy control. The same staining and data analysis strategy was 
applied to al healthy controls, MS and CIS patients. FACS analysis was caried out 
using BD Diva Software.	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Figure 6. 2: Analysis of KIR expression on NKT cels. 
Representative flow cytometry  dot  plots and  histograms showing  gating strategies 
used in this study.  Briefly, lymphocytes  were identified  on the  basis  of forward and 
side scater (A). Doublet events were excluded from the analysis (B). NKT cels were 
identified  on the  basis  of CD3 and  CD56 expression (C). Anti-KIR antibodies  used 
were  CD158b,  CD158e and  CD158a/h. Cels  were  gated for (C)  CD56+CD3+ NKT 
cels and KIR expression was measures as percentage of gated population. Histograms 
showing  KIR2DL2/L3 (D),  KIR3DL1 (E) and  KIR2DL1/S1 (F) expression  on  NKT 
cels.   Each sample was run alongside  with their isotype control (G), (H) and (I). 
These plots are representative  of a healthy control. The same staining and  data 
analysis strategy  was applied to al  healthy controls,  MS and  CIS  patients.  FACS 
analysis was caried out using BD Diva Software.	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Figure 6. 3: Analysis of KIR expression on iNKT cels. 
Representative flow cytometry  dot  plots and  histograms showing  gating strategies 
used in this study.  Briefly, lymphocytes  were identified  on the  basis  of forward and 
side scater (A), and then  gated  on CD3+ cels (B). iNKT cels  were identified as 
double  positive  population  by  ploting  Vα24  versus  Vβ11 (C). Anti-KIR antibodies 
used were CD158b, CD158e and CD158a/h. Cels were gated for (C) iNKT cels and 
KIR expression was measures as percentage of gated population. Histograms showing 
KIR2DL2/L3 (D),  KIR3DL1 (E) and  KIR2DL1/S1 (F) expression  on iNKT cels. 
Each sample was run alongside with their isotype control (G), (H) and (I). These plots 
are representative  of a healthy control. The same staining and  data analysis strategy 
was applied to al healthy controls, MS and CIS patients. FACS analysis was caried 
out using BD Diva Software.	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6.1 KIR2DL1/S1 expression on iNKT, NKT and NK cels. 
 
 
A lower gene carier frequency for the inhibitory KIR2DL1 gene has been observed 
within  MS  patients compared to  healthy controls (Lorentzen et al.,  2009).  Carying 
both  KIR2DL1 and  HLA-C2 is associated  with lower risk  of  developing  MS than 
carying  only  HLA-C2 (Lorentzen et al.,  2009).  However, cariers  of the activating 
KIR2DS1  gene  had a lower risk  of  developing  MS in the absence  of  HLA-C2 than 
non-cariers (Lorentzen et al., 2009). Another study performed genotyping of HLA-A, 
B,  C,  DRB1 and  KIRs loci in Italian  RRMS  patients and  healthy controls, showing 
that MS patients had a lower frequency of the activating KIR2DS1 gene compared to 
controls, suggesting a  possible  protective role for this activating  gene against  MS 
(Fusco et al., 2010). This finding was augmented in the existence of its ligand HLA-
C2 (Fusco et al., 2010). Therefore, the activating KIR2DS1/C2 complex is believed to 
be protective against MS in at least two diferent populations. However, another study 
showed that cariage  of the  KIR2DL1 and  HLA-C2  pair  was  higher in  MS  patients 
with  higher  progression index compared to controls (Garcia-Leon et al.,  2011), in 
disagreement  with the results  described  by  Lorentzen et al. (2009). I therefore 
considered there would be value in phenotypic analysis. 
 
My  data showed that  NK cels of RRMS-active patients expressed a significantly 
lower frequency  of  KIR2DL1/S1 compared to healthy controls (*p<0.05) and  CIS 
patients (**p<0.01) (Figure 6.4A). However, PMS patients expressed a significantly 
higher frequency  of KIR2DL1/S1 compared to  RRMS-active patients (**p<0.01, 
Figure 6.4A).  
 
In  NKT cels, there is a trend towards  decreased expression  of KIR2DL1/S1 in  MS 
patients with respect to healthy controls and  CIS  patients (Figure  6.4B). NKT cels 
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expressed a significantly lower frequency of KIR2DL1/S1 in CIS patients compared 
to healthy controls (*p<0.05) (Figure  6.4B). CIS  patients expressed a significantly 
higher frequency  of KIR2DL1/S1  with respect to  RRMS-stable and  RRMS-active 
patients (*p<0.05, Figure 6.4B). NKT cels from PMS seem to express similar level 
of KIR2DL1/S1 to CIS patients (Figure 6.4B). 
 
In iNKT cels, there is a trend towards decreased expression of KIR2DL1/S1 in MS 
patients compared to healthy controls and CIS patients (Figure 6.4C). However, MS 
patients receiving  Natalizumab therapy (RR-NatAb) expressed significantly lower 
levels  of KIR2DL1/S1 when compared to RRMS-active and  RRMS-stable patients 
(*p<0.05, Figure 6.4C). Again iNKT cels from PMS patients seem to express similar 
levels of KIR2DL1/S1 of CIS patients (Figure 6.4C). 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 6. 4: Relative percentage of KIR2DL1/S1 expression in MS patients. 
Lymphocytes from HC, CIS, RRMS-stable, RRMS-active, RR-IFNb, RR-NatAb and 
PMS were analysed. NK (A), NKT (B) and iNKT (C) cels. Analysis was determined 
using BD Diva software and GraphPad Prism 5 Software. Statistical analysis caried 
out using the Mann-Whitney test: *p<0.05, **p<0.01. 
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6.2 KIR2DL2/L3 expression on iNKT, NKT and NK cels. 
 
 
MS  patients carying the inhibitory  KIR2DL2  genes have  been reported to show an 
elevated  Multiple  Sclerosis  Severity  Score (MSSS) compared to  non-cariers  MS 
patients, demonstrating that cariers of KIR2DL2 acquire a more severe form of the 
disease (Lorentzen et al.,  2009). The inhibitory  KIR2DL3  gene frequency  was 
significantly  decreased in  CIS and  MS  patients even after exclusion  of  patients 
carying  MS-associated aleles, indicating that the lack  of the inhibitory  KIR2DL3 
gene is corelated with the development of CIS and MS in patients carying HLA-C1 
aleles (Jelcic et al.,  2011). Interestingly,  peripheral  blood from  MS  patients treated 
with cytosine-phosphate-guanosine (CpG) sequences and infected  with  HSV-1 
increased  KIR2DL2 expression during  viral infection at  both  mRNA and  protein 
levels and associated  with decreased NK cel activation, cytotoxicity and IFN-γ 
production (Rizzo et al., 2012).  
 
The monoclonal antibody used in this study does not discriminate between KIR2DL2 
and  KIR2DL3  due to the  high  homology  of these two  KIRs in the extracelular 
domains.  
 
As shown in  Figure  6.5A, the  patern  of  KIR2DL2/L3 expression  on  NK cels is 
similar in MS and  CIS  patients and slightly lower compared to  healthy controls. 
However, the expression  of  KIR2DL2/L3 is slightly increased in  RRMS-active 
patients compared to MS patients receiving IFNβ treatment (*p<0.05, Figure 6.5A). 
 
In  NKT cels, there is a trend towards  decreased expression  of KIR2DL2/L3 in  MS 
and  CIS  patients compared to healthy controls (Figure  6.5B),  but  none  of the  data 
reaches statistical significance. 
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In iNKT cels, the  general tendency is a  decrease in expresion  of  KIR2DL2/L3 in 
MS  patients,  with  RRMS stable and  RRMS active  being even lower than  PMS 
(Figure  6.5C).  However, the  data show expression  of KIR2DL2/L3 significantly 
increased in MS patients receiving Natalizumab treatment (RR-NatAb) compared to 
RRMS-stable (**p<0.01) and RRMS-active patients (*p<0.05, Figure 6.5C). 
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(B) NKT cels 
(C) iNKT cels 
(A) NK cels 
Figure 6. 5: Relative percentage of KIR2DL2/L3 expression in MS patients. 
Lymphocytes from HC, CIS, RRMS-stable, RRMS-active, RR-IFNb, RR-NatAb and 
PMS were analysed. NK (A), NKT (B) and iNKT (C) cels. Analysis was determined 
using BD Diva software and GraphPad Prism 5 Software. Statistical analysis caried 
out using the Mann-Whitney test: *p<0.05, **p<0.01 
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6.3 KIR3DL1 expression on iNKT, NKT and NK cels. 
 
 
The ligand  HLA-Bw4  of the inhibitory  KIR3DL1 receptor  has  been reported 
significantly reduced in MS patients compared to healthy controls, suggesting that the 
presence  of the ligand  HLA-Bw4 is protective against MS (Lorentzen et al.  2009). 
Fusco and coleagues also observed a lower frequency of HLA-Bw4 in MS patients 
compared to  healthy controls, although  not statisticaly significant (Fusco et al., 
2010). In agreement  with  data reported  by (Lorentzen et al.,  2009 and  Fusco et al., 
2010), two  other studies demonstrated that the frequency  of  HLA-Bw4 aleles was 
significantly decreased in  MS  patients compared to controls, implying a  protective 
role for HLA-Bw4 against MS (Jelcic et al., 2011; Garcia-Leon et al., 2011). 
 
My analysis showed  no significant  diference in  KIR3DL1 expression  on  NK cels 
between MS patients and healthy controls (Figure 6.6A). 
 
Expression  of  KIR3DL1  on  NKT cels is  decreased in  RRMS-active and  PMS 
patients compared to healthy controls but it is  not statisticaly significant (Figure 
6.6B). 
 
The trend in iNKT cels is a  decrease  of cels expressing  KIR3DL1 in  MS  patients 
compared to healthy controls and  CIS (Figure  6.6C).  Also,  RRMS-active  patients 
have a lower frequency  of iNKT cels expressing  KIR3DL1 compared to  RRMS-
stable patients (Figure 6.6C). 
 
Interestingly,  RR-NatAb  patients expressed a  higher frequency  of  KIR3DL1 
compared to  RRMS-stable (*p<0.05) and  RRMS-active patients (**p<0.01, Figure 
6.6C), while PMS patients showed an even higher expression level than both RRMS-
active and RRMS-stable patients, albeit not reaching statistical significance. 
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(A) NK cels 
(B) NKT cels 
(C) iNKT cels 
Figure 6. 6: Relative percentage of KIR3DL1 expression in MS patients. 
Lymphocytes from HC, CIS, RRMS-stable, RRMS-active, RR-IFNb, RR-NatAb and 
PMS were analysed. NK (A), NKT (B) and iNKT (C) cels. Analysis was determined 
using BD Diva software and GraphPad Prism 5 Software. Statistical analysis caried 
out using the Mann-Whitney test: *p<0.05 
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6.4  Comparison  between  KIR  genotype  and surface expression  on 
iNKT, NKT and NK cels. 
 
To characterise further the impact  of  diferences in  KIR2DL1/S1,  KI2DL2/L3 and 
KIR3DL1 expression on iNKT,  NKT and  NK cels, genotyping  data  was  matched 
with the coresponding surface expression  data in  both control  groups and  MS 
patients (Table 6.4A, B and C). 
 
As expected, the level of KIR expression is always higher on NK cels compared to 
NKT and iNKT cels (Table 6.4A, B and C). Importantly, KIR expression on any cel 
population was not detectable where the genotype was negative. On the other hand, in 
two cases for  KIR3DL1  positive individuals (one  HC and  one  MS), there  was  no 
surface expression  on  NK cels and/or  only a slight expression in  NKT and iNKT 
cels.  These  divergent  data  might  be atributed to an alelic  variant  of  KIR3DL1 
(KIR3DL1  *004),  which exhibits a  predominant intracelular retention (Taner et al., 
2011). In our classification, it is evident as wel that MS donors seem to express less 
surface level  of  KIR3DL1  on  NK cels than healthy controls (Table  6.4C).  Because 
we did not conduct any analysis at alelic level, we cannot be certain whether or not 
this might be due to a specific KIR3DL1 alelic variant. 
 
From Table 6.4B, lack of KIR2DL2 at a genomic level is indeed reflected as lack of 
surface expression  on iNKT cels.  None  of the healthy controls showed a lack  of 
KIR2DL3 at the genetic level; this is not true for MS, where we found 2 cases out of 
33 analysed.  Unfortunately the smal sample  data  does  not alow  us to clinicaly 
classified MS patients into diferent groups as we did for surface analysis. 
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 KIR2DL1 KIR2DS1 KIR2DL1/S1  on NK cels 
KIR2DL1/S1  
on NKT cels 
KIR2DL1/S1  
on iNKTcels 
HC1 +  -    
HC2 +  +    
HC4 +  -    
HC5 +  -    
HC6 +  +    
HC7 +  -    
HC8 - -    
HC10 +  +    
HC11 +  -    
HC13 +  -    
HC14 +  -    
HC15 +  +     
HC17 +  +     
HC18 +  +     
HC19 +  +     
HC20 +  +     
HC21 +  -    
HC22 +  -    
HC23 +  -    
HC24 +  -    
HC25 +  -    
HC26 +  +     
HC27 +  +     
HC28 +  -    
HC29 +  -    
HC30 +  -    
	  
MS227 + -    
MS228 + -    
MS229 + -    
MS230 + -    
MS234 + -    
MS235 + -    
MS237 + -    
MS238 + -    
MS239 + -    
MS240 + +    
MS241 + -    
MS242 + -    
MS244 + -    
MS245 + -    
MS246 + -    
MS247 + +    
MS249 + +    
MS250 + -    
MS251 + -    
MS252 + -    
MS253 + +    
MS254 - -    
MS255 + +    
MS256 + +    
MS257 + -    
MS258 + -    
MS259 + -    
MS261 + +    
MS262 + -    
MS264 + -    
MS265 + +    
MS266 + -    
MS268 + -    
	  
CIS232 + -    
CIS 260 + -    
CIS 263 + +    
CIS 270 + +    
CIS P38 + -    
CIS P51 + -    
 
  < 10% 
  5.1 – 10 % 
  1.1 -5 % 
  0.1 – 1% 
  0 
HC 
Genotyping Surface expression  
MS 
CIS 
Table  6.4 A: Comparison  of 
KIR2DL1  and  KIR2DS1 
genotype  vs. surface 
expression  of  KIR2DL1/S1 
on iNKT, NKT and NK cels 
in HC, MS and CIS patients. 
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 2DL2 2DL3 KIR2DL2/L3  on NK cels 
KIR2DL2/L3  
on NKT cels 
KIR2DL2/L3  
on iNKTcels 
HC1 + +    
HC2 - +    
HC4 - +    
 HC5 + +    
HC6 + +    
HC7 - +    
HC8 + +    
HC10 + +    
HC11 + +    
HC13 - +    
HC14 - +    
HC15 - +    
HC17 - +    
HC18 + +    
HC19 - +    
HC20 + +    
HC21 - +    
HC22 + +    
HC23 - +    
HC24 - +    
HC25 + +    
HC26 - +    
HC27 - +    
HC28 + +    
HC29 + +    
HC30 + +    
	  
	  
MS227 + +    
MS228 - +    
MS229 + +    
MS230 + +    
MS234 - +    
MS235 - +    
MS237 - +    
MS238 + +    
MS239 + +    
MS240 + +    
MS241 - +    
MS242 - +    
MS244 + +    
MS245 - +    
MS246 - +    
MS247 - +    
MS249 + +    
MS250 + +    
MS251 - +    
MS252 - +    
MS253 - +    
MS254 + -    
MS255 - +    
MS256 + +    
MS257 - +    
MS258 - +    
MS259 + -    
MS261 + +    
MS262 + +    
MS264 - +    
MS265 + +    
MS266 + +    
MS268 - +    
	  
  < 10 % 
  5.1 – 10 % 
  1.1 -5 % 
  0.1 – 1 % 
  0 
CIS232 - +    
CIS 260 - +    
CIS 263 - +    
CIS 270 + +    
CIS P38 + +    
CIS P51 + +    
HC 
MS 
CIS 
Table  6.4 B: Comparison  of 
KIR2DL2  and  KIR2DL3 
genotype  vs. surface 
expression  of  KIR2DL2/L3 
on iNKT,  NKT  and  NK cels 
in HC, MS and CIS patients. 
 
Genotyping Surface expression  
Genotyping Surface expression  
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 3DL1 KIR3DL1  on NK cels 
KIR3DL1  
on NKT cels 
KIR3DL1  
on iNKTcels 
HC1 +    
HC2 +    
HC4 +    
HC5 +    
HC6 +    
HC7 +    
HC8 +    
HC10 +    
HC11 +    
HC13 +    
HC14 +    
HC15 +    
HC17 +    
HC18 +    
HC19 +    
HC20 -    
HC21 +    
HC22 +    
HC23 +    
HC24 +    
HC25 +    
HC26 +    
HC27 +    
HC28 +    
HC29 +    
HC30 +    
	  
	  
MS227 +    
MS228 +    
MS229 +    
MS230 +    
MS234 +    
MS235 +    
MS237 +    
MS238 +    
MS239 +    
MS240 +    
MS241 +    
MS242 +    
MS244 +    
MS245 +    
MS246 +    
MS247 +    
MS249 +    
MS250 +    
MS251 +    
MS252 +    
MS253 +    
MS254 +    
MS255 +    
MS256 +    
MS257 +    
MS258 +    
MS259 +    
MS261 +    
MS262 +    
MS264 +    
MS265 +    
MS266 +    
MS268 +    
	  
	  
  < 10 % 
  5.1 – 10 % 
  1.1 -5 % 
  0.1 – 1 % 
  0 
CIS232	   +	   	   	   	  
CIS	  260	   +	   	   	   	  
CIS	  263	   +	   	   	   	  
CIS	  270	   +	   	   	   	  
CIS	  P38	   +	   	   	   	  
CIS	  P51	   +	   	   	   	  
Genotyping Surface expression  
Table  6.4 C: Comparison  of 
KIR3DL1  genotype  vs. 
surface expression  of 
KIR3DL1  on iNKT,  NKT 
and NK cels in HC, MS and 
CIS patients. 
HC 
MS 
CIS 
Genotyping Surface expression  
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6.5 Discussion 
 
 
It has long been clear that both human and murine iNKT cels express various NK cel 
markers such as CD161, CD94, NKG2D, IL2Rβ (CD122), Ly49A and Ly49C (Bix et 
al., 1995; MacDonald et al., 1995; Exley et al., 1998; Gumperz et al., 2002; Lee et al., 
2002; Brigl and Brenner, 2004). Although, iNKT cels in mice are known to express 
Ly49 receptor (the functional equivalents  of  KIR in  human), it  has  previously  been 
reported that human iNKT cels do not express KIR (Exley et al., 1997; Raulet et al., 
2001; Lee et al.,  2002).  However,  more recently  Paterson and coleagues 
demonstrated that a smal  percentage  of  human iNKT cels  do indeed express  KIR 
using flow cytometry,  RT-PCR and immunobloting (Paterson et al.,  2008).  KIR 
expression on iNKT cels has not been detected in previous studies, possibly because 
of inadequate iNKT cel events acquired during flow cytometry analysis. I addressed 
this issue by staining 3 milion cels in order to have enough events in the iNKT cels 
gate to make me confident of the data. However, because iNKT are a rare population 
and even rarer in MS patients, even colecting al stained samples did not alow me to 
perform a multivariate analysis looking at double or triple expression of KIRs on this 
population because of the smal numbers I was dealing with. This comes back to the 
point raised  by  Mario  Roederer regarding the statisticaly significance  of  one single 
event in a gate (Roederer, 2008). 
 
Increased expression of activating KIR genes may result in augmentation of cytotoxic 
functions of T cels and NK cels or favour sustained activation state of the immune 
system,  potentialy tipping the  balance towards  pathology in autoimmune  diseases 
such as MS (Snyder et al., 2004; Garcia-Leon et al., 2011).  
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However, ligation  of inhibitory  KIRs functions acts as a  negative regulator for  NK 
and  T cels activation, leading to  down-regulation  of  Th1 cytokine  production, cel 
cytotoxicity and apoptosis (Vivier and  Anfossi,  2004;  Garcia-Leon et al.,  2011). 
Imbalances  between activating and inhibitory signals  wil  mainly  have an afect  on 
cel activation rather than single specific interaction (Fusco et al., 2010; Garcia-Leon 
et al., 2011). 
 
A number of immunogenetic studies indicate an association between the presence of 
specific KIR receptors and susceptibility to MS. However very litle has been done at 
a celular level. Therefore, I was keen to gain a beter understanding of the expression 
of  KIR2DL1/S1,  KIR2DL2/L3 and  KIR3DL1  on iNKT,  NKT and  NK cels in  MS 
and  CIS  patients compared to  healthy controls. I  performed  detailed 
immunophenotyping analysis by flow cytometry with the aim of quantifying the KIRs 
being realy expressed on the cel surface. Table 6.5 summarises the most important 
findings discussed in this chapter. 
Table 6.5: Summary of the KIR expression results for the diferent cel subsets 
presented in chapter 6. 
 (Increase) or  (decrease) refers to percentage of positive cels. 
	  
 NK cels NKT cels iNKT cels 
HC vs. CIS  KIR2DL1/S1  
HC vs. RRMS-active KIR2DL1/S1   
CIS vs. RRMS-stable  KIR2DL1/S1 KIR2DL2/L3 
CIS vs. RRMS-active KIR2DL1/S1 KIR2DL1/S1  
PMS vs. RRMS-active KIR2DL1/S1   
RRMS-stable vs. RR-NatAb   
KIR2DL1/S1 
KIR3DL1 
KIR2DL2/L3 
RRMS-active vs. RR-NatAb   
KIR2DL1/S1 
KIR3DL1 
KIR2DL2/L3 
RRMS-active vs. RR-IFNb KIR2DL2/L3   
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The absence  of the  HLA-Bw4 ligand  of the inhibitory  KIR3DL1 receptor was 
observed in  MS  patients compared to  healthy controls  using  KIR and  HLA 
genotyping techniques, which implied a protective role for the HLA-Bw4 against MS 
(Lorentzen et al.,  2009;  Fusco et al.,  2010;  Garcia-Leon et al.,  2011; Jelcic et al., 
2012). However, the inhibitory KIR3DL1 gene frequency was slightly higher among 
Norwegian untreated RRMS and PPMS patients compared to controls (Lorentzen et 
al.,  2009). Another study found that  KIR3DL1 frequency  was similar  between 
Spanish  Caucasian RRMS  patients  on IFN therapy and  SPMS patients compared to 
healthy controls (Garcia-Leon et al.,  2011). Also, Jelcic and coleagues found  no 
diference in KIR3DL1 expression between RRMS and PPMS patients compared to 
healthy controls (Jelcic et al.,  2012). This  discrepancy suggests that  KIR3DL1  gene 
expression  might  vary according to  diferent ethnic  backgrounds and type  of  MS 
disease.  
 
Observations from my study, looking specificaly at phenotypic expression, seems to 
indicate that  KIR3DL1 expression on  NKT and iNKT cels are  decreased in  MS 
patients compared to healthy controls. Moreover, the frequency  of iNKT and  NKT 
cels expressing  KIR3DL1 is lower in PMS  patients compared to healthy controls. 
Interestingly, active and stable RRMS  untreated  patients  had significantly lower 
iNKT cels expressing  KIR3DL1  with compared to  RRMS  patients treated  with 
Natalizumab, suggesting a significant association between KIR3DL1 and iNKT cels 
with the therapeutic response to Natalizumab. 
 
The  data  demonstrated that KIR3DL1 expression  on iNKT and  NKT  was less 
frequent in MS patients than in controls, potentialy resulting in decreased inhibitory 
signals and thus  unrestricted activation  of the  NK  or  T cel in  MS, supporting a 
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protective efect of inhibitory KIR3DL1 receptor during MS. 
 
KIR2DL2 and  KIR2DL3  were thought to represent  diferent  genes  but  genomic 
analysis revealed that KIR2DL2 and KIR2DL3 could be termed KIR2DL2/L3 since 
they are aleles at the same locus (Uhrberg et al., 2002). It seems that KIR2DL2 and 
KIR2DL3 have similar ligand specificity but diferent afinity for HLA-C molecules, 
with KIR2DL2 being a stronger receptor than KIR2DL3 (Moesta et al., 2008). 
 
The patern of KIR2DL2/L3 expression on NK, NKT and iNKT cels is slightly lower 
in  MS and  CIS patients compared to  healthy controls, complementing a recently 
published immunogenetic study  which reported that inhibitory  KIR2DL3  gene 
frequency was significantly decreased in CIS and MS patients, indicating that the lack 
of the inhibitory KIR2DL3 gene is corelated with the development of CIS and MS 
patients (Jelcic et al.,  2011). However, the expression  of  KIR2DL2/L3  on  NK cels 
only is slightly increased in  RRMS-active compared to  RRMS  patients  on IFNβ 
therapy and  our cohort  of RRMS-active  patients  have highly active  disease course 
with active  MRI scans and they were about to start  Natalizumab. Interestingly, the 
diferential expression of KIR2DL2/L3 on iNKT cels is significantly increased in MS 
patients receiving  Natalizumab treatment compared to  untreated  RRMS-stable and 
RRMS-active patients. This may relate to previous genomic findings, which reported 
that  MS  patients carying the inhibitory  KIR2DL2 acquire  more severe form  of the 
disease (Lorentzen et al., 2009). Our cohort of MS patients on Natalizumab therapy 
has  more severe  disease  with  higher  EDSS scores than  RRMS-stable and  RRMS-
active patients.  
 
When looking at the expression of KIR2DL1/S1 on NK cels, the level of expression 
was similar in healthy controls,  CIS,  RRMS-stable and  PMS  patients.  However, the 
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expression of KIR2DL1/S1 is significantly lower in RRMS-active patients compared 
to healthy controls and  CIS  patients. Interestingly, PMS  patients expressed 
significantly higher frequency of KIR2DL1/S1 compared to RRMS-active patients. 
 
MS is an autoimmune disease with a very heterogeneous disease patern, meaning that 
some  patients  would  go through  RRMS  phases  while  others  would acquire a 
progressive type  of  disease,  with increasing  neurological  deterioration (Compston, 
2008). Our data seem to support the hypothesis that some aspects of the immune cel 
surface phenotype in PMS are completely diferent to RRMS. This finding might be 
of interest in relation to the observation that some disease modifying therapies that are 
working for RRMS has poor or no eficacy on PMS patients (Stys, 2012). 
 
The patern of KIR2DL1/S1 expression on NK cels is diferent to the expression on 
NKT and iNKT cels. Interestingly, within the  NKT and iNKT  population,  both 
healthy controls and  CIS  patients expressed a  higher frequency  of KIR2DL1/S1 
compared to RRMS and progressive patients. This finding extends previous genotypic 
studies,  which reported that MS  patients  had a lower frequency  of the activating 
KIR2DS1 (Fusco et al.,  2010) and the inhibitory  KIR2DL1  gene (Lorentzen et al., 
2009) compared to controls.  Moreover,  within iNKT  population, MS  patients 
receiving  Natalizumab therapy expressed significantly lower levels  of KIR2DL1/S1 
when compared to RRMS-active and  RRMS-stable,  while the contrary is true  when 
looking at expression of KIR2DL2/L3 and KIR3DL1. 
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The mechanisms by which inhibitory KIRs may be protective in MS is likely due to 
limiting the activation  of the  NK cels and the  other expressing cel types  via 
inhibitory KIR signaling through ITIMs, thus reducing cytotoxic and other pathogenic 
efector functions.  Lack  of the inhibitory signal leads to a  weaker inhibition  of  NK 
cels resulting in skewed cytokine production (Orange et al., 2006) and up-regulates 
co-stimulatory signals to antigen  presenting cels including  DCs (Hamerman et al., 
2005;  Corthay et al.,  2006),  potentialy  promoting the activity  of  pathogenic, 
autoreactive T cels (Shi et al., 2006). The diferent levels of KIR expression on NKT 
and iNKT cels raises the  possibility that  KIR-expressing cel types  other than  NK 
cels might also contribute to autoimmune diseases. In addition to this we noticed that 
KIR expression  on iNKT cels  were  distinct from that  of  NK cels  within the same 
donor.  Such intra-individual  discrepancies in  KIR expression  between  diferent cel 
types could  be that  KIR expression  on iNKT cels act as an “immune check  point” 
mechanism in case of unbalancing of activating vs. inhibitory receptors. 
 
An interesting observation made in this chapter when matching the genetic data with 
surface expression, was KIR genes were sometimes present in individuals that lacked 
surface expression  of the coresponding  KIR  by flow cytometry, as  has  been 
suggested (Vely et al., 2001). This observation applied to NK, NKT and iNKT cels.  
 
It  has  been found that  KIR expression  on iNKT cels  behave in a  dynamic  manner 
since activation of iNKT cels was accompanied with the up-regulation of KIR in the 
first  6  hours folowed  by  down-regulation (Paterson et al.,  2008).  Also, it  has  been 
shown that iNKT cels and  T cels  may  modulate their  KIR expression levels in an 
MHC/peptide-dependent manner (Valiante et al., 1997b; Chan et al., 2003; Paterson 
et al., 2008). 
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The data reported in this chapter represent the first atempt to mary up KIR genetics 
with lymphocyte subset protein expression. I speculate that a beter understanding of 
KIR expression may help us gain insights into the variations that occur within disease 
progression and their clinical outcome.  
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7. Conclusions 
 
Although reductions in  peripheral iNKT cels have  been reported in a  variety  of 
autoimmune diseases including MS (Sumida et al., 1995; Wilson et al., 1998; Ilés et 
al.,  2000; Kojo et al., 2001; Van  der  Vilet et al.,  2001; Araki et al.,  2003), litle is 
known functionaly about the role of iNKT cels in MS. There is stil no clear model 
as to the  mechanism  by  which changes  within the iNKT cel  population  may 
contribute to disease initiation and progression. 
	  
The fact that iNKT cels are such a low frequency population in peripheral blood has 
sometimes  been taken to imply that they  perhaps could  not  play a  major role in 
autoimmune  pathogenesis  or its control (Gumperz et al.,  2002). However, in  other 
disease contexts such as asthma and sarcoidosis, the case  has  been  made that local 
changes in cel numbers at the site of disease may be suficient to make a large impact 
on  pathogenesis, especialy  when considering a cel-type that can release such 
abundant cytokines so rapidly (Ho et al.,  2005; Boyton, 2008). Functional and 
quantitative studies  on iNKT cels in  human  disease  have sometimes been  hindered 
by technical problems and methodological disputes about the best ways of accurately 
gating and enumerating such a minor population (Ho, 2007). 
 
My results, acquired with two diferent methods, using CD1d-αGalCer tetramers and 
anti-Vα24 and anti-Vβ11  monoclonal antibodies to identify iNKT cels, strengthen 
the conclusion that there is a significant reduction in the frequency of iNKT cels in 
the  periphery of MS patients compared to healthy controls. It is  however  more 
striking that while the frequency of iNKT cels is drasticaly reduced in the peripheral 
blood  of  MS  patients compared  with healthy controls, also the frequency  of iNKT 
cels was significantly decreased in MS patients compared to CIS patients, suggesting 
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that iNKT cel alterations may indeed contribute to the early events in disease onset. 
 
Moreover, despite the existence of CD4+, CD8+ and CD4+/CD8+ iNKT cels, previous 
published studies have predominantly paid atention on CD4-/CD8- iNKT cels due to 
the larger numbers of the later subset. However, my results  demonstrated a trend 
towards an elevation in the frequency of CD4+ iNKT cels in RRMS patients treated 
with either IFNβ or Natalizumab. A significant reduction in  CD4-/CD8- iNKT cels 
was observed in RRMS and PMS patients when compared to healthy controls. CD4+ 
and CD4- iNKT cels are considered to represent diferent functional lineages 
(Gumperz et al.,  2002;  Lee et al.,  2002); while CD4- iNKT cels predominantly 
produce Th1 cytokines, CD4+ iNKT cels produce both Th1 and Th2 cytokines. The 
CD4-/CD8- iNKT subset resembles NK cels with respect to enhanced cytotoxic 
function, as suggested by high NCR3 expression and homing to non-lymphoid tissue 
and in terms of response to IL-2 and IL-12 (Gumperz et al., 2002; Lin et al., 2006), a 
phenotype that is rather  distinct from CD4+ NKT cels. This  may  perhaps suggest a 
protective role  of CD4-/CD8- iNKT cels in the regulation  of autoreactive  T cel 
clones  via cytolysis. It is an important curent  priority to  properly characterize the 
subsets  of iNKT cels that segregate with respect to distinct  properties, confering 
diferent immunological functions (Cohen et al., 2013). 
 
I considered a  number  of  possible  mechanisms to account for the depletion  of 
circulating iNKT cels in  PBMC  of  MS  patients. Recruitment and accumulation of 
iNKT cels in target organs, namely the brain, is implausible since MS lesions rarely 
expressed Vα24Jα18  TCR iNKT cels (Iles et al.,  2000). My  preliminary 
observations using an IF staining method revealed very few CD1d tetramer positive 
cels in  post-mortem  MS  brain sections, and then only in  2  out of 5 cases.  The 
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assumption  must  be that the reduction in  peripheral iNKT cels in  MS  patients is 
absolute rather a reflection of migration to CNS.  
 
It is possible that iNKT cels in MS patient are unable to signal properly (or at least 
bind their ligand with altered afinity) through the Vα24/Vβ11 TCR. Analysis of the 
TCR  Vβ11  CDR3 region in iNKT cels  of  MS  patients in this thesis is the first to 
show that iNKT TCRβ repertoire appears constrained relative to the pool of cels in 
healthy controls. This may indicate that these cels in the patients have been selected 
on the basis of particular features of afinity, conceivably associated with a disease-
related cytokine  profile. From these  preliminary results, it seems that iNKT cel 
perturbations in RRMS patients could be a consequence of a perturbation within the 
Vβ11+ repertoire, namely a reduced clonality within the iNKT Vβ11+ cel population. 
However, due to the relative smal number of donors recruited and smal number of 
sequences analysed we can only speculate at present. Maybe deep sequence analysis 
could be more suitable to this purpose and wil give a beter resolution of TCR level. 
Also, analysis of CSF cels from MS patients might provide us with a clearer picture.  
 
Another  hypothesis is that selective expression  of specific  TCR  or receptors  on the 
iNKT cel surface  might  be important in  defining  whether a  defined  phenotype  of 
iNKT cels is predominant in MS. Interestingly, a recently submited paper from our 
lab demonstrated that NKT cels could also express the activating  NKp46 receptor, 
which is considered a  halmark  of functional  kiler capability in  NK cels.  The  key 
finding was, although quantitative deficiency in presumed regulatory NKT cels was 
observed in MS patients, those cels that are present are of a more activated, NKp46hi 
phenotype.  
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This  prompted me to  design an antibody  panel for  multiparameter flow cytometry 
enabling  us to look at  diferent lymphocyte  populations and the expression  of 
diferent maturation, activation and homing markers in the periphery of MS patients. 
The fact that the frequency of iNKT cels expressing CD62L is higher in peripheral 
blood of  MS  patients might  be explained  with acquisition  of a more  memory-like 
phenotype. 
 
In  general, if  we consider IL-17 the cytokine involved in regulatory functions and 
virtualy al cels producing IL-17 express CD161, then iNKT cels in the periphery of 
MS  patients may  be less able to regulate  or  modulate the activity  of  other 
lymphocytes. This inability appears to relate to disease progression, as PMS patients 
seems to have fewer iNKT cels expressing CD161 than RRMS. Another explanation 
is that our RRMS patients are not in relapse, therefore the expression level of IL-17 
and CD161 is lower. 
 
Indeed I observed that the frequency of CD25 expression on iNKT cels increased in 
MS  patients compared to  healthy  donors.  Another interesting feature is that iNKT 
cels expressing both CD25 and CD161 are increased in patients. This may reflect a 
switch  of  phenotype in lymphocytes in MS  patients. Overexpression  of these 
molecules  on iNKT cels may dampen immunological responses  by the failure  of 
iNKT cels to  proliferate in response to  Ag and  by an inability to mediate efector 
cytokines secretion in some cases leading to cytokine  deprivation-mediated iNKT 
cels programmed cel death. 
 
Failure of iNKT cels to  proliferate efectively in response to  TCR engagement  or 
cytokine stimulation might result from exhaustion  or induction  of  programmed cel 
death (PCD). Preliminary  data  generated  by a  master student in  our  group (Ruchi 
	   214	  
Maniar) on mRNA extracted from sorted iNKT cels showed diferential expression 
of  genes involved in  PCD such as  FAS,  FASL, IL1b, and TNFα, between  healthy 
donors and MS patients. Particularly, FAS was up-regulated and biologicaly active in 
MS patients, while FASL was down-regulated and inhibited, potentialy resulting in 
an imbalance  of  FAS and  FASL and impairment  of regulation  of cel  death 
programme. Moreover, IL1b and  TNFα  were  down-regulated in  untreated  RRMS 
patients compared to healthy controls and  RRMS patients on  Natalizumab. Taken 
together, this is compatible with a hypothesis that programmed cel death might play 
an important role in the reduction or selection  of a specific peripheral iNKT cel 
population in RRMS patients. 
 
From these  data one  may speculate that both qualitative and  quantitative  defects in 
iNKT cels in some way have a profound efect on development and exacerbation of 
autoimmunity, either through the loss to  very rapidly secrete anti-inflammatory 
cytokines or the loss of a function in cytolysis of autoreactive T cels.  
 
I noted that paterns of KIR expression on iNKT cels were diferent from that of NK 
cels within the same donor; it has long been appreciated that KIR expression can be 
variegated  within an individual, even comparing between  NK cels clones.  One 
possible reason for such intra-individual  discrepancies in  KIR expression  might  be 
that  one cel type  has  been exposed to an active selection  process  by  HLA class I 
molecules.  Another  possible explanation is a diference in the transcriptional 
regulation or epigenetic control of KIR expression in distinctive cel types. 
 
Several theories  may  be  proposed from these  observations (Figure  7.1). My 
hypothesis is that therapies aiming at the restoration of iNKT cels could be clinicaly 
relevant to the treatment of autoimmune disease in humans. 
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  Figure 7. 1: Schematic diagram of a hypothesis for a role of iNKT cels in MS. 
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8. Future Work 
 
During this  project, several innovative areas  of iNKT cel  biology  have  been 
addressed and numerous remarks made regarding iNKT cel behavior in autoimmune 
diseases including MS. Analysis of iNKT cels in MS has been mounting remarkably 
across another  of labs, though  greater insights are  now  needed into the celular 
interactions and alterations deriving from these quantitative and qualitative changes. 
My  work  on the role  of iNKT cels in  MS requires  definitive experiments able to 
address the fundamental issue  of the extent to which individual iNKT subsets are 
protective or pathogenic in MS. A detailed evaluation of the factors controling iNKT 
cels numbers in  MS required. Future  work to  beter comprehend the role  of iNKT 
cels in MS should include: 
 
• Detailed functional experiments to evaluate the function  of iNKT cels in  MS 
assessing cytokine  profiles to  beter annotate the implications  of subset 
diferences between disease states or before and after response to treatments. A 
major caveat to  design  of such experiments is the smal events  number in the 
iNKT cel  gate in  MS  patients that could  be compared  with control cels. 
Cytokine  quantification assays include intracelular cytokine staining,  ELISOT 
and qPCR analysis.  Alternatively, the  paucity in  yield may to some extent  be 
overcome  by increasing the amount  of stained samples at  origin.  However, 
another possibility wil be to sort iNKT cels and expand these cel populations ex 
vivo using proliferation assay. Stimulation of iNKT cels by αGalCer for 7 days 
wil result in proliferation and release of cytokines. PBMCs wil be resuspended 
in complete RPMI culture medium with recombinant human IL-2 and αGalCer. 
The  proliferative ability  of iNKT cels  wil  be assessed at  day  7  using flow 
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cytometry. Proliferation experiments  wil assess if such low  numbers  of iNKT 
cels in  MS  patients could  be expanded and  wil estimate and compare the 
expansion  potential  of  patients compared to  healthy controls. This would also 
alow a series of functional experiments: starting from measurements of cytokine 
production  upon stimulation  with αGalCer including IFNγ, IL-17 and IL-4,  but 
also extending  much  more  widely to  other efector  molecules  of iNKT cels, 
clarifying the role of iNKT cels and whether there is a functional defect. Also, 
this would alow one to diferentiate on a functional basis, the cytokine response 
in treated-MS  vs.  non-treated  MS and  RRMS  vs.  progressive  MS.  No 
experiments to date have defined why and how iNKT cels may exert a regulatory 
role in  MS  or  other autoimmune  diseases.  Presumably, they  may  be releasing 
cytokines that  modulate the efector functions  of  other cels.  Most  obviously, 
these target cel-types may be autoreactive CD4 or CD8 cels, or they may be the 
APC that present to them. To pin down these interactions would require a major 
programme of work, including precise delineation of the iNKT cel subsets and 
their diferential efector functions, purification of autoreactive T cel populations 
and then, co-culture experiments.  Some  of this  work  may  possibly  be  done 
initialy in Line 7 mouse model, though some caution would be needed in view of 
species diferences in these cel-types. A combination of flow cytometry analysis, 
real-time  PCR and IF staining could  be  performed  on  Line  7  mice at  diferent 
stages  of the  disease.  An enzymatic  digestion technique for lymphocyte 
extraction from the  CNS  has  been  developed in  our lab  by  Dr  Dan  Lowther to 
investigate the infiltration  of  diferent cel  populations including iNKT cels at 
each stage  of  disease. In addition to iNKT cels surface staining, intracelular 
cytokine staining for IFNγ, IL-17 and IL-4 can  be conducted. Brain and spinal 
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cord cryosections of the line  7  mice can also  be stained  with antibodies and 
CD1d-αGalCer tetramers to identify the presence of iNKT cels. 
• Investigating in  more  detail the  qualitative alteration in iNKT cels  using new 
techniques such as  TCR  deep sequencing, from  more  healthy controls and  MS 
patients.  The possibility, from the data shown here, that there may be diferences 
in  TCRβ  CDR3 sequences in  disease, if  built  upon, could  have important 
ramifications  both for characterising  diferential afinity and functions  of these 
cels, and for defining the ligands. While the vast majority of work on iNKT cels 
in autoimmunity has depended on αGalCer as a model ligand, one must presume 
that, in this context, it is a surogate for some unknown glycolipid target, either on 
other lymphoid  or  myeloid cels,  or indeed, in tissue. Identifying the actual 
identity of these glycolipid targets in the control of autoimmunity would be a very 
important endeavour. 
 
• Folowing recent publications it is believed that matured iNKT cells are derived 
from CD4+/CD8+ iNKT cels (Egawa et al., 2005). Studies have shown that iNKT 
cels require transcription factors for their  development (Egawa et al.,  2005). 
Furthermore, it  has  been reported that  SAP is a strong regulator for iNKT cel 
development (Pasquier et al.,  2005).  SAP  deficient  human and  mice  have 
severely impaired iNKT cel  development (Pasquier et al.,  2005).     Thus, an 
important  notion to explore is that iNKT cels  might  be  blocked in a specific 
maturation stage and this leads finaly to a reduction number of functional cels 
and onset of disease as there is miscommunication between iNKT cels and DCs. 
An alternative  hypothesis for investigation is that iNKT cels turnover in vivo 
more rapidly,  perhaps  due to an enhanced  drive to apoptosis.  qRT-PCR assays 
wil be designed to evaluate genes related to apoptosis. 
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• Moreover, to  beter  understand events in the  brain, results from IF should be 
validated and confirmed  by conducting further staining  with increased  numbers 
of  MS cases  not  only in  WM  but also in  GM and sub-meningeal lymphoid 
folicles.  Moreover, the  phenotype  of these cels remains to  be confirmed  by 
performing double staining and triple staining using appropriate markers such as 
CD3, CD4, CD8 and TCR Vα24. While the number of iNKT cels is clearly low, 
obtaining a beter grasp of precisely the cel-type that has migrated there and the 
transcriptional programme they express wil be important. This could be achieved 
with the help of laser capture dissection of lesions from fresh post-mortem tissue. 
 
In conclusion, this study and future work aims to investigate the role of iNKT cels in 
MS to increase  our  knowledge  on the exact role  of lymphocytes subsets as a step 
towards elucidation of new target molecules for disease therapies. 
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